| Excerpt | Reference |
|---|
| "Thorotrast-induced liver cancers are inclined to grow rapidly, so early diagnosis of liver tumor accompanied by thorotrastosis is very difficult, as in this case." | ( Furuta, S; Gibo, Y; Imai, H; Kiyosawa, K; Nakamura, M; Sodeyama, T, 1988) |
| "Thorotrast-related liver cancer is rare." | ( Khan, AA, 1985) |
| "Liver cancer is one of the most prevalent forms of cancer in the world." | ( Harris, CC; Sun, TT, 1986) |
| "Hepatocellular cancer is a highly vascular tumor, where the neovasculature is unique in that it arises only from the hepatic arterial circulation, whereas normal liver has both hepatic arterial and portal venous blood supply." | ( Cahill, PA; Sitzmann, JV; Wu, Y, 1996) |
| "Small liver cancers are diagnosed by US, US-guided biopsies, computed tomography (CT), magnetic resonance imaging (MRI), and angiography." | ( Nishikawa, K; Takikawa, H; Yamanaka, M, 1996) |
| "Primary liver cancer is a significant health problem; treatment options are limited and prognosis is poor." | ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "Primary liver cancer is also strongly associated with liver cirrhosis." | ( Bolondi, L; Gaiani, S; Gebel, M, 1998) |
| "The risk of liver cancer is greatest in people both infected with hepatitis B virus (HBV) and highly exposed to aflatoxin B(1) (AFB(1))." | ( Egner, PA; Groopman, JD; Kensler, TW; Li, Y; Qin, L; Roebuck, BD; Su, J; Wang, J, 2000) |
| "Liver cancer is one of the most common cancers worldwide." | ( Egner, PA; Gange, SJ; Groopman, JD; Jacobson, LP; Kensler, TW; Kuang, SY; Muñoz, A; Qian, GS; Wang, JB; Zhang, BC; Zhu, YR, 2002) |
| "Primary cancer of the liver is characterized not only by laboratory evidence for cytolytic (87." | ( Krashutskiĭ, VV; Pikurin, SM, 2003) |
| "Liver cancer is one of the most common diseases around the world." | ( Gong, LS; Liu, S; Zhang, YD, 2004) |
| "Since hepatic neoplasms are principally supplied by the hepatic artery, various arterially delivered cytotoxic agents have been developed to achieve these objectives." | ( Ahrar, K; Cohen, A; Coldwell, DM; Erwin, W; Gupta, S; Hicks, ME; Kennedy, AS; Madoff, DC; Murthy, R; Nunez, R; Szklaruk, J; Wallace, MJ, 2005) |
| "Liver cancer is the fifth most frequent malignancy worldwide." | ( Astrakianakis, G; Chang, CK; Checkoway, H; Fitzgibbons, ED; Gao, DL; Ray, RM; Seixas, NS; Thomas, DB; Vaughan, TL; Wernli, KJ, 2006) |
| "Liver cancer is the fifth most common neoplastic disease and the fourth leading cause of cancer-related death." | ( Chen, W; Jiang, B; Jiang, JD; Liu, H; Liu, J; Liu, W; Luo, C; Wang, L; Wu, Y; Xue, R; Zhao, W; Zhou, Y, 2006) |
| "Hepatocellular cancer is the fifth most frequent cancer in men and the eighth in women worldwide." | ( Seitz, HK; Stickel, F, 2006) |
| "Most patients with liver cancer are diagnosed when they are not suitable for resection." | ( Chaicumpa, W; Cowawintaweewat, S; Khuhaprema, T; Manoromana, S; Sriplung, H; Tapchaisri, P; Tongtawe, P, 2006) |
| "Liver cancer is among the most common malignancies, impacting significantly across all societies worldwide." | ( DePinho, RA; Farazi, PA, 2006) |
| "Liver cancer is the fifth common malignant tumor worldwide, and is closely related to the infections of hepatitis B virus (HBV) and hepatitis C virus (HCV)." | ( Jiang, JT; Wu, CP; Xu, N; Zhang, XY, 2007) |
| "Liver cancer is one of the most dreaded cancers, and it is highly prevalent in the developing countries, where the resources are extremely scarce to deal with this disease using the current commercially available and expensive therapeutic radiopharmaceuticals." | ( Dondi, M; Padhy, AK, 2008) |
| "Liver cancer is the fifth most common cancer worldwide and despite increasing implementation of ultrasonographic surveillance strategies, its incidence is rising, especially in western countries." | ( Villa, E, 2008) |
| "Liver cancer is the predominant cause of cancer mortality in males of Southern China and Taiwan." | ( Chang, CP; Lei, HY, 2009) |
| "Liver cancer is a heterogeneous disease in terms of etiology, biologic and clinical behavior." | ( Feng, ZQ; Guan, XH; Li, YH; Liu, YF; Zha, BS; Zhang, HL; Zhang, JP; Zhu, J; Zhu, XJ, 2009) |
| "Primary hepatocellular cancer is the fifth most common solid tumor worldwide." | ( Dank, M, 2010) |
| "Because only 20% of hepatic cancers are operable in patients, several types of regional therapy (RT) are emerging as alternate treatment modalities." | ( Alcala, MA; Bartlett, DL; Kwan, SY; Lang, M; Lee, YJ; Petoud, S; Shade, CM; Uh, H; Wang, M; Weber, SG, 2011) |
| "Liver cancer is one of the most commonly diagnosed cancers and the leading cause of death in human populations." | ( Chen, PY; Chueh, FS; Chung, JG; Ji, WT; Ma, CY; Yang, JS; Yu, CC, 2011) |
| "Because liver cancer is the most endemic cancer in Taiwan and in a large region of the world, we hereby investigate the anti-metastatic effects of BI and its mechanisms of actions in a highly metastatic human hepatocarcinoma SK-Hep-1 cells." | ( Chen, JY; Hu, ML; Huang, CS; Lyu, SC, 2012) |
| "Hepatocellular cancer is a significant global health problem yet the prognosis for the majority of patients has not changed significantly over the past few decades." | ( Asghar, U; Meyer, T, 2012) |
| "Liver cancer is one of the most common malignant cancers worldwide." | ( Lu, X; Wang, W; Wu, JZ; Yan, DL; Zhang, YW; Zhao, HW; Zhou, JR, 2012) |
| "Primary liver cancer is the fifth most common malignancy in men and the eighth in women worldwide." | ( Heerschap, A; Heijmen, L; ter Voert, EG; van Laarhoven, HW, 2011) |
| "Liver cancer is the most common form of cancer in Taiwan and it usually responds to chemotherapy." | ( Chen, PY; Chiang, SY; Chung, JG; Huang, HY; Ip, SW; Lin, JG; Lu, HF; Ni, CH; Wood, WG; Wu, CT; Wu, SH; Yang, JS, 2012) |
| "Primary liver cancer is one of the highly malignant tumours." | ( Chen, Y; Cui, JF; Leng, AM; Li, XH; Liu, T; Xiong, T; Yang, J; Zhang, G; Zhu, YN, 2012) |
| "Liver cancer is the fifth most common cause of cancer deaths worldwide." | ( Cameron, AG; Gao, X; Ke, S; Li, M; Lin, J; Qiu, X; Wang, W; Zhang, F; Zhu, VF; Zou, C, 2012) |
| "Liver cancer is the third leading cause of cancer death worldwide and about half of the patients with liver cancer require adjuvant therapy after surgical resection." | ( Chen, W; Feng, L; Nie, H; Zheng, X, 2012) |
| "Hepatocellular cancer is notorious for recurrence even after curative therapy." | ( Amir, M; Badshah, MB; Kazi, AN; Rahman, S; Riaz, H; Riaz, IB; Riaz, T, 2012) |
| "Liver cancer is a common human cancer with a high mortality rate and currently there is no effective chemoprevention or systematic treatment." | ( Bai, XM; Chen, M; Guo, Y; Leng, J; Ma, J; Shu, W; Wang, YH; Wang, YP; Xia, SK; Xu, Y; Zhang, H; Zhang, L; Zhang, M, 2013) |
| "Liver cancer is one of the most common tumors worldwide and drug resistance is a major obstacle to successful therapy." | ( Deng, T; Gao, J; Jia, Q; Zhang, X, 2013) |
| "Primary liver cancer is the fifth most common cancer worldwide and the third most common cause of cancer mortality." | ( Chang, CW; Wang, SN; Wei, RJ; Yeh, YT, 2013) |
| "Liver cancer is the fifth most common cause of cancer death worldwide." | ( Hsu, CM; Tsai, FJ; Tsai, Y; Wan, L, 2013) |
| "Liver cancer is one of the highest rate diseases in southeastern Asia." | ( Chang, HF; Wu, CH; Yang, LL, 2013) |
| "Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far." | ( Gan, Y; Huang, W; Li, T; Lou, G; Ma, X; Meng, Z; Tang, J; Van Ness, C; Wang, X; Wang, Y; Wu, J; Xu, R; Yen, Y; Zhou, H, 2013) |
| "Liver cancer is a malignant tumour with high morbidity and fatality rates that is common worldwide." | ( Deng, J; Dong, X; He, S; Huang, G; Liao, L; Liao, Z; Tang, B; Tang, K; Yang, H, 2014) |
| "Liver cancer is widespread liver malignancy in the world, for an estimated one million deaths annually." | ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014) |
| "Liver cancer is one of the most serious life-threatening diseases in the world." | ( Ahn, H; Kim, J; Lee, E; Lee, GS; Woo, HM, 2014) |
| "The development of hepatic cancer is tightly regulated by multiple intracellular signaling pathways." | ( Chen, H; Liao, J; Lin, J; Liu, L; Peng, J; Shen, A; Xu, T, 2014) |
| "Liver cancer is one of the leading causes of cancer death worldwide." | ( Cheung, WM; Ho, JW; Jie, M; Tong, PH; Yu, V; Zhou, Y, 2014) |
| "Liver cancer is one of the most drug-resistant cancer types, and cancer stem cells are related to drug resistance." | ( Ahn, YH; Jee, HG; Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, JH; Lee, M; Park, SY; Yoon, JH; Yu, SJ, 2015) |
| "Liver cancers are one of the deadliest known malignancies which are increasingly becoming a major public health problem in both developed and developing countries." | ( Bukong, TN; Saha, B; Szabo, G, 2015) |
| "Liver cancer is a leading cause of cancer deaths worldwide." | ( Chen, Q; Li, Y; Liu, W; Liu, X; Tang, H; Yang, X; Zhao, X, 2015) |
| "Liver cancer is the fifth most common cancer in human with male dominance." | ( Li, Z; Zhao, Y, 2015) |
| "Liver cancer is the third most common cancer, and the incidence as well as the mortality rate of liver cancer are on the increase." | ( Choi, YK; Heo, SH; Jeong, ES; Lee, KS; Lee, WK; Seo, JH, 2015) |
| "Liver cancer is the fifth commonest malignancy worldwide and the third leading cause of death." | ( Abdelaziz, A; Ashmawy, AM; Badary, O; ElKhoely, A; Hafez, HF; Mostafa, A; Shouman, SA, 2015) |
| "Liver cancer is the second-most frequent cause of cancer death in the world and is highly treatment resistant." | ( Chen, P; Chu, Y; Dong, Z; Hoffman, RM; Hu, T; Jeong, LS; Jia, L; Jiang, Y; Li, C; Li, P; Liang, Y; Pan, Y; Qi, H; Wei, D; Yang, M; Zhang, P, 2015) |
| "Although liver cancer is one of the most responsive types of cancer for reduction of incidence by metformin, the molecular mechanism of the suppression of mTOR in liver remains unknown." | ( Abudukadier, A; Fujita, Y; Fukushima, T; Harashima, S; Hosokawa, M; Inagaki, N; Obara, A; Ogura, M; Oguri, Y, 2015) |
| "Liver cancer is a major health-care concern and its oncogenic mechanisms are still largely unclear." | ( Eguchi, A; Feldstein, AE; Font-Burgada, J; Johnson, CD; Karin, M; Povero, D; Wree, A, 2015) |
| "Liver cancer is one of the most common human malignancies, and transforming growth factor-beta (TGF-β) pathway plays a key role in its pathogenesis." | ( Chen, J; Li, BX; Liu, J; Liu, MN; Sun, X; Wang, XH; Xu, CH; Xu, RL, 2016) |
| "Liver cancer is the fifth most frequently diagnosed type of cancer in men worldwide." | ( Cheng, Y; Fu, DZ; He, H; Liu, HY; Liu, YF, 2015) |
| "Liver cancers are characterized by high morbidity and mortality owing to few effective drugs for its treatment." | ( Lin, XY; Liu, YX; Shen, XJ; Song, YH; Yue, M; Zhou, SQ, 2015) |
| "Human liver cancer is the cancer commonly seen clinically." | ( Fan, L; Shen, X; Yu, F; Yu, Z, 2015) |
| "Liver cancer is one of the most common and highly malignant cancers in the world." | ( Bai, X; Chen, X; Liu, H; Pan, Y; Wang, N; Zhang, B, 2016) |
| "Primary liver cancer is a common cancer and the mortality of liver cancer ranks the second of all malignancy-related deaths in China." | ( Huo, S; Li, C; Liu, T; Yu, H; Zhang, J, 2015) |
| "Liver cancer is a common malignant tumor with high mortality." | ( Li, S; Zheng, L, 2016) |
| "Currently, primary liver cancer is the second leading cause of cancer-related deaths, and as the rates of other cancers have been declining, the incidence of liver cancer continues to rise with an alarming rate." | ( Dhar, D; Karin, M, 2016) |
| "Although primary hepatic neoplasms are less common than other intra-abdominal tumors in children, these neoplasms are a significant source of morbidity and mortality in the pediatric population." | ( Pugmire, BS; Towbin, AJ, 2016) |
| "Liver cancer is the fifth most commonly diagnosed malignancy, of which hepatocellular carcinoma (HCC) represents the dominating histological subtype." | ( Gao, Y; Gu, S; Li, X; Liu, G; Liu, Y; Wu, X; Zhang, D; Zhang, J; Zhu, G, 2016) |
| "Liver cancer is one of the common malignancies in many countries and an increasing cause of cancer death." | ( Chang, S; Jang, SJ; Kim, I; Lee, HY; Lee, SE; Park, S; Seol, HS; Singh, SR; Song, JS, 2016) |
| "The incidence of liver cancer is higher in men than in women." | ( Grant, DM; Hanna, D; Riedmaier, AE; Sugamori, KS, 2016) |
| "Human liver cancer is one of the most frequently diagnosed cancers worldwide." | ( Fang, K; Hsieh, CH; Kim, SH; Liu, CY; Ni, YL; Su, CL; Wang, JP; Yao, CF, 2016) |
| "Liver cancer is the second leading worldwide cause of cancer‑associated mortalities." | ( Biondi, A; Costa, C; Costanzo, V; Fago, L; Fenga, C; Ferrante, M; Fuccio Sanzà, G; Ledda, C; Loreto, C; Marconi, A; Matera, S; Palmucci, S; Pomara, C; Rapisarda, V; Zammit, C, 2017) |
| "Liver cancer is the second most common cause of death worldwide." | ( Chang, CH; Chang, YJ; Chen, LC; Chen, SJ; Lee, TW; Lee, WC; Shien, JH, 2017) |
| "Liver cancer is a common malignant tumor in the digestive system." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "Liver cancer is the second cause of death from cancer worldwide, without effective treatment." | ( Dai, Y; Guo, Q; He, Z; Wei, L; Yang, L; Yao, J; Zhao, L; Zhou, Y, 2017) |
| "Liver cancer is one of the common gastrointestinal cancers." | ( Bi, XX; Hu, WJ; Huang, Z; Su, GF; Wan, G; Zhang, L, 2017) |
| "The detection of liver cancer is imperfect and laborious." | ( Mitchell, GA; Yang, H, 2017) |
| "Liver cancer is one of the major diseases affecting human health." | ( Dong, H; Gao, M; Lv, L; Ma, X; Tian, L; Tian, Y; Wang, C; Xu, H; Zhang, C; Zhang, J, 2017) |
| "Liver cancer is the second leading cause of cancer death." | ( Fan, A; Ge, D; Liu, L; Ma, L; Ma, Y; Song, C; Wang, X; Xie, H; Xu, Y; Yu, X; Zhang, Q, 2017) |
| "Liver cancer is a globally leading malignancy that has a poor five-year survival rate of less than 20%." | ( Cheng, L; Fang, Y; Meng, F; Yang, W; Zhang, J; Zhong, Z, 2017) |
| "Liver cancer is one of the top five leading causes of cancer death worldwide." | ( Cheng, L; Fang, Y; Meng, F; Yang, W; Zhang, J; Zhong, Z, 2017) |
| "Liver cancer is an emerging global health issue, with rising incidence in both the United States and the economically developing world." | ( Egner, PA; Freedman, ND; Groopman, JD; Guallar, E; Kroker-Lobos, MF; Lazo, M; McGlynn, KA; Ramirez-Zea, M; Rivera-Andrade, A; Smith, JW; Torres, O; Wedemeyer, H, 2017) |
| "Primary liver cancer is a lethal malignancy with a high mortality worldwide." | ( Fan, XG; Fu, Y; Hu, X; Huang, Y; Li, N; Quan, J; Sun, L; Xiao, Y; Zhou, P; Zhou, R, 2017) |
| "Liver cancer is a globally prevalent cancer with poor prognosis." | ( Ai, S; Fu, H; Pan, T; Tang, L; Wang, F; Zhang, J, 2018) |
| "Liver cancer is a leading cause of cancer death worldwide, and novel chemotherapeutic drugs to suppress liver cancer are urgently required." | ( Lv, SX; Qiao, X, 2018) |
| "Liver cancer is one of the most common digestive system malignant solid tumors." | ( Chu, JZ; Ding, Y; Huang, Z; Wang, B; Wang, XL; Zhang, S; Zhou, S, 2018) |
| "Liver cancer is one of the top death causing cancers, traditional treatments have not settled for the requirement of patients." | ( Cheng, F; Cheng, J; He, J; Huang, Y; Liu, Z; Wei, X; Yan, T, 2018) |
| "Liver cancer is one of the most lethal malignancies with very poor prognosis once diagnosed." | ( Abu-Remaileh, M; Aqeilan, RI; Khalaileh, A; Pikarsky, E, 2018) |
| "Hepatic cancer is well known, and leading cancer around the world and remain asymptomatic diseases." | ( Falls, N; Kumar, V; Ramteke, PW; Singh Dangi, D; Singh, D; Singh, M; Verma, A; Yadav, E, 2018) |
| "Liver cancer is one of the most devastating types of cancer worldwide." | ( Li, H; Li, S; Li, Y; Meng, X; Xu, X; Zhang, D, 2019) |
| "Liver cancer is one of the leading causes of cancerous deaths worldwide." | ( Chen, XZ; Li, XJ; Li, YS; Shang, HC; Tang, HB; Tian, GH; Zhang, WK, 2018) |
| "Liver cancer is the third most common cause of global cancer-related deaths." | ( Hou, J; Jiang, S; Ning, Q; Wang, J; Xia, X; Yang, L; Zhang, Z, 2018) |
| "Liver cancer is the third leading cause of cancer-related deaths worldwide." | ( Chen, D; Gao, J; Lu, Y; Pan, X; Xie, F; Yin, C; Zhang, Y; Zou, H, 2018) |
| "The metastasis of liver cancer is a major cause of clinical treatment failure, restrain, and control the cancer metastasis is the major strategy of the treatment and prevention of the disease." | ( Ding, Y; Guo, H; Kong, D; Pang, D; Xu, C, 2018) |
| "Liver cancer is the leading cause of cancer‑related mortality worldwide and its incidence is increasing." | ( Deng, F; Hu, JQ; Hu, XP; Tian, XF; Zeng, XC; Zhang, W, 2018) |
| "Liver cancer is among the most common types of cancer worldwide." | ( Fang, D; Hou, JZ; Li, W; Liang, C; Niu, J; Sun, H; Wang, X; Xi, ZQ; Xie, SQ, 2019) |
| "Liver cancer is a kind of high mortality cancer due to the difficulty of early diagnosis." | ( Duan, Q; Jia, P; Li, Z; Liu, C; Sheng, W; Wang, Z; Zhang, X; Zhu, B; Zhu, H; Zhuang, Z, 2019) |
| "Liver cancer is a very common and significant health problem." | ( Dai, H; Hu, X; Li, M; Liu, D; Liu, W; Wang, P; Wang, X; Xie, L; Yang, W; Zhao, M, 2019) |
| "Liver cancer is the third most common cause of cancer related death worldwide." | ( Gu, D; Luo, J; Shao, G; Wen, S; Zeng, H; Zheng, J, 2019) |
| "BACKGROUND Liver cancer is one of the most commonly diagnosed cancers across the globe." | ( Chang, X; Gao, J; Hua, Y; Xiao, T; Zhu, Z, 2019) |
| "Liver cancer is a life threating disease as it is the fifth most common cancer and the third most common cause of death worldwide with no safe, efficient, and economic drug available for treatment." | ( Badria, FA; El-Senduny, FF; Youssef, MM; Zidane, MM, 2019) |
| "Liver cancer is the fifth most common cancer, and hepatocellular carcinoma (HCC) is the major liver tumor type seen in adults." | ( Gribskov, M; Wang, S, 2019) |
| "Liver cancer is the fifth most commonly occurring cancer in men and the ninth most commonly occurring cancer in women, worldwide, and is associated with a high mortality rate." | ( Guo, Y; Jin, J; Liu, Y; Sun, S; Wang, Z; Yang, X, 2019) |
| "Liver cancers are highly heterogeneous with poor prognosis and drug response." | ( Cen, J; Chen, X; Fu, Y; Gu, Y; He, S; Huang, X; Hui, L; Ji, Y; Li, C; Li, H; Li, Y; Lv, H; Meng, Z; Min, L; Qin, J; Qiu, Z; Shi, X; Shu, Y; Sun, L; Wang, C; Wang, P; Wang, W; Wang, X; Xie, F; Zhang, H; Zhang, Z; Zhou, H; Zhu, Z; Zhuang, L; Zou, K, 2019) |
| "Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year." | ( Ning, S; Xia, X; Zhou, L; Zhu, K; Zou, M, 2019) |
| "Liver cancer is a kind of lethal and aggressive malignant neoplasm with a high rate of relapse and metastasis after therapy." | ( Chen, W; Chen, Y; Feng, X; He, B; Liu, H; Lv, Z; Mao, Z; Sun, W; Tong, R; Wu, J; Yang, B; Yang, H; Yu, G; Yu, H; Zheng, S, 2019) |
| "BACKGROUND Liver cancer is one of the most common malignancies around the world and one of the major causes of cancer related mortality." | ( Huang, J; Huang, L; Liu, J; Liu, Y; Shi, C; Wang, G; Wang, J; Xu, X, 2019) |
| "Primary liver cancer is one of the leading causes for cancer-related death worldwide." | ( Huang, C; Huang, W; Luo, Z; Tu, S; Yan, X, 2019) |
| "Liver cancer is one of the leading causes of cancer mortality worldwide." | ( Duan, X; Lv, Y; Wang, Z; Zhao, Y, 2019) |
| "Liver cancer is the fifth (6." | ( Bajaj, S; Bansal, H; Fayaz, F; Kumar, S; Manchanda, S; Pottoo, FH, 2020) |
| "Liver cancer is a worldwide threat to human health." | ( Chen, W; Dai, G; Guo, Z; Huang, Y, 2020) |
| "Liver cancer is distinguished as an irredeemable disease." | ( Sun, S; Tao, S; Wang, Y; Yu, X, 2020) |
| "Liver cancer is a major health problem facing mankind." | ( Chen, XP; Li, GW; Li, Y; Zhang, Y, 2019) |
| "Liver cancer is one of the leading causes of death worldwide." | ( Huang, W; Wang, L; Zhan, J, 2019) |
| "Primary liver cancer is the second most frequent cause of cancer-related deaths." | ( Bai, T; Liang, R; Sun, Y; Wang, W; Zhou, L; Zhu, R, 2020) |
| "Liver cancer is the fifth most common cancer and the second cause of cancer-related deaths worldwide." | ( Abousalihac, M; Decaens, T; Ghelfi, J; Roth, GS; Seigneurin, A; Sengel, C; Teyssier, Y, 2020) |
| "Liver cancer is otherwise known as Hepatic cancer which originated from the liver." | ( K, L; P, S, 2021) |
| "Presently, liver cancer is still one of the malignant tumors with high mortality." | ( Feng, H; Jiang, H; Wang, L; Wang, M; Wang, X; Zhou, J, 2020) |
| "Liver cancer is a common cancer worldwide." | ( Chen, M; Wong, CM, 2020) |
| "Liver cancer is a malignant tumor with extremely high morbidity and mortality." | ( Li, G; Zhao, L; Zhao, M, 2020) |
| "Liver cancer is considered to be the sixth deadliest cancer worldwide." | ( Asghar, S; Manzoor, S; Umar, M; Waqar, W, 2020) |
| "Liver cancer is the fourth leading cause of cancer-related mortality worldwide and incidence is on the rise." | ( Bresnahan, E; Lindblad, KE; Lujambio, A; Ruiz de Galarreta, M, 2020) |
| "Liver cancer is a major threat to human life and health, and chemotherapy has been the standard non-surgical treatment for liver cancer." | ( Dong, C; Jiang, K; Li, R; Lv, J; Sun, R; Wang, L; Wang, Q; Yin, Z; Zhang, J; Zhou, Y, 2020) |
| "Liver cancer is an aggressive malignancy associated with high levels of mortality and morbidity." | ( Lim, ZW; Miserez, A; Ramanujan, RV; Varma, VB, 2020) |
| "BACKGROUND Liver cancer is a common cancer with high morbidity and mortality." | ( Wu, X; Zeng, X; Zhou, W, 2020) |
| "Liver cancer is the second leading cause of cancer‑related deaths." | ( Gao, Y; Ji, Z; Xia, Y; Xie, F; Xu, P; Yin, L; Zheng, W, 2020) |
| "Liver cancer is a devastating disease that has second highest cancer mortality rate worldwide." | ( Chen, B; Chen, SY; Cheng, SH; Huang, Z; Li, YX; Liu, JX; Pan, Y; Wang, WH; Wu, F; Xu, X; Zhao, YT; Zheng, X, 2020) |
| "Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated with very poor patient prognosis." | ( Cheng, Z; Jin, D; Wei-Qi, J, 2020) |
| "Liver cancer is the sixth most common cancer in terms of incidence and the fourth in terms of mortality." | ( Abdul Majid, N; Alshawsh, MA; Badroon, NA, 2020) |
| "Liver cancer is a disease with high mortality; it is often diagnosed at intermediate and advanced stages and has a high recurrence rate." | ( Jia, S; Jiao, Y; Li, Y; Liu, N; Pan, G; Wang, R, 2020) |
| "Primary liver cancer is a lethal cancer." | ( Bai, JX; Chen, YJ; Chou, JY; Fu, XQ; Lam, DF; Li, JK; Liang, C; Liu, YX; Wang, YP; Wu, JY; Wu, Y; Yin, CL; Yu, ZL; Zhu, PL, 2020) |
| "Liver cancer is the sixth most prevalent cancer worldwide and the third leading cause of cancer-related deaths." | ( Peng, XQ; Xu, XP; Yin, XM; Yu, Q, 2021) |
| "Liver cancer is the 6th leading cause of cancer related deaths in the US even though it ranks 14th in incidence." | ( Basha, R; Ghabach, B; Narra, K; Neerukonda, L; Sankpal, UT; Sharma, I; Sridhar, S, 2020) |
| "Liver cancer is the fourth leading cause of cancer-related mortality globally, of which hepatocellular carcinoma (HCC) accounts for 85-90% of total primary liver cancer." | ( Chen, CH; Huang, FM; Lee, CJ; Lee, WT; Pan, YR; Su, TF; Wu, TK, 2020) |
| "Liver cancer is the third leading cause of death in the world and the fifth most often diagnosed cancer." | ( Jain, AK; Mishra, K; Sahu, H; Thareja, S, 2021) |
| "Liver cancer is a serious liver disease in which hepatoma cells and activated hepatic stellate cells (HSCs) overproduce extracellular matrix (ECM), which involves the Golgi apparatus." | ( Gong, T; Luo, J; Ma, L, 2020) |
| "Primary liver cancer is predicted to be the sixth most common cancer and the fourth leading cause of cancer mortality worldwide." | ( Sunami, Y, 2020) |
| "The reason why liver cancer is difficult to cure is that in addition to the low lethality of cancer drugs to cancer cells, another important factor is that the drugs do not have liver targeting, and there is no way to efficiently deliver anti-cancer drugs to the liver lesions." | ( Chen, Y; Fan, W; Hu, Z; Liao, W; Tang, Y; Wang, C; Zhang, Y, 2021) |
| "Liver cancer is one of the most common cancer worldwide with a high mortality." | ( Badone, B; Bonanomi, M; Coccetti, P; Gaglio, D; Maffioli, E; Milanesi, R; Nonnis, S; Tedeschi, G; Tripodi, F; Vescovi, M, 2020) |
| "We also show that liver cancer is dependent on TERT reactivation and telomere maintenance, which could be targeted through a novel therapeutic approach called antisense oligonucleotides." | ( Amaddeo, G; Bayard, Q; Blanc, JF; Calderaro, J; Caruso, S; Franconi, A; Ganne, N; Guettier, C; Hirsch, TZ; Kim, Y; MacLeod, AR; Morcrette, G; Nault, JC; Ningarhari, M; Noblet, B; Paradis, V; Rebouissou, S; Védie, AL; Ziol, M; Zucman-Rossi, J, 2021) |
| "Liver cancer is a critical clinical condition with augmented malignancy, rapid progression, and poor prognosis." | ( Alahmadi, TA; Chinnathambi, A; Li, Z; Lu, B; Xie, Y; You, Y; Zhang, L; Zhu, F, 2021) |
| "Liver cancer is classified amongst the foremost causes of tumor-associated deaths around the world." | ( Aliya, S, 2021) |
| "Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes." | ( Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT, 2021) |
| "Liver cancer is the most common type of cancer in many countries." | ( Ali, IAI; Boraei, ATA; Eltamany, EH; Gebriel, SM; Nafie, MS, 2021) |
| "Liver cancer is currently the third leading cause of cancer related death worldwide, and Hepatocellular Carcinoma (HCC) accounts for 75-90% of all liver cancer cases." | ( de Oliveira, S; Martínez-Navarro, FJ; Michael, C, 2021) |
| "Liver cancer is one of the most common types of malignant tumor, and is characterized by high malignancy, rapid progression, high morbidity and mortality." | ( Hu, J; Wen, L; Yang, J; Zhang, J, 2021) |
| "However, liver cancer is mostly found at an advanced stage, is difficult to remove by surgery, and has a very high recurrence rate after surgery." | ( Li, Z; Liu, H; Tan, H; Zhang, Y, 2021) |
| "Liver cancer is one of the most common and high recurrence malignancies." | ( Chen, A; Chen, L; Chen, S; Dai, X; He, F; Huang, C; Jiang, Y; Li, S; Li, T; Lian, J; Sun, L; Xiang, L; Xiao, H; Yan, X; Yang, M; Zhang, Y, 2021) |
| "Liver cancer is the sixth most common cancer worldwide with high morbidity and mortality." | ( Kongtawelert, P; Phitak, T; Pothacharoen, P; Shwe, TH; Wudtiwai, B, 2021) |
| "Liver cancer is the most frequent cancer, making it the leading cause of cancer death globally." | ( Guest, PC; Nguyen, TT; Van Vo, G; Vo, TK, 2022) |
| "Liver cancer is one of the most common malignancies that is difficult to treat due to late diagnosis and chemo-resistance." | ( Fan, H; Meng, F; Qu, K; Ren, B; Ren, L; Wang, H; Wang, Z; Yu, W; Zhou, L, 2021) |
| "Liver cancer is a leading cause of cancer‑related mortality globally." | ( Chiu, CC; Hsiao, MH; Hsu, TC; Huang, PJ; Tzang, BS; Yow, JL, 2021) |
| "Liver cancer is a gastrointestinal malignant tumor with high lethality." | ( Chen, Y; Qu, Y; Wang, J; Zhang, Y, 2021) |
| "Liver cancer is one of the commonly detected malignancy and third highest cause of deaths caused by cancer worldwide." | ( Hu, X; Li, J, 2021) |
| "Liver cancer is a leading cause of cancer death globally." | ( Abdulla, MH; Al-Eidi, H; Alehaideb, ZI; Alghamdi, SS; Alghanem, B; Kokane, M; Matou-Nasri, S; Mohamed, SA; Rameshbabu, S; Suliman, RS; Venkatraman, A, 2022) |
| "Liver cancer is one of the most lethal cancers having worldwide prevalence." | ( Alemohammad, H; Asadzadeh, Z; Baradaran, B; Farsad, N; Hemmat, N; Motafakkerazad, R; Najafzadeh, B; Vasefifar, P, 2022) |
| "Liver cancer is the sixth most diagnosed cancer worldwide with few available curative treatments." | ( Azhie, A; Bhat, M; Grant, RC; Herman, M; Knox, JJ; Wang, L, 2022) |
| "Liver cancer is the third most common cancer, with increasing morbidity and mortality rates worldwide." | ( Chen, X; Dong, P; Huang, Z; Liu, H; Zeng, X, 2022) |
| "Liver cancer is one of the most deadly and prevalent cancers." | ( He, Z; Hong, W; Lu, W; Qiu, H; Xie, J; Zeng, W; Zhong, W; Zhou, Z, 2022) |
| "Liver cancer is a malignant cancer phenotype for which there currently remains a lack of reliable biomarkers and therapeutic targets for disease management." | ( Chen, K; Dai, ZT; Huang, Y; Liao, XH; Liu, H; Lu, ZX; Ponnambalam, S; Shen, C; Wang, J; Wu, H; Wu, Y; Xiang, Y; Zhang, HM; Zhang, TC; Zong, QB, 2022) |
| "Currently, Liver cancer is the fifth most common tumor and the second most important reason for cancer-related death in the world." | ( Chen, D; Lei, J; Li, Y; Lin, B; Su, J; Wang, Y; Wu, Y; Zhang, K; Zheng, R; Zhu, B, 2022) |
| "Poor prognosis in liver cancer is due to its high frequency of intrahepatic metastasis." | ( Hazama, S; Iida, M; Ioka, T; Kimura, Y; Matsui, H; Matsukuma, S; Nagano, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S; Yoshimura, K, 2022) |
| "The development of liver cancer is strongly tied with fibrosis and cirrhosis that alters the microenvironmental landscape, especially ECM composition." | ( Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y, 2022) |
| "Liver cancer is one of the common malignancies." | ( Ding, H; Han, L; Li, S; Pu, W; Shao, Y; Wang, T; Yin, S; Yu, H; Zhou, S, 2023) |
| "Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases." | ( Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY, 2022) |
| "Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases." | ( Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY, 2022) |
| "Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases." | ( Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY, 2022) |
| "Liver cancer is one of the most common tumors with the seventh-highest incidence and the third-highest mortality." | ( Chai, Z; Dong, W; Jin, J; Qiu, Z; Wang, J; Wang, X; Xia, Z; Yang, Z; Zhang, Q; Zhang, T, 2022) |
| "Liver cancer is one of the most common tumors with the seventh-highest incidence and the third-highest mortality." | ( Chai, Z; Dong, W; Jin, J; Qiu, Z; Wang, J; Wang, X; Xia, Z; Yang, Z; Zhang, Q; Zhang, T, 2022) |
| "Liver cancer is the fourth most prevalent and the second most lethal cancer in China." | ( Fan, J; Gao, Q; Shi, J; Xie, D; Zhou, J, 2023) |
| "Liver cancer is a kind of malignant tumor with poor sensitivity to chemotherapy." | ( Chen, M; Chen, W; Chen, X; Ding, J; Fang, S; Ji, J; Shen, L; Shu, G; Su, Y; Tu, J; Zhao, Z; Zheng, L, 2023) |
| "Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide." | ( Liu, Y; Ouyang, W; Peng, Z; Wang, R; Wen, P; Xing, Y; Yuan, Y; Zhang, S, 2023) |
| "Liver cancer is highly heterogeneous and has a poor prognosis." | ( Chen, J; Hu, C; Huang, X; Li, Y; Zhang, Y, 2023) |
| "Liver cancer is the sixth most prevalent cancer and ranks third in cancer-related death, after lung and colorectal cancer." | ( Abdalkareem Jasim, S; Abulkassim, R; Ahmad, I; Hasan Hammoodi, S; Jaafar Saadoon, S; Javed Ansari, M; K Alkhafaje, W; M Hameed, N; M Kadhim, M; Mustafa, YF; Romero Parra, RM; Shelash Al-Hawary, SI, 2023) |
| "Centrally located liver cancer is usually defined as a tumor located at segments 4, 5, or 8 that requires resection of the middle section of the liver." | ( Duan, J; Li, A; Min, J; Shang, C; Wei, J; Xie, J; Yang, W; Zhang, H; Zhong, J; Zhuo, W, 2023) |
| "Liver cancer is the most common and frequentlyoccurring cancer." | ( Chen, A; Chen, L; Dai, X; He, M; Li, S; Lian, J; Liao, Q; Liu, D; Shan, M; Sun, L; Xiang, L; Yang, M; Zhai, L; Zhang, Y, 2023) |
| "Liver cancer is a serious global health problem and a common cause of cancer-related death." | ( Wang, T; Wang, WT, 2023) |
| "Liver cancer is an extremely common cancer with the highest mortality rate and poor prognosis." | ( Bai, Z; Li, J; Ma, R; Tian, J; Xi, J; Xi, L; Zhang, B; Zhang, M, 2023) |
| "Primary liver cancer is one of the most common malignant cancers of the digestive system that lacks effective chemotherapeutic drugs in clinical settings." | ( Bai, YP; Li, L; Liu, YQ; Luo, HB; Peng, LZ; Wang, ZP; Xu, CR; Yan, JX; Yang, CJ; Zhang, M; Zhang, ZJ; Zhu, LZ, 2023) |
| "Liver cancer is the third leading cause of cancer-related mortality, and hepatocellular carcinoma (HCC) is the most common form of liver cancer, and it usually occurs in the setting of chronic liver disease and cirrhosis." | ( Firtina Karagonlar, Z; Sariyar, E, 2023) |
| "Liver cancer is one of the most lethal malignant cancers worldwide." | ( Chen, VC; Hsu, TC; Huang, JY; Huang, SL; McIntyre, RS; Tzang, BS, 2023) |
| "Liver cancer is the third leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) is the most common type of liver cancer." | ( Alotaibi, H; Atabey, N; Baris, E; Demir, AB; Kaner, UB; Koc, A, 2023) |
| "Liver cancer is a topical global health issue." | ( Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y, 2023) |
| "Liver cancer is one of common types of cancer with poor prognosis and limited therapies." | ( Guo, Z; Hua, H; Jiang, Y; Liu, Y; Wang, J; Zhang, H; Zhang, J, 2024) |
| "Liver cancer is among the leading cause of cancer related death worldwide." | ( He, B; Qiu, M; Raza, F; Su, J; Yuan, WE; Zheng, M; Zhong, H, 2023) |
| "Liver cancer is the second main reason of death globally." | ( Dilshad, E; Javid, S, 2023) |
| Excerpt | Reference |
|---|
| "Patients with liver cancer were treated with adriamycin." | ( Olweny, CL, 1978) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "Ten patients with unresectable primary liver cancer, eight of whom had elevated serum alpha-fetoprotein levels, were treated with intrahepatic fluorodeoxyuridine (FUDR) and mitomycin C administered through an implantable pump." | ( Atiq, OT; Botet, J; Kemeny, N; Niedzwiecki, D, 1992) |
| "Forty patients with unresectable liver cancer were treated by hepatic arterial infusion chemotherapy plus embolization (HAI+HAE)." | ( Wang, JH, 1992) |
| "We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy." | ( Noguchi, S; Shibata, N, 1992) |
| "The risk of americium-induced liver cancer in beagle dogs that received long-term dietary ethanol was two to three times that of their nonalcoholic cohorts, even though the radionuclide retention time in hepatic tissue was shortened by the alcohol treatment." | ( Lloyd, RD; Mays, CW; Miller, SC; Shabestari, L; Taylor, GN, 1992) |
| "Four patients with metastatic liver cancer were treated with Yttrium-90 to deliver radiation doses above that considered tolerable when given by conventional external sources." | ( Burton, MA; Gray, BN; Kelleher, D; Klemp, P; Matz, L, 1990) |
| "In the treatment of metastatic liver cancer, arterial chemotherapy and transarterial embolization are the major modality." | ( Abe, M; Hirai, K; Kubo, Y; Majima, Y, 1987) |
| "Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy." | ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989) |
| "Seven cases of liver cancer with replaced right hepatic artery were treated with arterial infusion therapy using implanted reservoir." | ( Gondo, H; Ishimura, M; Kamiyama, T; Matsuoka, S; Misawa, K; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Tamura, M; Une, Y, 1989) |
| "In the patients with metastatic liver cancer, tumor regression over 50% was observed in 65% of the patients treated with chemoembolization alone and in 33% of those with chemoembolization and HT." | ( Itani, K; Kondo, M; Oyamada, H; Seto, O; Sugino, S; Tainaka, K; Yoshikawa, T, 1988) |
| "No increase in incidence of liver neoplasms was observed after treatment with any of the four compounds, thenyldiamine, chlorothen, methafurylene, or methaphenilene, although each differed structurally from methapyrilene only in one atom or one position of substitution." | ( Kovatch, RM; Lijinsky, W, 1986) |
| "Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil." | ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985) |
| "The MMC MS treatment for metastatic hepatic cancer had superiority to the conventional infusion treatment at p = 0." | ( Endoh, F, 1987) |
| "Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU." | ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987) |
| "Three patients with primary liver cancer were treated with DSM (600-1200 mg) and ADR (20-60 mg), and five with metastatic liver cancer were treated with DSM and MMC (10-20 mg)." | ( Fujita, M; Nakamura, H; Ota, J; Taguchi, T, 1988) |
| "Eight hepatocellular cancer patients and eighteen metastatic liver cancer patients were treated with intrahepato-arterial infusion of CDDP (cis-diamminedichloro-platinum II) plus 5-FU (5-fluorouracil); CDDP (0." | ( Ikeda, Y; Inoue, Y; Ishiguro, M; Koga, S; Maeta, M; Wakatsuki, T, 1987) |
| "Of the 118 patients with primary liver cancer treated in our clinic during a 6 year 7 month period, 11 patients had cholangiocellular carcinoma of the liver." | ( Kawarada, Y; Mizumoto, R, 1984) |
| "Since 1977 multiple primary liver cancers including AGS developed in thorotrast-administered patients in both groups." | ( Hosoda, S; Kido, C; Takahashi, S; Tateno, H; Yamada, S, 1983) |
| "Twenty liver cancer patients, including 9 hepatocellular carcinoma and 11 with metastatic liver cancer, were treated by intra-arteral one-shot chemotherapy." | ( Fujii, H; Katake, K; Miyoshi, M; Nishimura, S; Nishitani, T; Seki, S; Suyama, Y; Tada, M; Tanaka, Y, 1983) |
| "To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0." | ( Hirooka, Y; Kanayama, H; Koga, S; Maeta, M; Murakami, A; Oda, M; Osaki, Y, 1984) |
| "To prevent probable occult metastatic liver cancer from progressing to clinical disease, the author used internal radiation therapy as an effective adjuvant to surgical excision of primary Dukes' C colonic cancer." | ( Grady, ED, 1984) |
| "Ascitic fluid of patients with primary liver cancer was shown to contain a latent thiol proteinase which can be activated by pepsin treatment or by autolysis at acidic environment." | ( Bures, L; Dufek, V; Král, V; Matous, B, 1984) |
| "The incidence of liver neoplasms in the rats given pyrilamine in the drinking-water did not differ from that in the untreated controls, of which five males and three females had neoplastic nodules in the liver." | ( Lijinsky, W, 1984) |
| "The incidence of liver neoplasms, which were carcinomas and neoplastic nodules, in the two groups of females treated with sodium nitrite in feed was significantly higher than in the controls, but there was no significant difference in the males." | ( Kovatch, R; Lijinsky, W; Riggs, CW, 1983) |
| "Sixteen patients were treated for liver cancer (primary and metastatic) by a combination of internal radiation therapy with intra-arterial yttrium 90 microspheres and regional hyperthermia with electromagnetic radiation." | ( Auda, SP; Grady, ED; McGinley, PH; McLaren, J, 1983) |
| "Patients with unresectable liver cancer (primary and metastatic) were treated with a newly-devised arterial infusion chemotherapy using Cis-DDP and its antidote Sodium thiosulfate (STS)." | ( Abe, R; Akiyoshi, T; Arinaga, S; Asoh, T; Baba, T; Koba, F; Miyazaki, S; Shirasaka, C; Takeuchi, Y; Tsuii, H; Uchida, I; Wada, T, 1983) |
| "Eighteen patients with nonresectable liver cancer were treated by dearterialization of the liver." | ( Inokuchi, K; Nagasue, N, 1982) |
| "Ninety-four patients with primary liver cancer have been treated with electrochemical therapy (ECT) in our hospital." | ( Wang, HL, 1994) |
| "Fischer 344 rats readily develop liver cancer when exposed to aflatoxin B1 (AFB1) but dietary administration of the antioxidant ethoxyquin (EQ) provides protection against hepatocarcinogenesis." | ( Hayes, JD; Judah, DJ; Neal, GE, 1993) |
| "The clinical therapy in six liver cancer patients was successful." | ( Pu, YL; Shi, TS; Wang, YM; Zhao, YL; Zhu, JG, 1995) |
| "Similarly, when CBRH-7919 rat liver cancer cells were treated with phorbol 12-myristate 13-acetate, a proliferation stimulator of the cells, gamma-GT and Ca2+-dependent activities of PC-PLC and the expression of alpha-fetoprotein increased significantly." | ( Chen, H; Huang, Y; Lu, H; Wu, X; Zhou, L, 1997) |
| "Primary liver cancer is a significant health problem; treatment options are limited and prognosis is poor." | ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "Human liver cancer cell lines HepG2 and Hep3B were treated with 5-azaC alone, butyrate alone, or 5-azaC and butyrate." | ( Evers, BM; Li, J; Wang, X; Wang, XM, 1998) |
| "Many cases with metastatic hepatic cancer have a poor prognosis because of the appearance of extrahepatic lesions in spite of the fact that a partial response can be obtained by hepatic arterial infusion chemotherapy." | ( Hasegawa, K; Ichikawa, T; Kawai, S; Kirihara, M; Kume, S; Maruo, H; Tominaga, S, 1998) |
| "Patients with unresectable liver cancer treated with intra-arterial doxorubicin lived no longer than untreated controls (median 8 months (range 1-56) compared with 7 months (range 1-28))." | ( Hafström, L; Holmberg, S; Lindnér, P; Naredi, P; Scherstén, T, 1998) |
| "Treatment of patients with primary liver cancer is still an unsolved problem." | ( Hafström, L; Holmberg, S; Lindnér, P; Naredi, P; Scherstén, T, 1998) |
| "The most frequent form of primary liver cancer is hepatocellular carcinoma, which is essentially refractory to chemotherapy." | ( Diaconu, CC; Kéri, G; Szathmári, M; Venetianer, A, 1999) |
| "A novel strategy for immune therapy of liver neoplasms with the use of redox-modulating agents has been proposed." | ( Inamoto, T; Tsuyuki, S; Yamaoka, Y; Yamauchi, A, 1999) |
| "Seventeen patients with liver cancer were treated with glass microspheres from August 1996 to May 1998." | ( Cao, X; He, N; Li, J; Lu, T; Sun, J; Tan, J; Yang, J; Zhang, C, 1999) |
| "Twenty-nine advanced primary liver cancer and 4 gallbladder cancer patients were treated with As2O3 injection only, 15 mg i." | ( He, Z; Qian, J; Qin, S, 2001) |
| "For most patients with primary liver cancer surgical treatment is not feasible and prognosis without treatment is poor." | ( Achenbach, T; Junginger, T; Pitton, MB; Schunk, K; Seifert, JK, 2002) |
| "These results suggest that (1) intrahepatic cancer responds to 5FC when cells express yCD; (2) the luciferin-luciferase system permits non-invasive real time imaging of viable intrahepatic cancer; and (3) this system can be used to carry out gene therapy experiments using yCD adenovirus." | ( Dornfeld, KJ; Kievit, E; Lawrence, TS; Nyati, MK; Rehemtulla, A; Ross, BD; Rynkiewicz, SD; Symon, Z, 2002) |
| "This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis." | ( Beppu, T; Doi, K; Hirota, M; Ishiko, T; Ogawa, M, 2002) |
| "Transarterial therapy for primary liver cancer is gaining more acceptance." | ( Kim, P; Prapong, W; Razavi, MK; So, SK; Sze, DY, 2002) |
| "In 5 patients with metastases of liver cancer in retroperitoneal lymph nodes who received 1 to 3 times of PEI, all the foci treated were completely necrotic and smaller demonstrated by dynamic contrast-enhanced CT or MRI 3 months later." | ( Hao, XY; Ren, FY; Shao, CW; Tian, JM; Wang, MJ; Wang, PJ; Xiao, Y; Yuan, M; Zuo, CJ, 2004) |
| "The observed excess mortality from liver cancer is compatible, to some extent, with exposures that may have occurred during the manufacture of phenolic and furfuryl resins treated products, although a role of lifestyle factors and viral infections cannot be excluded." | ( Ceppi, M; Covolo, L; Donato, F; Garattini, S; Gelatti, U; Merlo, DF; Simonati, C, 2004) |
| "65 patients with advance stage of liver cancer were randomly into two groups, the control group (regular protective therapy) and the treatment group (regular protective therapy + JWSJZT)." | ( Chen, X; Hu, P; Huang, G; Xu, B; Zhang, B; Zhang, Y, 2004) |
| "Survival correlated with pretreatment Cancer of the Liver Italian Program scores ( P = ." | ( Carr, BI; Geschwind, JF; Goin, JE; Goin, KA; Roberts, CA; Salem, R; Soulen, MC; Thurston, KG; Van Buskirk, M, 2004) |
| "Forty-nine patients with liver cancer were retrospectively divided into two groups: Treatment group, on the basis of TACE, 23 patients received oral capecitabine at 2500 mg/m(2), twice-daily for 14 days followed by 7-day rest period and repeated in every three week intervals for more than two cycles." | ( Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH, 2004) |
| "Thirty patients with 38 lesions of liver cancer were treated by the CT mediated intratumor injection of HAS6." | ( Hongmei, Z; Lei, Z; Ni, J; Suhong, H; Weijian, F; Yanjie, Z; Yi, C; Zan, L, 2006) |
| "In rat liver cancer, a functional sodium iodide symporter expression was triggered as from the early preneoplastic steps, and was amplified during clonal tumor cell expansion, allowing complete tumor suppression after (131)I radiotherapy." | ( Bioulac-Sage, P; Boisgard, R; Bréchot, C; Calès, P; Clerc, J; Faivre, J; Guettier, C; Hervé, J; Liu, B; Roux, J; Samuel, D; Tavitian, B; Valogne, Y; Yilmaz, F, 2007) |
| "Primary and secondary liver cancer have longtime been characterized by an overall poor prognosis since the majority of patients are not candidates for surgical resection with curative intent, systemic chemotherapy alone has rarely resulted in long-term survival, and the role of conventional external beam radiation therapy has traditionally been limited due to the relative sensitivity of the liver parenchyma to radiation." | ( Hobbelink, MG; Nijsen, JF; van Het Schip, AD; Vente, MA; Zonnenberg, BA, 2007) |
| "The increased risk of primary liver cancer in ursodeoxycholic acid-treated patients was 3-fold (HR, 3." | ( Aithal, GP; Card, TR; Jackson, H; Logan, R; Solaymani-Dodaran, M; West, J, 2007) |
| "Patients with intrahepatic cancer undergoing conformal radiotherapy underwent dynamic contrast-enhanced computed tomography (to measure perfusion distribution) and an indocyanine extraction study (to measure liver function) before, during, and 1 month after treatment." | ( Balter, JM; Ben-Josef, E; Cao, Y; Francis, IR; Knol, JA; Lawrence, TS; Normolle, D; Pan, C; Platt, JF; Ten Haken, RK, 2008) |
| "Fifty primary liver cancer patients were randomly divided into two groups: therapeutic and control group, and all were treated with transfemoral artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5-Fu 750 mg, CF 300 mg and lipiodol 20 ml." | ( Li, T; Li, ZW; Wen, HC, 2007) |
| "Advanced hepatocellular cancer (HCC) is a highly vascularised tumor with limited treatment options." | ( Malfertheiner, P; Treiber, G; Wex, T, 2009) |
| "Patients with primary or secondary liver cancer who are not suitable for surgical resection may be treated with selective internal radiation therapy with yttrium-90." | ( Bester, L; Chernyak, I; Freund, J; Richardson, M, 2008) |
| "Human liver cancer line 7402 was treated by Tet and Nap in various concentrations respectively or in combination in vitro,and then the cell growth was assayed by MTT method, periodic return changes were observed by aridine orange (AO)-/ethidiumbromide (EB) fluorescent staining, DNA gel eledtophoresis and flow cytometry, and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method." | ( Chen, XB; Deng, WY; Han, LL; Li, N; Luo, SX; Zhou, MQ, 2008) |
| "In patients with unresectable primary liver cancer, HAI therapy can be effective and safe." | ( Blumgart, LH; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Tse, A, 2009) |
| "Conventional chemotherapy of liver cancer fails to provide satisfactory remission and may cause serious side effects, thus it is crucial to derive alternative treatments that effectively inhibit cancer cell growth with known mechanisms of action." | ( Auyeung, KK; Ko, JK, 2009) |
| "In summary, human liver cancer cells treated with chrysophanol exhibited a cellular pattern associated with necrosis and not apoptosis." | ( Chou, ST; Chung, JG; Hsia, TC; Huang, AC; Kuo, CL; Lee, TH; Lu, CC; Lu, HF; Wood, WG; Yang, JS, 2010) |
| "CD133+ liver cancer cells are characterized by resistance to chemotherapy, self-renewal, multilineage potential, increased colony formation, and in vivo cancer initiation at limited dilution." | ( Ding, W; Rountree, CB; You, H, 2010) |
| "Treatment options for advanced hepatocellular cancer (HCC) are limited." | ( Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A, 2012) |
| "Twenty-eight patients with liver cancer were treated with Nexavar." | ( Kan, HP; Tan, YF; Wang, Y; Zhou, J, 2010) |
| "Because only 20% of hepatic cancers are operable in patients, several types of regional therapy (RT) are emerging as alternate treatment modalities." | ( Alcala, MA; Bartlett, DL; Kwan, SY; Lang, M; Lee, YJ; Petoud, S; Shade, CM; Uh, H; Wang, M; Weber, SG, 2011) |
| "The relative resistance of liver cancer cells to ionizing radiation (IR) and chemotherapeutic agents due to autophagic response limits the available treatment options for this type of cancer." | ( Chiang, HC; Chou, FP; Kuo, WH; Liu, WS; Tseng, HC; Tyan, YS, 2011) |
| "Seventy five patients with liver cancer adjacent to major blood vessels were randomly divided into two groups: PRFA+PEI therapy group (38 cases) and PRFA control group (37 cases)." | ( Du, JD; Jiao, HB; Li, T; Li, ZC; Li, ZL; Liu, R; Xiang, DD; Yin, HN; Zhu, ZM, 2011) |
| "Our results suggest that Cancer of the Liver Italian Program scores or Okuda stages, along with performance status, can be useful in stratifying patients with advanced HCC treated with sorafenib." | ( Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE, 2011) |
| "The failure of existing treatments for liver cancer has recently been attributed to the existence of cancer stem cells, which are difficult to kill using current drugs due to their chemoresistant properties as well as their ability to stimulate neoangiogenesis." | ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
| "Mesenchymal liver cancer post-EMT demonstrates TISC characteristics such as tumor-sphere formation but are not resistant to cytotoxic therapy." | ( Dang, H; Ding, W; Emerson, D; Rountree, CB, 2011) |
| "We report on five patients with liver cancer, not suitable for conventional therapies, treated with hepatic intra-arterial administration of fotemustine in combination with IFNα2b." | ( Arcoria, D; Calì, S; DI Maggio, EM; Ferraù, F; Malaponte, E; Panebianco, V; Parisi, A; Romeo, P; Vasta, F; Vitale, FV, 2011) |
| "Discussion Refractory biliary tract and hepatocellular cancers are difficult to treat, and no chemotherapy or biologically targeted therapies have impacted survival." | ( Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M, 2012) |
| "According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence." | ( Lee, IJ; Seong, J, 2011) |
| "According to Barcelona Clinic Liver Cancer (BCLC) staging, the curative treatment group included early stage HCC (BCLC-A), and the noncurative treatment group consisted of intermediate and advanced stages of HCC (BCLC-B, C)." | ( Choi, JY, 2011) |
| "Similarly, treatment of liver cancer cell lines HepG2 and Huh7, colon cancer cell line RKO, and breast cancer cell line MCF-7 with SAMe or its metabolite 5'-methylthioadenosine (MTA) reduced only Ubc9 protein level." | ( Giordano, P; Lu, SC; Mato, JM; Pascale, RM; Ramani, K; Tomasi, I; Tomasi, ML; Xu, J, 2012) |
| "Considering the high incidence of hepatic cancer and limited therapeutic approaches for treating this disease, it is important to develop liver cancer-specific chemopreventive agents." | ( Ahn, B; Kim, DJ; Kim, TM; Kim, TW; Shin, SK; Youm, SY, 2012) |
| "Seventeen patients with intrahepatic cancer undergoing focal radiation therapy (RT) were enrolled in institution review board-approved prospective studies to obtain DCE-MRI (to measure regional perfusion) and indocyanine green (ICG) clearance rates (to measure overall liver function) prior to, during, and at 1 and 2 months after treatment." | ( Balter, JM; Ben-Josef, E; Cao, Y; Feng, M; Hussain, H; Johnson, TD; Lawrence, TS; Normolle, D; Pan, C; Ten Haken, RK; Wang, H, 2013) |
| "Advanced hepatocellular cancer (HCC) is an incurable disease with limited options for systemic treatment." | ( Byrne, M; Estfan, B; Kim, R, 2013) |
| "The levels of liver cancer markers, including α-fetoprotein and carcinoembryonic antigen, were substantially increased by NDEA treatment." | ( Fareed, S; Hussain, T; Rao, CV; Siddiqui, HH; Vijayakumar, M, 2012) |
| "Treatment of Hep3B, human liver cancer cells, with the prodrug 5-fluorocytosine (5-FC) in the presence of HB1." | ( Choi, KC; Hwang, KA; Jeung, EB; Kang, NH; Kim, HC; Kim, SU; Yi, BR, 2012) |
| "Thirty advanced-stage liver cancer cases (primary and metastatic) treated with RE over a 3-year period were included." | ( Carpizo, DR; Foran, DJ; Gendel, VM; Gensure, RH; Jabbour, SK; Lee, VM; Nosher, JL; Yang, L, 2012) |
| "Using liver cancer-derived cell lines, we specifically show that the IRE1 and phosphorylated extracellular signal-regulated kinase arms of the unfolded protein response (UPR) become activated upon sorafenib treatment, whereas the ATF6 arm is inhibited." | ( Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P, 2012) |
| "For recurrence of hepatocellular cancer after hepatic resection or local ablative therapy, compared with controls, participants receiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0." | ( Amir, M; Badshah, MB; Kazi, AN; Rahman, S; Riaz, H; Riaz, IB; Riaz, T, 2012) |
| "The heterogeneity of liver cancer, in particular hepatocellular carcinoma (HCC), portrays the requirement of multiple targets for both its treatment and prevention." | ( Cao, M; Nelson, D; Prima, V; Svetlov, S, 2013) |
| "The multi-targeted therapy for liver cancer has been considered as a novel strategy to fight hepatocellular carcinoma." | ( Dong, X; Jiang, Y; Jin, HW; Li, N; Ma, ZZ; Tu, PF; Zeng, KW, 2013) |
| "The nude mouse model of human liver cancer was made by transplantation of human highly metastatic liver cancer cell line HCCLM3 cells, and the tumor-bearing nude mice were treated with sorafenib, 5-Fu or both, respectively, and mock-treated tumor-bearing nude mice as negative control." | ( Shen, HJ; Wang, YH; Xu, J, 2013) |
| "According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, patients with advanced stage (BCLC-C) hepatocellular carcinoma (HCC) are recommended for systemic treatment or palliative therapy." | ( Blaszkowsky, LS; Ganguli, S; Kalva, SP; Liu, R; Pectasides, M; Rachamreddy, N; Surakanti, S; Wicky, S; Yeddula, K; Zhu, AX, 2014) |
| "The prognosis for patients with hepatocellular cancer (HCC) undergoing transarterial therapy (TACE/TAE) is variable." | ( Benini, R; Burroughs, AK; Fox, R; Hackshaw, A; Johnson, P; Kadalayil, L; Marelli, L; Meyer, T; O'Beirne, J; Pallan, L; Palmer, DH; Yu, D, 2013) |
| "Primary liver cancer has one of the highest mortality rates of all cancers, and the main current treatments have a poor prognosis." | ( Li, B; Liu, S; Pan, Y; Wu, H; Yin, H; Zhang, Y; Zhou, X, 2014) |
| "APE1 overexpression observed in hepatic cancer cells may reflect an adaptive response to cell damage and may be responsible for further cell resistance to chemotherapy and for the onset of inflammatory response." | ( Cesaratto, L; Codarin, E; Kelley, MR; Leonardi, A; Tell, G; Tiribelli, C; Vascotto, C, 2013) |
| "Induction of hepatic cancer was confirmed after 7 days of DENA administration by measurement of elevated level of serum α-feto protein (AFP)." | ( Ahmad, K; Ahmad, P; Al-Harbi, NO; Alam, MJ; Imam, F; Iqbal, M; Khusroo, MJ; Rahman, RU; Saleem, S; Shaharyar, MA, 2013) |
| "The IPS cells of liver cancer patients can be established effectively from fibrocytes and can be cultured stably in vitro, which provides an approach for the treatment of intermediate or advanced stage liver cancer." | ( Hu, JT; Li, JJ; Yan, P; Zhang, DM, 2014) |
| "Treatment of PC3 prostate and HepG2 liver cancer cells with compound 8." | ( Casey, PJ; Go, ML; Guo, D; Lau, HY; Ramanujulu, PM; Wang, M; Wirawan, M; Yang, T, 2014) |
| "According to the Barcelona Clinic Liver Cancer (BCLC) algorithm, intermediate-stage HCC is defined as extensive multifocal disease without vascular invasion in patients with preserved liver function and absence of cancer-related symptoms; in this context, transarterial chemoembolization (TACE) is considered the standard treatment." | ( Bruix, J; Forner, A; Gilabert, M; Raoul, JL, 2014) |
| "The Barcelona Clinic Liver Cancer (BCLC) system is the preferred staging system to evaluate patients with HCC and links prognosis assessment with treatment recommendation." | ( Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC, 2016) |
| "Patients with advanced hepatic cancer who underwent liver transplant and subsequent therapy between March 2007 and March 2009 in our hospital were selected for this study." | ( Fan, H; Gu, L; Jin, W; Kan, L; Shan, C; Wang, X, 2015) |
| "Currently, the Korean Liver Cancer Study Group and National Comprehensive Cancer Network guidelines recommend combined radiotherapy (RT) and chemotherapy for some selected cases." | ( Seong, J; Yoon, HI, 2014) |
| "Our study included 78 liver cancer patients who were treated with Y-90 radioembolization." | ( Aydin, F; Boz, A; Bozcuk, H; Coşkun, HS; Erkilic, M; Gunduz, S; Karayalçin, B; Ozdogan, M; Ozgur, O; Savas, B; Sindel, T; Yldlzs, A; Ylmaz, S, 2014) |
| "The morbidity and mortality rate of liver cancer continues to rise in China and advanced cases respond poorly to chemotherapy." | ( Guo, YL; Kong, QS; Liu, HS; Tan, WB, 2014) |
| "This study opens a new direction for liver cancer treatment." | ( Do, MS; Doan, CC; Doan, NT; Le, VD; Nguyen, MH; Nguyen, QH, 2015) |
| "Unresectable liver cancer presents a major problem in the treatment of solid tumors." | ( Mahnken, AH, 2015) |
| "Treatment of human liver cancer cell lines with FFAs exacerbated the EMT phenotype, whereas chemical inhibition of CD36 mitigated these effects." | ( Chan, C; Li, I; Nath, A; Roberts, LR, 2015) |
| "Human liver cancer HepG2 cell were treated with 10, 20, 30 and 40 µM xanthohumol for 48 h." | ( Huang, X; Jiang, K; Liang, B; Zhao, X, 2016) |
| "The Barcelona clinical liver cancer (BCLC) score endorsed by the European Society of the Liver EASL divides patients into five prognostic categories, each with a distinct treatment indication." | ( Colombo, M; Sangiovanni, A, 2016) |
| "MSFCs, CD90+ liver cancer cells (CD90+ LCCs), and parental MHCC97H cells were treated with no drug, LY294002 alone, 5-FU alone, or both drugs together and then compared in terms of stem cell-related gene expression, proliferation, and invasion." | ( Li, LQ; Lu, SD; Peng, NF; Peng, YC; Xie, ZB; You, XM; Zhong, JH, 2016) |
| "A promising strategy for liver cancer treatment is to deliver chemotherapeutic agents with multifunctional carriers into the tumor tissue via intra-arterial (IA) transcatheter infusion." | ( Chung, JW; Gordon, AC; Jeon, MJ; Kim, DH; Kim, YI; Larson, AC, 2016) |
| "To enhance locoregional therapies for liver cancer treatment, we propose in this study a mathematical model to optimize the transcatheter arterial delivery of therapeutical agents." | ( Belharet, K; Ferreira, A; Folio, D; Mellal, L, 2016) |
| "Using in vivo and in vitro models of liver cancer, we demonstrate that an increase in the level of p53 protein in nuclei, a decrease in the level of cytoplasmic p53, and, consequently, an increase in the ratio of nuclear/cytoplasmic p53 in rat preneoplastic livers and in rat and human HCC cell lines caused by tributyrin or sodium butyrate treatments was associated with a marked increase in the level of nuclear chromosome region maintenance 1 (CRM1) protein." | ( Beland, FA; de Conti, A; Fernandes, LH; Furtado, KS; Heidor, R; Horst, MA; Moreno, FS; Ortega, JF; Pogribna, M; Pogribny, IP; Shpyleva, S; Tavares, PE; Tryndyak, V, 2016) |
| "The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) recommends transarterial chemoembolization (TACE) as the first line therapy for stage B patients and sorafenib treatment for stage C patients." | ( Achakzai, R; Gou, CY; Li, JY; Li, L; Li, XH, 2016) |
| "Since the liver cancer cells have a strong capacity to repair irradiative injury, new medicines to enhance this treatment are urgently required." | ( Cheng, X; Feng, Z; Jiang, X; Liu, X; Wang, Q; Yang, C; Zhang, Y; Zhou, P, 2016) |
| "causes apoptosis of liver cancer cells through ER stress pathway, which supports the ethnomedicinal use of this herb as an alternative or complementary therapy for cancer." | ( Lee, SC; Liu, N; Lu, YC; Wang, L; Wang, P; Yang, HL; Yang, YJ, 2016) |
| "Surgery is the main treatment for liver cancer, but the most common liver cancer – called hepatocellular carcinoma – can sometimes become too large to remove safely." | ( Chao, M; Hu, X; Jin, K; Li, B; Wu, H; Wu, J; Yang, G; Zhang, G, 2016) |
| "Incubation of liver cancer cells with TLCL significantly restored apoptotic sensitivity accompanied by an increase of CL and its oxidation products when treated with staurosporine (STS) or Sorafenib (the standard treatment for late stage HCC patients)." | ( Chen, Q; Cheng, S; Lu, J; Sa, R; Tao, Y; Waeg, G; Xia, L; Xiao, M; Yin, H; Zarkovic, K; Zarkovic, N; Zhong, H; Zhu, M, 2017) |
| "The antitumor effect in mice liver cancer cells (H22) in tumor-bearing Kunming (KM) mice demonstrated that this nanocarrier exhibits high therapeutic efficiency in artificial solid tumors and low toxicity to normal tissues, with a survival rate of approximately 100% after 160 days of treatment." | ( Wang, Y; Wei, X; Xiong, X; Zhang, L; Zhang, X; Zhou, S, 2017) |
| "However, the effects of BA treatment on liver cancer have little to be known." | ( Feng, YL; Li, J; Li, QJ; Pan, F; Xu, Y, 2017) |
| "Human liver cancer cell strain SMMC-7721 was cultured and treated with different curcumin concentrations for different times followed by measuring the changes of cell proliferation activity and cycle by MTT and flow cytometry, respectively." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "The number of human liver cancer SMMC-7721 cells increased in G1 stage and decreased in S stage after treated with different concentrations of curcumin." | ( Fang, ZY; Li, D; Liu, JS; Xiang, H; Zhang, H; Zhang, YJ, 2017) |
| "Barcelona clinic liver cancer-stage C (BCLC-C) encompasses a broad spectrum of tumor burdens, liver function statuses, patient prognoses, and treatment strategies." | ( Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH, 2017) |
| "Determining the origin of liver cancer stem cells is important for treating hepatocellular carcinoma." | ( Bian, Z; Chen, C; Dai, B; Huang, Q; Liu, W; Pu, M; Qu, X; Shen, L; Tang, H; Tao, K; Zhao, G, 2017) |
| "Examination of liver cancer in diethylnitrosamine (DEN)-treated CUGBP1-S302A mice showed these mice develop much more severe liver cancer that is associated with elimination of the mutant CUGBP1." | ( Cast, A; Iakova, P; Karns, R; Lewis, K; Stock, L; Timchenko, L; Timchenko, N; Valanejad, L; Wei, C; Wright, M, 2017) |
| "Traditional chemotherapy for liver cancer has big side effects for patients, whereas targeted drugs, such as sorafenib, commonly have drug resistance." | ( Dai, Y; Guo, Q; He, Z; Wei, L; Yang, L; Yao, J; Zhao, L; Zhou, Y, 2017) |
| "Various liver cancer cell lines were treated with either sorafenib only or with sorafenib after infection of adenovirus expressing short hairpin RNA (shRNA) against transforming growth factor-β (TGF-β) and p38 activity was examined using western blotting." | ( Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ, 2017) |
| "Treating liver cancer cells with antioxidant N-acetyl cystein (NAC) partly blocked AGEs-induced ChREBP expression and cell proliferation." | ( Chen, H; Ding, W; Li, M; Li, Y; Lin, N; Meng, J; Su, Q; Tong, X; Wu, L; Yang, D; Zhu, Y, 2017) |
| "High mortality rates in ovarian and liver cancer are largely a result of resistance to currently used chemotherapy." | ( Bukowska, B; Marczak, A; Rogalska, A, 2018) |
| "Treatment of the liver cancer stem cells with mefloquine markedly decreased the potential to undergo self-renewal at 10 μM concentration after 48 h." | ( Gong, LL; Li, YH; Lin, RX; Wu, JC; Yang, SL; Zhang, GF, 2018) |
| "We also report that the liver cancer patients non-responding to sorafenib treatment exhibit higher expression of SULF2 and LCN2." | ( Bae, MH; Choi, JH; Chung, T; Im, JY; Kim, DY; Kim, HC; Kim, HH; Kwon, JH; Lee, EJ; Park, YN; Wang, HJ; Woo, HG; Yoon, S, 2018) |
| "Forty-nine patients with liver cancer who received drug-eluting beads transarterial chemoembolization treatment were consecutively enrolled in this cohort study." | ( Chen, R; Hu, H; Wu, X; Zheng, W, 2018) |
| "Treatment of liver cancer remains challenging because of a paucity of drugs that target critical dependencies." | ( Beijersbergen, RL; Bernards, R; Evers, B; Gao, D; Jin, G; Jin, H; Lieftink, C; Qin, W; Wang, C; Wang, L; Xue, Z, 2018) |
| "Our results provide novel insight into liver cancer therapy." | ( Chen, X; Li, X; Lv, H; Shang, P; Shen, Y; Wang, S; Xue, Y; Yang, J; Zhao, B, 2018) |
| "In this study, patients with liver cancer exhibited reduced VM in tumor tissues after treatment with Rhizoma Paridis." | ( Chen, S; Lei, Y; Liang, Y; Liu, H; Liu, Y; Meng, J; Qian, B; Qiao, K; Sun, T; Wang, H; Xiao, T; Yang, C; Zhang, H; Zhao, J; Zhong, W; Zhou, H; Zong, S, 2018) |
| "Barcelona Clinic Liver Cancer (BCLC) C patients with nonsegmental shunts who received lobar administrations had a grade ≥3 AE rate of 38% compared with the remaining cohort, which was 12% (P = ." | ( Geller, BS; Kapp, M; Pepin, EW; Shah, JL; Thornton, LM; Toskich, BB, 2018) |
| "Herein, we show in 2 different liver cancer models that myeloid-derived suppressor cells are increased in response to cytokine-induced killer cell therapy." | ( Agdashian, D; Brown, ZJ; Fu, Q; Greten, TF; Heinrich, B; Korangy, F; Ma, C; Rosato, U; Sandhu, M; Yu, SJ; Zhang, Q, 2019) |
| "In this study, sera samples, staged hepatic cancer tissues from Sor-treated patients with advanced HCC were harvested for a group of biochemical tests and immunoassays." | ( Liu, M; Su, M; Wu, X; Xu, X; Yang, B; Zhou, R, 2018) |
| "The treatment of liver cancer includes surgery and medication, of which, the former is more effective." | ( Cui, H; Cui, X; Jin, W; Jin, Y; Shen, X; Sun, H, 2019) |
| "The metastasis of liver cancer is a major cause of clinical treatment failure, restrain, and control the cancer metastasis is the major strategy of the treatment and prevention of the disease." | ( Ding, Y; Guo, H; Kong, D; Pang, D; Xu, C, 2018) |
| "Advanced liver cancer often exhibits a poor response to chemotherapy and poor prognosis due to acquired chemoresistance and tumor recurrence." | ( Deng, F; Hu, JQ; Hu, XP; Tian, XF; Zeng, XC; Zhang, W, 2018) |
| "The most effective way of treating liver cancer is surgical resection, which usually requires blocking the hepatic portal circulation, and may result in hepatic ischemia-reperfusion injury (HIRI)." | ( Gao, Y; Huang, JH; Huo, X; Lv, Y; Qi, D; Sheng, S; Wang, F; Wu, E; Zhou, S; Zhou, Y, 2018) |
| "Ex vivo cultured liver cancer tissues from a patient were treated with vismodegib as a single‑agent or in combination with entinostat, and analyzed by histological and immunohistochemical methods." | ( Cai, H; Li, H; Li, J; Liu, Y; Shi, Y; Song, H; Sun, Y; Wang, D; Wang, Y, 2019) |
| "Thus, after treatment of liver cancer cell line HepG-2 with 50 μM of each compound, cell viability was determined." | ( Badria, FA; El-Senduny, FF; Youssef, MM; Zidane, MM, 2019) |
| "Gene therapy strategies for liver cancer have broad application prospects but still lack a stable and efficient delivery vehicle." | ( Dong, S; Lee, RJ; Liu, L; Lu, J; Meng, Q; Teng, L; Xie, J; Yao, Y; Zhang, J; Zhang, Y; Zhao, Y, 2019) |
| "Malignancies treated included hepatocellular cancer (n = 14; 30%), colorectal cancer (n = 11; 23%), cholangiocarcinoma (n = 8; 17%), neuroendocrine (n = 8; 17%) and other tumors (n = 6)." | ( Abbott, DE; Alseidi, A; Bentrem, DJ; Borel Rinkes, IHM; Chadalavada, S; Choi, GH; Dhar, VK; Eng, OS; Fisher, AV; Fong, Y; Hagendoorn, J; Johnson, AC; Kies, D; Latorre, K; Lewandowski, R; Maithel, SK; Makris, E; Melstrom, LG; Poultsides, G; Raoof, M; Rocha, F; Ronnekleiv-Kelly, S; Salem, R; Sekhar, A; Shah, SA; Singh, G; Weber, SM; Winslow, ER, 2019) |
| "The CP classification, Barcelona Clinic Liver Cancer staging system, and treatment modality might predict mortality in patients with HCC." | ( Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SH; Sulaiman, AS, 2020) |
| "Stimulating ferroptosis in liver cancer cells is a strategy to treat liver cancer." | ( Bian, Z; Chen, Y; Liu, Y; Pan, Q; Sun, F; Wu, Q; Zhang, X; Zhang, Y; Zhu, G, 2019) |
| "Animal studies in liver cancer xenograft model demonstrated significant suppression of tumor burden, reduced tumor cell and elevated TUNEL positive apoptosis with no toxicity concerns in animals treated with G-S27LN formulation." | ( Duan, X; Wang, Z; Zhang, Y; Zhao, K; Zhao, Y, 2019) |
| "Briefly, liver cancer cells were treated with muscone and the rates of cellular apoptosis and autophagy were investigated using staining techniques and western blotting." | ( Jiangshan Dai, J; Li, Z; Qi, W; Wang, D; Wu, C; Xia, L; Xu, S; Yang, C; Zhang, Q, 2020) |
| "Targeting AMPK and lipid metabolism of hepatocellular cancer stem cells is a promising strategy to face stemness and chemotherapy resistance." | ( Bort, A; de Miguel, I; Diaz-Laviada, I; Mateos-Gómez, PA; Sánchez, BG, 2020) |
| "The Barcelona Clinic Liver Cancer (BCLC) stages following downsizing after prior treatment were A, B and C in 17, 22 and 30 patients, respectively." | ( Ando, S; Fuchigami, A; Fujii, Y; Imai, Y; Mochida, S; Nakayama, N; Nakazawa, M; Sugawara, K; Tomiya, T; Uchida, Y; Uchiya, H, 2020) |
| "Thirteen liver cancer cell lines were cultured followed by treatment with varying concentrations of quercetin (0-100 μM) or quercetin and 5-FU, and the cell viability was analysed by the MTT assay." | ( Akagi, Y; Akiba, J; Fujita, F; Fukutomi, S; Goto, Y; Hisaka, T; Mizobe, T; Naito, Y; Nakashima, K; Nakashima, O; Nomura, Y; Ogasawara, S; Okuda, K; Sakai, H; Sato, T; Tanigawa, M; Yano, H, 2020) |
| "Treatment of liver cancer with conventional method bears several side effects, thus to undertake these side effects as a formulation challenge, it is necessary to develop novel target-specific drug delivery system for the effective and better localization of drug into the proximity of target with restricting the movement of the drug in normal tissues." | ( Jain, AK; Mishra, K; Sahu, H; Thareja, S, 2021) |
| "According to Barcelona Clinic Liver Cancer classification, transarterial chemoembolization (TACE) is preferred treatment for stage B and in certain cases for stage A hepatocellular carcinoma (HCC)." | ( Dimov, V; Dimova, B; Gjoreski, A; Grozdanovska Angelovska, B; Jovanoska, I; Mitrevski, N; Nedelkovski, D; Popova Jovanovska, R; Prgova Veljanova, B; Risteski, F, 2021) |
| "The Barcelona Clinic Liver Cancer criteria used to guide treatment considers performance status and assessment of liver function by Child-Pugh score in addition to tumor size and location." | ( Draper, A, 2020) |
| "The remaining 10 rats were the liver cancer model group and treated with diethylnitrosamine (DEN) to induce liver cancer." | ( Bai, MJ; Bu, JG; Chen, CY; Li, JQ; Liu, ZH; Yan, SH; Ye, XW, 2021) |
| "The Hep-G2 and SMMC-7721 liver cancer cell lines were treated with phenformin and Ku either alone or in combination, after which the impact of these drugs on cellular proliferation was assessed via 3-(4,5-dimethylthiazol) 2, 5-diphenyltetrazolium and colony formation assays, whereas Transwell assays were used to gauge cell migratory activity." | ( Deng, J; Hu, X; Huang, L; Huang, M; Li, G; Qin, M; Tang, J; Wu, J; Wu, T; Xiao, D; Yan, X; Yang, X; Zhou, S, 2021) |
| "Advanced stage liver cancer is predominantly treated with the multi-kinase inhibitor sorafenib; however, this therapeutic agent lacks selectivity in its cytotoxic actions and is associated with poor survival outcomes." | ( Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT, 2021) |
| "Ozone treatment inhibited liver cancer cell proliferation, colony formation." | ( He, X; Huang, Q; Li, J; Li, X; Tang, S; Zeng, T; Zhong, M, 2021) |
| "The fact that the three liver cancer cell lines responded differently, yet positively, to CDDP + APG cotreatment could be attributed to variations they present in gene expression." | ( Anninou, N; Koukoulis, G; Papachristou, F; Paraskakis, S; Pitiakoudis, M; Sertaridou, E; Simopoulos, C; Tsalikidis, C; Tsaroucha, A, 2021) |
| "Consequently, we treated three primary liver cancer cell lines with two anthracyclins (doxorubicin and idarubin) and studied the changes in the lipidome." | ( Balgoma, D; Calitz, C; Hedeland, M; Heindryckx, F; Kopsida, M; Kullenberg, F; Lennernäs, H, 2021) |
| "Three patients with advanced liver cancer treated at our institution had very poor ICG retention rates during treatment with lenvatinib." | ( Aratake, Y; Furukawa, M; Hisano, T; Iguchi, T; Inada, H; Lee, L; Mano, Y; Matsumoto, Y; Miki, M; Nakanishi, A; Okumura, Y; Senju, T; Sugimachi, K; Sugimoto, R; Taguchi, K; Tanaka, Y, 2021) |
| "Treatment of liver cancer has always been a challenge for clinicians and development of appropriate drug against hepatocellular carcinoma is the major focus for researchers working in the field." | ( Ali, S; Inam, A; Rizwan, M; Younas, M; Zubair, M, 2021) |
| "Metformin upregulated glycolysis in liver cancer cells, thereby increasing sensitivity to the DCA treatment." | ( Cho, Y; Choi, DH; Kim, SY; Kim, TS; Lee, CY; Lee, M; Park, M; Shim, MS, 2021) |
| "We aimed at finding and verifying new liver cancer markers by combining informatics analysis with experimental exploration to provide new ideas and methods for the diagnosis and treatment of clinical liver cancer." | ( Bai, M; Bao, Y; Cui, M; Huang, Y; Li, Y; Song, Z; Sun, L; Sun, Y; Wang, G; Yu, C; Yu, Z; Zheng, L, 2021) |
| "In the present study, hepatocellular cancer (HCC) induced by diethylnitrosamine (DEN) in rats and then treated with the new chromene derivative and the parameters TNF-α, VEGF, p53, Cyt C, MMP-9, Bcl2, and Bax were measured." | ( El-Mezayen, HA; Mahdy, EME; Mansour, SZ; Mohamed, SA; Nabeel, AI, 2022) |
| "NRG's efficiency in treating hepatic cancer was increased by using SLN's approach." | ( Kang, Q; Liang, X; Liu, Q; Wang, W; Wang, Z, 2022) |
| "HCC is one of the main types of primary liver cancer, with high morbidity and mortality and poor treatment effect." | ( Cheng, X; Guo, Z; He, M; Huang, L; Liu, Z; Lu, X; Ma, T; Peng, W; Tang, F; Tian, S; Tu, F; Wang, X; Wu, Y; Xu, X; Yang, J; Ye, J; Zeng, X; Zhang, L; Zhang, P; Zou, J, 2022) |
| "Careful treatment of both RHF and liver cancer might be necessary for patients with RHF with primary or metastatic liver cancer." | ( Doi, H; Hashi, K; Hishikawa, D; Ikegami, T; Inui, A; Kage, M; Kanto, T; Kawai, H; Komatsu, H; Kusano, H; Matsuda, M; Mori, T; Okawara, M; Okuzaki, D; Osawa, Y; Oyama, C; Sakamoto, Y; Shimagaki, T; Shindou, H; Sugiyama, M; Tamura-Nakano, M; Tsunoda, T; Tsutsui, Y; Yamazoe, T; Yanaga, K; Yanagida, K; Yoshida, Y; Yoshikawa, S; Yoshio, S, 2022) |
| "In parallel to the incidence of hepatic cancer, we found lung, heart, and kidney cancer after treatment with DEN." | ( Abdelhafez, MA; Darwish, AM; Mahrous, KF; Zoheir, KMA, 2022) |
| "Current treatments to combat liver cancer are limited." | ( Cheng, WC; Chu, YC; Lin, CC; Lin, SC; Lin, YC; Lu, IT; Sheu, JH; Wen, Y, 2022) |
| "Despite the increasing occurrence of liver cancer, it has a poor prognosis and potential treatment options are still lacking." | ( Chen, X; Dong, P; Huang, Z; Liu, H; Zeng, X, 2022) |
| "As the most common pediatric primary liver cancer with rising incidence, hepatoblastoma remains challenging to treat." | ( Rangaswami, A; Wu, PV, 2022) |
| "The presence of liver cancer stem cells (LCSCs) is one of the reasons for the treatment failure of hepatocellular carcinoma (HCC)." | ( Chen, Y; Chen, Z; Fan, J; Fan, X; Li, L; Shi, Y; Tian, R; Wang, H; Yang, X; Zhang, J; Zhang, K, 2022) |
| "The Barcelona Clinic Liver Cancer (BCLC) classification is the most widely used staging system in management of HCC that helps allocate treatments." | ( Goyal, P; Mouli, SK; Salem, R, 2022) |
| "Poor diagnosis of primary liver cancer and limited treatment strategies aggravate the challenges." | ( Ahmad, A; Ahmad, I; Alabdallah, NM; Ansari, IA; Ashfaque, M; Bajpai, P; Mishra, A; Saeed, M; Shekh, R; Tiwari, RK, 2022) |
| "Barcelona Clinic Liver Cancer stages at treatment were A (13%), B (33%), C (52%), and D (2%)." | ( Al-Omary, A; Chan, C; Chan, MV; Chang, J; Cheng, R; Clark-Dickson, M; Danta, M; Davison, SA; Gupta, S; Hillhouse, JW; Huo, YR; Jebeili, H; Laube, R; Lee, AU; Levy, MT; Liu, K; Lockart, I; Nguyen, V; Prince, DS; Rogan, C; Schlaphoff, G; Strasser, SI; Thailakanathan, C; Tiwari, N; Xiang, H; Zekry, A, 2022) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "Although many treatments for liver cancer have been studied, the prognosis for liver cancer is still very poor." | ( Bai, X; Li, X; Peng, X; Qiao, C; Tang, Y; Zhao, R, 2023) |
| "The Chinese liver cancer (CNLC) staging system proposed in the 2017 guidelines continues to be the standard model for staging with modifications in the treatment allocations." | ( Fan, J; Gao, Q; Shi, J; Xie, D; Zhou, J, 2023) |
| "Eighty patients with liver cancer and cirrhosis undergoing elective LH were randomized into ulinastatin (administered immediately before hepatectomy) group, dexmedetomidine (administered before anesthesia induction) group, ulinastatin plus dexmedetomidine group, and saline group (groups U, D, UD, and C, respectively)." | ( Liu, G; Ou, Y; Yang, Y; Yin, F; Zhang, F, 2022) |
| "si‑PTBP1 introduction into SF‑treated liver cancer cells resulted in a significant reduction in the levels of MDA and iron." | ( Bi, T; Li, J; Liu, Z; Sun, W; Wang, Q; Wang, W; Xu, Y; Yang, H, 2023) |
| "To detect and treat liver cancers, it is imperative to study how HClO levels change in hepatocytes." | ( Cheng, D; He, L; Li, S; Liu, Y; Wang, P; Yang, K, 2023) |
| "HIGD2A promoted liver cancer cell growth by fueling mitochondrial ATP synthesis and activating the MAPK/ERK pathway, suggested that targeting HIGD2A may represent a new strategy for HCC therapy." | ( Chen, Y; Huang, K; Li, C; Li, X; Lin, Z; Liu, H; Liu, Z; Wang, Y; Xie, Z; Zhang, H; Zhang, X, 2023) |
| "TEM showed that lysionotin-treated liver cancer cells showed an extensively distended and dilated endoplasmic reticulum lumen." | ( Gao, Y; Li, D; Li, M; Lin, H; Shi, H; Wang, G; Wang, X; Yi, F; Yin, Y; Zou, Y, 2023) |
| "The 2022 Barcelona Clinic Liver Cancer (BCLC) guidelines incorporate a new section on clinical decision-making for personalized medicine, although the first treatment suggested by the BCLC guidelines is based on solid scientific evidence." | ( Irizato, M; Marugami, N; Minamiguchi, K; Nishiofuku, H; Taiji, R; Tanaka, T; Uchiyama, T, 2023) |
| "The treatment of liver cancer meets significant challenges in the high recurrence rate and invasive incidence." | ( Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y, 2023) |
| "The Huh-7 liver cancer cells and the H22 tumor-bearing mice were treated with Rh2 and Rh2-O." | ( Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y, 2023) |
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|
| acetylcarnitine | 0 | medium | 4 | 1 |
| dinitrochlorobenzene | 0 | low | 10 | 0 |
| ethylene dichloride | 0 | low | 1 | 0 |
| chloroacetaldehyde | 0 | low | 1 | 0 |
| tartronic acid | 0 | low | 1 | 0 |
| 2,3-diphosphoglycerate | 0 | low | 1 | 0 |
| 2-keto-4-methylvalerate | 0 | medium | 1 | 1 |
| protocatechuic acid | 0 | medium | 7 | 1 |
| 3-hydroxyanthranilic acid | 0 | low | 7 | 0 |
| 3-hydroxykynurenine | 0 | low | 1 | 0 |
| acetoacetic acid | 0 | low | 12 | 0 |
| phosphoserine | 0 | low | 18 | 0 |
| gamma-aminobutyric acid | 0 | medium | 10 | 1 |
| aminolevulinic acid | 0 | low | 37 | 0 |
| 5-hydroxytryptophan | 0 | medium | 14 | 4 |
| ethylene glycol | 0 | medium | 3 | 1 |
| acetic acid | 0 | medium | 72 | 12 |
| acetaldehyde | 0 | low | 29 | 0 |
| acetamide | 0 | low | 4 | 0 |
| acetoin | 0 | low | 1 | 0 |
| acetone | 0 | low | 12 | 0 |
| adenine | 0 | medium | 160 | 7 |
| agmatine | 0 | low | 5 | 0 |
| allantoin | 0 | low | 1 | 0 |
| curdlan | 0 | low | 1 | 0 |
| ammonium hydroxide | 0 | medium | 72 | 6 |
| anthranilic acid | 0 | low | 1 | 0 |
| quinacrine | 0 | low | 8 | 0 |
| phycoerythrin | 0 | low | 1 | 0 |
| beta-alanine | 0 | low | 9 | 0 |
| benzaldehyde | 0 | low | 5 | 0 |
| benzene | 0 | medium | 25 | 1 |
| benzoic acid | 0 | low | 1 | 0 |
| betaine | 0 | low | 16 | 0 |
| bis(4-nitrophenyl)phosphate | 0 | low | 1 | 0 |
| bromide | 0 | low | 1 | 0 |
| 1-butanol | 0 | low | 5 | 0 |
| butyric acid | 0 | low | 40 | 0 |
| cadaverine | 0 | low | 4 | 0 |
| carbamates | 0 | medium | 63 | 2 |
| carbamyl phosphate | 0 | low | 5 | 0 |
| carbon monoxide | 0 | low | 9 | 0 |
| formic acid | 0 | low | 3 | 0 |
| aminooxyacetic acid | 0 | low | 3 | 0 |
| carnitine | 0 | medium | 30 | 3 |
| catechol | 0 | low | 3 | 0 |
| methane | 0 | medium | 40 | 5 |
| chlordecone | 0 | low | 3 | 0 |
| choline | 0 | medium | 150 | 6 |
| aconitic acid | 0 | low | 2 | 0 |
| citric acid, anhydrous | 0 | medium | 18 | 2 |
| chlorine | 0 | medium | 57 | 4 |
| hydrochloric acid | 0 | low | 12 | 0 |
| coumarin | 0 | low | 6 | 0 |
| salicylic acid | 0 | low | 36 | 0 |
| octane | 0 | low | 1 | 0 |
| phloroglucinol | 0 | low | 5 | 0 |
| gallic acid | 0 | low | 19 | 0 |
| octanoic acid | 0 | low | 1 | 0 |
| 2-nitropropane | 0 | low | 4 | 0 |
| hydrogen sulfide | 0 | medium | 23 | 1 |
| nicotine 1-n-oxide | 0 | low | 1 | 0 |
| trimethylenediamine | 0 | low | 1 | 0 |
| 3-hydroxybutyric acid | 0 | medium | 16 | 1 |
| bupropion | 0 | low | 1 | 0 |
| n(1)-methylnicotinamide | 0 | low | 1 | 0 |
| guaiacol | 0 | low | 11 | 0 |
| hippuric acid | 0 | low | 1 | 0 |
| 4-aminoimidazole | 0 | low | 1 | 0 |
| n(g),n(g')-dimethyl-l-arginine | 0 | low | 1 | 0 |
| 2-methylcitric acid | 0 | low | 2 | 0 |
| malic acid | 0 | low | 2 | 0 |
| propionaldehyde | 0 | low | 2 | 0 |
| phosphonoacetic acid | 0 | medium | 7 | 1 |
| 3,4-dihydroxyphenylacetic acid | 0 | low | 1 | 0 |
| aminocaproic acid | 0 | low | 3 | 0 |
| dibenzofuran | 0 | low | 3 | 0 |
| creatine | 0 | low | 8 | 0 |
| cytosine | 0 | low | 43 | 0 |
| lactic acid | 0 | medium | 164 | 5 |
| dihydrouracil | 0 | medium | 2 | 1 |
| diacetyl | 0 | low | 1 | 0 |
| dihydroxyacetone | 0 | low | 1 | 0 |
| dimethylglycine | 0 | low | 3 | 0 |
| dimethyl sulfoxide | 0 | medium | 56 | 2 |
| ethanolamine | 0 | low | 12 | 0 |
| formaldehyde | 0 | medium | 65 | 1 |
| formamide | 0 | low | 1 | 0 |
| 3-phosphoglycerate | 0 | low | 1 | 0 |
| gamma-butyrobetaine | 0 | low | 1 | 0 |
| hexachlorocyclohexane | 0 | low | 2 | 0 |
| glycine | 0 | medium | 100 | 4 |
| glyceraldehyde | 0 | low | 5 | 0 |
| glycerol | 0 | medium | 42 | 3 |
| glycolic acid | 0 | low | 5 | 0 |
| glycocyamine | 0 | low | 1 | 0 |
| hydrogen carbonate | 0 | medium | 19 | 1 |
| dalteparin | 0 | medium | 20 | 3 |
| histamine | 0 | medium | 33 | 5 |
| homogentisic acid | 0 | low | 2 | 0 |
| hydrogen | 0 | medium | 14 | 3 |
| hydroquinone | 0 | low | 4 | 0 |
| hydroxylamine | 0 | low | 1 | 0 |
| imidazole | 0 | low | 2 | 0 |
| indole | 0 | low | 2 | 0 |
| indoleacetic acid | 0 | low | 7 | 0 |
| iodine | 0 | medium | 93 | 15 |
| dihydroxyphenylalanine | 0 | medium | 26 | 1 |
| kynurenine | 0 | low | 17 | 0 |
| 2,3,4,5-tetrahydroxypentanal | 0 | low | 1 | 0 |
| thioctic acid | 0 | low | 22 | 0 |
| malonic acid | 0 | low | 1 | 0 |
| pyruvaldehyde | 0 | low | 5 | 0 |
| methanol | 0 | low | 43 | 0 |
| phytic acid | 0 | medium | 50 | 1 |
| inositol | 0 | medium | 11 | 1 |
| melatonin | 0 | medium | 60 | 4 |
| croton oil | 0 | low | 11 | 0 |
| naphthalene | 0 | low | 3 | 0 |
| nickel | 0 | medium | 30 | 2 |
| niacinamide | 0 | medium | 1,691 | 188 |
| niacin | 0 | low | 17 | 0 |
| nitrates | 0 | medium | 40 | 5 |
| nitroxyl | 0 | medium | 3 | 2 |
| nitrites | 0 | medium | 52 | 2 |
| nitrous oxide | 0 | medium | 8 | 1 |
| orotic acid | 0 | low | 70 | 0 |
| oxaloacetic acid | 0 | low | 1 | 0 |
| oxamic acid | 0 | low | 4 | 0 |
| 4-aminobenzoic acid | 0 | low | 4 | 0 |
| 4-nitrophenol | 0 | low | 4 | 0 |
| triphosphoric acid | 0 | low | 3 | 0 |
| palmitic acid | 0 | low | 50 | 0 |
| parathion | 0 | low | 1 | 0 |
| pentachlorophenol | 0 | low | 7 | 0 |
| phenanthrene | 0 | low | 1 | 0 |
| phenol | 0 | low | 13 | 0 |
| phenylpyruvic acid | 0 | low | 1 | 0 |
| phenylacetaldehyde | 0 | low | 1 | 0 |
| phenylacetic acid | 0 | low | 1 | 0 |
| phosphoenolpyruvate | 0 | low | 6 | 0 |
| phosphorylcholine | 0 | medium | 15 | 2 |
| phosphorylethanolamine | 0 | low | 5 | 0 |
| phthalic acid | 0 | low | 1 | 0 |
| porphobilinogen | 0 | low | 8 | 0 |
| diphosphoric acid | 0 | low | 2 | 0 |
| pqq cofactor | 0 | low | 1 | 0 |
| propylene glycol | 0 | medium | 3 | 2 |
| 1-propanol | 0 | low | 4 | 0 |
| propionic acid | 0 | low | 1 | 0 |
| pteridines | 0 | low | 7 | 0 |
| purine | 0 | low | 15 | 0 |
| putrescine | 0 | low | 26 | 0 |
| pyrazinamide | 0 | low | 4 | 0 |
| pyrazole | 0 | low | 7 | 0 |
| pyridine | 0 | low | 3 | 0 |
| pyridoxal | 0 | low | 34 | 0 |
| pyridoxal phosphate | 0 | medium | 99 | 30 |
| pyridoxamine | 0 | low | 1 | 0 |
| pyridoxine | 0 | medium | 21 | 1 |
| pyrogallol | 0 | low | 2 | 0 |
| pyruvic acid | 0 | low | 24 | 0 |
| dimethyl sulfide | 0 | low | 1 | 0 |
| thiosulfates | 0 | medium | 20 | 2 |
| dithionite | 0 | low | 1 | 0 |
| sarcosine | 0 | low | 7 | 0 |
| selenious acid | 0 | low | 2 | 0 |
| sulfites | 0 | medium | 14 | 1 |
| spermidine | 0 | low | 25 | 0 |
| spermine | 0 | medium | 32 | 1 |
| succinic acid | 0 | medium | 12 | 1 |
| sulfuric acid | 0 | low | 1 | 0 |
| sulfur dioxide | 0 | medium | 4 | 2 |
| taurine | 0 | low | 23 | 0 |
| thiamine | 0 | medium | 9 | 1 |
| thymine | 0 | medium | 45 | 1 |
| toluene | 0 | medium | 34 | 1 |
| trimethylamine | 0 | low | 1 | 0 |
| uracil | 0 | medium | 308 | 50 |
| uric acid | 0 | medium | 35 | 1 |
| urea | 0 | medium | 127 | 7 |
| vanillin | 0 | low | 5 | 0 |
| xanthine | 0 | low | 6 | 0 |
| isopentenyl pyrophosphate | 0 | low | 1 | 0 |
| isocitric acid | 0 | low | 1 | 0 |
| normetanephrine | 0 | low | 5 | 0 |
| vanilmandelic acid | 0 | low | 15 | 0 |
| menthol | 0 | low | 3 | 0 |
| mandelic acid | 0 | low | 1 | 0 |
| 1,10-phenanthroline | 0 | low | 3 | 0 |
| 1,2-dimethylhydrazine | 0 | medium | 30 | 1 |
| pk 11195 | 0 | low | 2 | 0 |
| 1-aminocyclohexanecarboxylic acid | 0 | low | 1 | 0 |
| 1-anilino-8-naphthalenesulfonate | 0 | medium | 119 | 1 |
| edelfosine | 0 | low | 4 | 0 |
| pd 173074 | 0 | low | 3 | 0 |
| 2,2'-dipyridyl | 0 | low | 5 | 0 |
| 2,4,5-trichlorophenoxyacetic acid | 0 | low | 8 | 0 |
| 2,4-dichlorophenoxyacetic acid | 0 | low | 5 | 0 |
| 2,4-dinitrophenol | 0 | low | 3 | 0 |
| 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | 0 | low | 10 | 0 |
| 2-aminofluorene | 0 | low | 5 | 0 |
| mercaptoethanol | 0 | low | 19 | 0 |
| 2-aminoethoxydiphenyl borate | 0 | low | 3 | 0 |
| 3,4-methylenedioxyamphetamine | 0 | low | 3 | 0 |
| amitrole | 0 | low | 8 | 0 |
| 3-aminobenzamide | 0 | low | 5 | 0 |
| aminopropionitrile | 0 | low | 2 | 0 |
| 3-methoxytyramine | 0 | low | 1 | 0 |
| 3-methylcholanthrene | 0 | low | 148 | 0 |
| enprofylline | 0 | low | 1 | 0 |
| 4'-bromoflavone | 0 | low | 1 | 0 |
| 4-(2-aminoethyl)benzenesulfonylfluoride | 0 | low | 3 | 0 |
| 4-amino-1,8-naphthalimide | 0 | low | 5 | 0 |
| 4-aminopyridine | 0 | low | 1 | 0 |
| homovanillic acid | 0 | low | 6 | 0 |
| phenytoin | 0 | low | 11 | 0 |
| 5,8,11,14-eicosatetraynoic acid | 0 | medium | 2 | 1 |
| 5-(n,n-hexamethylene)amiloride | 0 | low | 1 | 0 |
| ethylisopropylamiloride | 0 | low | 3 | 0 |
| hydroxyindoleacetic acid | 0 | medium | 100 | 9 |
| 5-methoxytryptamine | 0 | low | 1 | 0 |
| 8-cyclopentyl-1,3-dimethylxanthine | 0 | low | 1 | 0 |
| 8-phenyltheophylline | 0 | low | 2 | 0 |
| oxyquinoline | 0 | medium | 9 | 1 |
| tacrine | 0 | low | 3 | 0 |
| 2,2'-azobis(2-amidinopropane) | 0 | low | 2 | 0 |
| acetaminophen | 0 | medium | 68 | 5 |
| acetazolamide | 0 | medium | 5 | 1 |
| acetochlor | 0 | low | 1 | 0 |
| beta-aminoethyl isothiourea | 0 | low | 1 | 0 |
| tyrphostin ag 1024 | 0 | low | 1 | 0 |
| ag 127 | 0 | low | 1 | 0 |
| tyrphostin a23 | 0 | low | 1 | 0 |
| alachlor | 0 | low | 1 | 0 |
| albendazole | 0 | medium | 15 | 2 |
| albuterol | 0 | medium | 1 | 1 |
| alendronate | 0 | low | 7 | 0 |
| altretamine | 0 | medium | 3 | 1 |
| am 251 | 0 | low | 1 | 0 |
| amantadine | 0 | low | 10 | 0 |
| diatrizoic acid | 0 | medium | 31 | 1 |
| amifostine anhydrous | 0 | medium | 12 | 3 |
| aminoglutethimide | 0 | medium | 7 | 2 |
| pimagedine | 0 | low | 1 | 0 |
| p-aminohippuric acid | 0 | low | 1 | 0 |
| theophylline | 0 | medium | 31 | 1 |
| amiodarone | 0 | medium | 21 | 2 |
| amitriptyline | 0 | low | 3 | 0 |
| amlodipine | 0 | low | 3 | 0 |
| amobarbital | 0 | low | 9 | 0 |
| amoxapine | 0 | low | 1 | 0 |
| amsacrine | 0 | medium | 8 | 3 |
| anastrozole | 0 | medium | 8 | 3 |
| antipyrine | 0 | medium | 16 | 1 |
| acetovanillone | 0 | low | 4 | 0 |
| arecoline | 0 | low | 3 | 0 |
| aristolochic acid i | 0 | low | 14 | 0 |
| aspirin | 0 | medium | 127 | 1 |
| astemizole | 0 | low | 4 | 0 |
| atrazine | 0 | low | 1 | 0 |
| aurintricarboxylic acid | 0 | low | 1 | 0 |
| azasetron | 0 | medium | 2 | 1 |
| azathioprine | 0 | medium | 83 | 1 |
| azelastine | 0 | low | 1 | 0 |
| azobenzene | 0 | low | 13 | 0 |
| baclofen | 0 | low | 2 | 0 |
| barbital | 0 | low | 8 | 0 |
| bay-k-8644 | 0 | low | 2 | 0 |
| bencyclane | 0 | low | 1 | 0 |
| benefin | 0 | low | 1 | 0 |
| benzamidine | 0 | low | 2 | 0 |
| benzbromarone | 0 | low | 1 | 0 |
| benzethonium | 0 | low | 1 | 0 |
| benzo(a)pyrene | 0 | low | 89 | 0 |
| benzothiazide | 0 | medium | 5 | 2 |
| benzyl isothiocyanate | 0 | low | 7 | 0 |
| butylbenzyl phthalate | 0 | low | 3 | 0 |
| berberine | 0 | low | 68 | 0 |
| 5-methoxypsoralen | 0 | low | 2 | 0 |
| beta-naphthoflavone | 0 | low | 15 | 0 |
| 2,5-di-tert-butylhydroquinone | 0 | low | 1 | 0 |
| bicalutamide | 0 | low | 6 | 0 |
| biperiden | 0 | low | 1 | 0 |
| bisbenzimidazole | 0 | low | 5 | 0 |
| bisoprolol | 0 | low | 1 | 0 |
| bromhexine | 0 | low | 4 | 0 |
| buflomedil | 0 | medium | 1 | 1 |
| bumetanide | 0 | low | 1 | 0 |
| bunitrolol | 0 | low | 1 | 0 |
| bupivacaine | 0 | medium | 8 | 2 |
| busulfan | 0 | low | 10 | 0 |
| cacodylic acid | 0 | low | 1 | 0 |
| caffeine | 0 | medium | 47 | 1 |
| verapamil | 0 | medium | 47 | 8 |
| beta-glycerophosphoric acid | 0 | low | 1 | 0 |
| metrizoate | 0 | medium | 2 | 1 |
| calmidazolium | 0 | low | 1 | 0 |
| camostat | 0 | low | 1 | 0 |
| candesartan | 0 | low | 2 | 0 |
| carbamazepine | 0 | low | 4 | 0 |
| carbazilquinone | 0 | medium | 10 | 3 |
| carmofur | 0 | medium | 26 | 4 |
| carmustine | 0 | medium | 54 | 8 |
| carvedilol | 0 | low | 3 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | 0 | medium | 9 | 1 |
| celecoxib | 0 | medium | 54 | 7 |
| cetirizine | 0 | low | 1 | 0 |
| cetyltrimethylammonium ion | 0 | low | 4 | 0 |
| cetylpyridinium | 0 | low | 2 | 0 |
| cgp 12177 | 0 | low | 1 | 0 |
| cgs 15943 | 0 | low | 1 | 0 |
| chetomin | 0 | low | 1 | 0 |
| chelerythrine | 0 | low | 8 | 0 |
| chloral hydrate | 0 | low | 4 | 0 |
| chlorambucil | 0 | low | 25 | 0 |
| chlorcyclizine | 0 | low | 1 | 0 |
| chlormezanone | 0 | low | 1 | 0 |
| chloroquine | 0 | medium | 63 | 2 |
| chlorothiazide | 0 | low | 1 | 0 |
| chlorpromazine | 0 | medium | 28 | 1 |
| chlorpropamide | 0 | low | 1 | 0 |
| chlorpyrifos | 0 | low | 1 | 0 |
| ciclopirox | 0 | low | 1 | 0 |
| ciglitazone | 0 | low | 3 | 0 |
| cilostazol | 0 | low | 2 | 0 |
| cimetidine | 0 | medium | 20 | 1 |
| eucalyptol | 0 | low | 1 | 0 |
| ciprofibrate | 0 | low | 14 | 0 |
| ciprofloxacin | 0 | medium | 7 | 1 |
| citalopram | 0 | low | 2 | 0 |
| clioquinol | 0 | low | 2 | 0 |
| clofazimine | 0 | medium | 6 | 2 |
| clofibrate | 0 | low | 38 | 0 |
| clofibric acid | 0 | low | 18 | 0 |
| clonazepam | 0 | low | 1 | 0 |
| clonidine | 0 | low | 1 | 0 |
| clotrimazole | 0 | low | 4 | 0 |
| coumaphos | 0 | low | 1 | 0 |
| 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone | 0 | low | 4 | 0 |
| cycloleucine | 0 | low | 4 | 0 |
| cyproheptadine | 0 | low | 8 | 0 |
| cystamine | 0 | low | 3 | 0 |
| damnacanthal | 0 | low | 1 | 0 |
| dantrolene | 0 | low | 4 | 0 |
| dapi | 0 | low | 13 | 0 |
| deferiprone | 0 | low | 5 | 0 |
| deferoxamine | 0 | medium | 43 | 3 |
| desipramine | 0 | low | 3 | 0 |
| amphetamine | 0 | medium | 2 | 1 |
| eflornithine | 0 | low | 5 | 0 |
| diazepam | 0 | medium | 13 | 1 |
| diazoxide | 0 | low | 17 | 0 |
| dibutyl phthalate | 0 | low | 1 | 0 |
| dichlobanil | 0 | low | 1 | 0 |
| diclofenac | 0 | medium | 12 | 1 |
| dichlorodiphenyl dichloroethylene | 0 | low | 6 | 0 |
| ddt | 0 | low | 54 | 0 |
| dichlorophen | 0 | low | 1 | 0 |
| 3,4-dihydroxybenzohydroxamic acid | 0 | low | 1 | 0 |
| diethylcarbamazine | 0 | low | 1 | 0 |
| pentetic acid | 0 | medium | 153 | 12 |
| diflunisal | 0 | low | 1 | 0 |
| 3,3'-diindolylmethane | 0 | low | 8 | 0 |
| dimercaprol | 0 | low | 2 | 0 |
| dimethadione | 0 | low | 1 | 0 |
| dimethoate | 0 | low | 1 | 0 |
| diphenhydramine | 0 | medium | 6 | 1 |
| diphenyleneiodonium | 0 | low | 3 | 0 |
| benzophenone | 0 | low | 3 | 0 |
| dipyridamole | 0 | low | 20 | 0 |
| disopyramide | 0 | low | 1 | 0 |
| disulfiram | 0 | medium | 19 | 1 |
| valproic acid | 0 | low | 34 | 0 |
| racemetirosine | 0 | low | 2 | 0 |
| p-chloroamphetamine | 0 | low | 1 | 0 |
| domperidone | 0 | low | 3 | 0 |
| doxazosin | 0 | low | 1 | 0 |
| e 4031 | 0 | low | 2 | 0 |
| ebselen | 0 | low | 4 | 0 |
| econazole | 0 | low | 1 | 0 |
| ellipticine | 0 | low | 2 | 0 |
| embelin | 0 | low | 2 | 0 |
| emodin | 0 | low | 44 | 0 |
| endosulfan | 0 | low | 3 | 0 |
| endothall | 0 | low | 1 | 0 |
| enflurane | 0 | low | 2 | 0 |
| enoxacin | 0 | low | 3 | 0 |
| erythrosine | 0 | medium | 35 | 1 |
| ethacrynic acid | 0 | medium | 3 | 1 |
| ether | 0 | low | 4 | 0 |
| ethoxyquin | 0 | low | 8 | 0 |
| ethoxyresorufin | 0 | low | 7 | 0 |
| etidronate | 0 | low | 3 | 0 |
| etodolac | 0 | low | 8 | 0 |
| brl 42810 | 0 | low | 5 | 0 |
| famotidine | 0 | medium | 8 | 2 |
| felbamate | 0 | low | 1 | 0 |
| felodipine | 0 | low | 1 | 0 |
| fenbendazole | 0 | low | 1 | 0 |
| fendiline | 0 | low | 1 | 0 |
| fenfluramine | 0 | low | 1 | 0 |
| fenipentol | 0 | low | 1 | 0 |
| fenofibrate | 0 | medium | 16 | 1 |
| berotek | 0 | low | 2 | 0 |
| fentanyl | 0 | medium | 18 | 3 |
| fenthion | 0 | low | 1 | 0 |
| fluconazole | 0 | low | 3 | 0 |
| flucytosine | 0 | medium | 29 | 2 |
| flufenamic acid | 0 | low | 6 | 0 |
| fluphenazine | 0 | low | 1 | 0 |
| flumequine | 0 | low | 2 | 0 |
| fluorouracil | 0 | medium | 3,967 | 738 |
| fluoxetine | 0 | low | 7 | 0 |
| flurbiprofen | 0 | low | 3 | 0 |
| fluspirilene | 0 | low | 1 | 0 |
| flutamide | 0 | medium | 13 | 6 |
| fomepizole | 0 | low | 3 | 0 |
| furazolidone | 0 | low | 2 | 0 |
| furosemide | 0 | low | 12 | 0 |
| fusaric acid | 0 | low | 3 | 0 |
| gabapentin | 0 | low | 2 | 0 |
| gabexate | 0 | medium | 8 | 2 |
| vanoxerine | 0 | low | 1 | 0 |
| gemfibrozil | 0 | low | 7 | 0 |
| gentamicin | 0 | low | 10 | 0 |
| 2,5-dihydroxybenzoic acid | 0 | low | 1 | 0 |
| gliclazide | 0 | medium | 2 | 1 |
| glimepiride | 0 | medium | 2 | 1 |
| glipizide | 0 | low | 2 | 0 |
| glutaral | 0 | medium | 9 | 1 |
| glutethimide | 0 | low | 1 | 0 |
| glyburide | 0 | low | 5 | 0 |
| glyphosate | 0 | low | 3 | 0 |
| gö6983 | 0 | low | 1 | 0 |
| go 6976 | 0 | medium | 4 | 1 |
| gossypol | 0 | low | 13 | 0 |
| guaifenesin | 0 | low | 10 | 0 |
| guanethidine | 0 | low | 1 | 0 |
| guanidine | 0 | low | 2 | 0 |
| n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide | 0 | low | 1 | 0 |
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine | 0 | low | 22 | 0 |
| ha 1004 | 0 | low | 1 | 0 |
| fasudil | 0 | low | 6 | 0 |
| ha14-1 | 0 | low | 3 | 0 |
| haloperidol | 0 | low | 7 | 0 |
| halothane | 0 | low | 19 | 0 |
| heptachlor | 0 | low | 2 | 0 |
| miltefosine | 0 | medium | 2 | 1 |
| hexestrol | 0 | low | 1 | 0 |
| hexobarbital | 0 | low | 9 | 0 |
| beta-thujaplicin | 0 | low | 1 | 0 |
| hexamethylene bisacetamide | 0 | medium | 9 | 1 |
| ethidium | 0 | low | 11 | 0 |
| hycanthone | 0 | low | 4 | 0 |
| hydralazine | 0 | low | 4 | 0 |
| hydrochlorothiazide | 0 | medium | 3 | 1 |
| hydroxychloroquine | 0 | low | 3 | 0 |
| velnacrine | 0 | low | 1 | 0 |
| hydroxyurea | 0 | medium | 42 | 2 |
| hydroxyzine | 0 | medium | 1 | 1 |
| hypericin | 0 | low | 5 | 0 |
| ibuprofen | 0 | low | 6 | 0 |
| phenelzine | 0 | low | 2 | 0 |
| lidocaine | 0 | medium | 29 | 2 |
| mephentermine | 0 | low | 1 | 0 |
| ifenprodil | 0 | low | 1 | 0 |
| ifosfamide | 0 | medium | 85 | 11 |
| imipramine | 0 | low | 2 | 0 |
| indirubin-3'-monoxime | 0 | low | 1 | 0 |
| indole-3-carbinol | 0 | low | 15 | 0 |
| indomethacin | 0 | medium | 39 | 2 |
| iodamide | 0 | low | 8 | 0 |
| iodixanol | 0 | medium | 26 | 3 |
| iodoacetamide | 0 | low | 6 | 0 |
| iofetamine | 0 | low | 11 | 0 |
| iohexol | 0 | medium | 158 | 19 |
| iomeprol | 0 | medium | 35 | 7 |
| iopanoic acid | 0 | low | 4 | 0 |
| iopromide | 0 | medium | 76 | 6 |
| iothalamic acid | 0 | medium | 9 | 1 |
| iodipamide | 0 | low | 3 | 0 |
| ioversol | 0 | medium | 16 | 3 |
| ioxaglate | 0 | low | 1 | 0 |
| ioxilan | 0 | low | 1 | 0 |
| iproniazid | 0 | low | 1 | 0 |
| avapro | 0 | low | 2 | 0 |
| irsogladine | 0 | low | 1 | 0 |
| 1-methyl-3-isobutylxanthine | 0 | low | 9 | 0 |
| isocarboxazid | 0 | low | 1 | 0 |
| isoflurane | 0 | medium | 9 | 2 |
| isoniazid | 0 | low | 26 | 0 |
| isoproterenol | 0 | low | 20 | 0 |
| juglone | 0 | low | 3 | 0 |
| staurosporine aglycone | 0 | low | 2 | 0 |
| nsc 664704 | 0 | low | 1 | 0 |
| ketamine | 0 | medium | 7 | 4 |
| ketanserin | 0 | low | 4 | 0 |
| ketoconazole | 0 | medium | 27 | 2 |
| ketoprofen | 0 | low | 2 | 0 |
| ketorolac | 0 | medium | 1 | 1 |
| kojic acid | 0 | low | 5 | 0 |
| kynurenic acid | 0 | low | 1 | 0 |
| labetalol | 0 | low | 1 | 0 |
| lansoprazole | 0 | low | 2 | 0 |
| lapachol | 0 | low | 1 | 0 |
| beta-lapachone | 0 | low | 4 | 0 |
| lauric acid | 0 | low | 1 | 0 |
| leflunomide | 0 | low | 3 | 0 |
| letrozole | 0 | medium | 10 | 1 |
| tetramisole | 0 | low | 1 | 0 |
| lg 100268 | 0 | low | 3 | 0 |
| lomustine | 0 | medium | 17 | 1 |
| lorazepam | 0 | low | 1 | 0 |
| losartan | 0 | low | 3 | 0 |
| ly 171883 | 0 | low | 1 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 0 | low | 53 | 0 |
| 6-anilino-5,8-quinolinedione | 0 | low | 1 | 0 |
| edaravone | 0 | low | 2 | 0 |
| mebendazole | 0 | low | 3 | 0 |
| mecamylamine | 0 | low | 1 | 0 |
| mechlorethamine | 0 | medium | 64 | 2 |
| meclizine | 0 | low | 1 | 0 |
| meclofenamic acid | 0 | low | 1 | 0 |
| medazepam | 0 | low | 1 | 0 |
| mefenamic acid | 0 | low | 1 | 0 |
| memantine | 0 | medium | 3 | 2 |
| vitamin k 3 | 0 | medium | 12 | 1 |
| meperidine | 0 | low | 1 | 0 |
| mepivacaine | 0 | low | 1 | 0 |
| mesalamine | 0 | low | 1 | 0 |
| metaproterenol | 0 | low | 1 | 0 |
| metformin | 0 | medium | 201 | 7 |
| methacrylic acid | 0 | low | 1 | 0 |
| methadone | 0 | medium | 8 | 3 |
| methapyrilene | 0 | low | 15 | 0 |
| methenamine | 0 | low | 3 | 0 |
| methoxsalen | 0 | low | 4 | 0 |
| methoxychlor | 0 | low | 4 | 0 |
| methoxyflurane | 0 | low | 3 | 0 |
| nocodazole | 0 | low | 9 | 0 |
| methyl salicylate | 0 | medium | 3 | 2 |
| methyl methanesulfonate | 0 | low | 6 | 0 |
| methylphenidate | 0 | low | 1 | 0 |
| metoclopramide | 0 | medium | 5 | 1 |
| metoprolol | 0 | low | 3 | 0 |
| metronidazole | 0 | medium | 16 | 2 |
| metyrapone | 0 | low | 6 | 0 |
| n-methyl-d-glucamine dithiocarbamate | 0 | low | 1 | 0 |
| mianserin | 0 | low | 1 | 0 |
| miconazole | 0 | low | 1 | 0 |
| midazolam | 0 | low | 11 | 0 |
| milrinone | 0 | low | 1 | 0 |
| mirtazapine | 0 | low | 1 | 0 |
| mitotane | 0 | low | 21 | 0 |
| mitoxantrone | 0 | medium | 79 | 21 |
| moclobemide | 0 | low | 1 | 0 |
| molsidomine | 0 | low | 2 | 0 |
| monodansylcadaverine | 0 | low | 1 | 0 |
| entinostat | 0 | low | 8 | 0 |
| muscimol | 0 | low | 2 | 0 |
| myristicin | 0 | low | 1 | 0 |
| 1,3-dicyclohexylurea | 0 | low | 1 | 0 |
| n(1),n(11)-diethylnorspermine | 0 | medium | 1 | 1 |
| ethylmaleimide | 0 | low | 19 | 0 |
| nafamostat | 0 | low | 6 | 0 |
| nafoxidine | 0 | low | 1 | 0 |
| activins | 0 | low | 25 | 0 |
| neostigmine | 0 | low | 1 | 0 |
| ubiquinone q1 | 0 | low | 1 | 0 |
| nevirapine | 0 | low | 2 | 0 |
| nicardipine | 0 | low | 2 | 0 |
| niclosamide | 0 | low | 8 | 0 |
| nifedipine | 0 | low | 7 | 0 |
| niflumic acid | 0 | low | 1 | 0 |
| nilutamide | 0 | medium | 1 | 1 |
| nimesulide | 0 | low | 7 | 0 |
| nimodipine | 0 | low | 1 | 0 |
| nitidine | 0 | low | 10 | 0 |
| nitroglycerin | 0 | medium | 8 | 1 |
| norfloxacin | 0 | low | 1 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | 0 | low | 22 | 0 |
| o(6)-benzylguanine | 0 | low | 1 | 0 |
| octopamine | 0 | low | 2 | 0 |
| ofloxacin | 0 | medium | 6 | 3 |
| olprinone | 0 | medium | 2 | 1 |
| omeprazole | 0 | low | 19 | 0 |
| ondansetron | 0 | low | 3 | 0 |
| orphenadrine | 0 | low | 3 | 0 |
| oxonic acid | 0 | medium | 387 | 34 |
| 1,2-cyclohexanediamine | 0 | low | 2 | 0 |
| oxamniquine | 0 | low | 1 | 0 |
| oxazepam | 0 | low | 4 | 0 |
| oxidopamine | 0 | low | 1 | 0 |
| oxprenolol | 0 | low | 2 | 0 |
| oxybutynin | 0 | low | 2 | 0 |
| oxyphenbutazone | 0 | low | 1 | 0 |
| aminosalicylic acid | 0 | low | 4 | 0 |
| quinone | 0 | low | 2 | 0 |
| fenclonine | 0 | low | 8 | 0 |
| pamidronate | 0 | low | 7 | 0 |
| pantoprazole | 0 | low | 3 | 0 |
| papaverine | 0 | low | 5 | 0 |
| 4-dichlorobenzene | 0 | low | 2 | 0 |
| 1,7-dimethylxanthine | 0 | low | 1 | 0 |
| pargyline | 0 | low | 4 | 0 |
| patulin | 0 | low | 2 | 0 |
| pd 153035 | 0 | low | 3 | 0 |
| pd 98059 | 0 | low | 38 | 0 |
| pentobarbital | 0 | low | 10 | 0 |
| pentoxifylline | 0 | medium | 12 | 3 |
| perhexiline | 0 | low | 2 | 0 |
| phenacetin | 0 | medium | 13 | 2 |
| phenindione | 0 | low | 1 | 0 |
| phenobarbital | 0 | low | 322 | 0 |
| phenolsulfonphthalein | 0 | low | 4 | 0 |
| phenoxybenzamine | 0 | low | 6 | 0 |
| 4-phenylbutyric acid | 0 | low | 11 | 0 |
| oxophenylarsine | 0 | low | 1 | 0 |
| phenylbutazone | 0 | low | 10 | 0 |
| phenylmethylsulfonyl fluoride | 0 | low | 3 | 0 |
| phloretin | 0 | low | 5 | 0 |
| pifithrin | 0 | low | 6 | 0 |
| pimobendan | 0 | low | 1 | 0 |
| pindolol | 0 | low | 2 | 0 |
| pioglitazone | 0 | medium | 21 | 1 |
| piperazine | 0 | low | 2 | 0 |
| potassium chloride | 0 | low | 19 | 0 |
| potassium iodide | 0 | medium | 4 | 2 |
| 4-aminobenzoic acid | 0 | low | 2 | 0 |
| ag 1879 | 0 | low | 5 | 0 |
| practolol | 0 | low | 2 | 0 |
| praziquantel | 0 | low | 5 | 0 |
| prazosin | 0 | low | 1 | 0 |
| prilocaine | 0 | low | 1 | 0 |
| primaquine | 0 | low | 13 | 0 |
| proadifen | 0 | low | 7 | 0 |
| probenecid | 0 | low | 3 | 0 |
| probucol | 0 | low | 4 | 0 |
| procaine | 0 | low | 5 | 0 |
| procarbazine | 0 | medium | 16 | 1 |
| proglumide | 0 | medium | 10 | 3 |
| promazine | 0 | low | 1 | 0 |
| propantheline | 0 | low | 1 | 0 |
| propidium | 0 | low | 13 | 0 |
| propofol | 0 | medium | 37 | 7 |
| propranolol | 0 | medium | 76 | 1 |
| propyl gallate | 0 | low | 2 | 0 |
| protopine | 0 | low | 1 | 0 |
| protoporphyrin ix | 0 | low | 17 | 0 |
| pyridinolcarbamate | 0 | low | 1 | 0 |
| pyrilamine | 0 | low | 4 | 0 |
| pyrimethamine | 0 | medium | 2 | 1 |
| opc 12759 | 0 | medium | 1 | 1 |
| resorcinol | 0 | low | 1 | 0 |
| riluzole | 0 | low | 2 | 0 |
| rimantadine | 0 | low | 1 | 0 |
| ro 31-8220 | 0 | low | 2 | 0 |
| rofecoxib | 0 | medium | 9 | 4 |
| rolipram | 0 | low | 1 | 0 |
| 4-bromotetramisole | 0 | low | 1 | 0 |
| s-methylisothiopseudouronium | 0 | low | 1 | 0 |
| saccharin | 0 | low | 12 | 0 |
| safrole | 0 | low | 16 | 0 |
| salicylamide | 0 | low | 1 | 0 |
| sanguinarine | 0 | low | 5 | 0 |
| sb 239063 | 0 | low | 1 | 0 |
| sb 202190 | 0 | low | 3 | 0 |
| scriptaid | 0 | low | 2 | 0 |
| sebacic acid | 0 | low | 1 | 0 |
| semustine | 0 | medium | 20 | 9 |
| sevoflurane | 0 | medium | 12 | 3 |
| sulfadiazine | 0 | medium | 2 | 1 |
| linsidomine | 0 | low | 2 | 0 |
| sodium fluoride | 0 | medium | 6 | 2 |
| fluoroacetic acid | 0 | low | 1 | 0 |
| sodium iodide | 0 | low | 2 | 0 |
| stearic acid | 0 | low | 10 | 0 |
| streptonigrin | 0 | low | 5 | 0 |
| vorinostat | 0 | medium | 43 | 2 |
| succinylacetone | 0 | low | 9 | 0 |
| succinylcholine | 0 | low | 2 | 0 |
| sulfadimethoxine | 0 | low | 1 | 0 |
| sulfamethazine | 0 | low | 1 | 0 |
| sulfamethoxazole | 0 | low | 1 | 0 |
| sulfamonomethoxine | 0 | low | 1 | 0 |
| sulfanilamide | 0 | low | 1 | 0 |
| sulfaphenazole | 0 | low | 2 | 0 |
| sulfapyridine | 0 | low | 1 | 0 |
| sulfasalazine | 0 | low | 13 | 0 |
| sulfinpyrazone | 0 | low | 2 | 0 |
| sulfisoxazole | 0 | low | 3 | 0 |
| sulfobromophthalein | 0 | low | 59 | 0 |
| sulforaphane | 0 | low | 20 | 0 |
| suramin | 0 | low | 7 | 0 |
| suxibuzone | 0 | low | 1 | 0 |
| tazarotene | 0 | low | 1 | 0 |
| 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | 0 | low | 6 | 0 |
| tegafur | 0 | medium | 696 | 85 |
| temazepam | 0 | low | 1 | 0 |
| temozolomide | 0 | medium | 31 | 9 |
| terbutaline | 0 | low | 2 | 0 |
| terfenadine | 0 | low | 3 | 0 |
| tetraethylammonium | 0 | low | 2 | 0 |
| krypton | 0 | low | 3 | 0 |
| thalidomide | 0 | medium | 83 | 19 |
| theobromine | 0 | medium | 2 | 1 |
| thiabendazole | 0 | low | 2 | 0 |
| 2,4-thiazolidinedione | 0 | low | 3 | 0 |
| thioridazine | 0 | low | 1 | 0 |
| thiotepa | 0 | medium | 32 | 5 |
| ticlopidine | 0 | low | 7 | 0 |
| tinidazole | 0 | low | 1 | 0 |
| tiopronin | 0 | medium | 2 | 1 |
| 8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate | 0 | low | 2 | 0 |
| nikethamide | 0 | low | 1 | 0 |
| tolazamide | 0 | low | 1 | 0 |
| tolazoline | 0 | low | 5 | 0 |
| tolbutamide | 0 | low | 16 | 0 |
| tranexamic acid | 0 | medium | 8 | 1 |
| trapidil | 0 | low | 1 | 0 |
| triamterene | 0 | medium | 3 | 1 |
| bromoform | 0 | low | 1 | 0 |
| trichlormethiazide | 0 | low | 1 | 0 |
| triclosan | 0 | medium | 5 | 1 |
| trientine | 0 | medium | 4 | 1 |
| trifluoperazine | 0 | low | 7 | 0 |
| trigonelline | 0 | low | 3 | 0 |
| trimethadione | 0 | low | 1 | 0 |
| trimethoprim | 0 | low | 1 | 0 |
| trimetrexate | 0 | medium | 6 | 3 |
| tripelennamine | 0 | low | 1 | 0 |
| troglitazone | 0 | low | 27 | 0 |
| tropicamide | 0 | low | 1 | 0 |
| tyramine | 0 | low | 12 | 0 |
| urapidil | 0 | low | 1 | 0 |
| urethane | 0 | low | 74 | 0 |
| usnic acid | 0 | low | 5 | 0 |
| vesnarinone | 0 | low | 1 | 0 |
| viloxazine | 0 | low | 1 | 0 |
| vinca | 0 | low | 1 | 0 |
| w 7 | 0 | low | 4 | 0 |
| pirinixic acid | 0 | medium | 25 | 1 |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | 0 | low | 11 | 0 |
| ici 204,219 | 0 | low | 1 | 0 |
| zardaverine | 0 | low | 1 | 0 |
| zinc chloride | 0 | low | 3 | 0 |
| zm 336372 | 0 | low | 1 | 0 |
| zolpidem | 0 | low | 1 | 0 |
| hydrocortisone acetate | 0 | low | 1 | 0 |
| mitomycin | 0 | medium | 896 | 126 |
| corticosterone | 0 | low | 29 | 0 |
| prednisolone | 0 | medium | 141 | 3 |
| estriol | 0 | low | 12 | 0 |
| reserpine | 0 | low | 5 | 0 |
| phentolamine | 0 | low | 4 | 0 |
| sorbitol | 0 | low | 11 | 0 |
| alloxan | 0 | low | 7 | 0 |
| thymidine | 0 | medium | 323 | 1 |
| floxuridine | 0 | medium | 523 | 104 |
| piperonyl butoxide | 0 | low | 4 | 0 |
| benzimidazole | 0 | low | 6 | 0 |
| triethylenemelamine | 0 | low | 7 | 0 |
| 2-aminophenol | 0 | low | 1 | 0 |
| bromouracil | 0 | low | 1 | 0 |
| 3,3',5-triiodothyroacetic acid | 0 | low | 2 | 0 |
| hydroxyproline | 0 | low | 19 | 0 |
| thyroxine | 0 | low | 76 | 0 |
| dibenzylchlorethamine | 0 | low | 1 | 0 |
| dextroamphetamine | 0 | low | 1 | 0 |
| methacetin | 0 | medium | 10 | 2 |
| carbachol | 0 | low | 1 | 0 |
| norethindrone acetate | 0 | low | 4 | 0 |
| spironolactone | 0 | medium | 8 | 1 |
| prednisolone acetate | 0 | low | 1 | 0 |
| aldosterone | 0 | low | 19 | 0 |
| allobarbital | 0 | low | 1 | 0 |
| penicillamine | 0 | low | 17 | 0 |
| trichlorfon | 0 | low | 2 | 0 |
| lynestrenol | 0 | low | 11 | 0 |
| norethandrolone | 0 | low | 10 | 0 |
| tetrahydrocortisol | 0 | low | 3 | 0 |
| prednisone | 0 | medium | 206 | 8 |
| estrone | 0 | medium | 31 | 2 |
| fluprednisolone | 0 | low | 1 | 0 |
| androsterone | 0 | low | 5 | 0 |
| etiocholanolone | 0 | low | 2 | 0 |
| dehydroepiandrosterone | 0 | medium | 30 | 2 |
| dichlororibofuranosylbenzimidazole | 0 | low | 1 | 0 |
| hydroxyacetylaminofluorene | 0 | low | 12 | 0 |
| 2-acetylaminofluorene | 0 | low | 334 | 0 |
| azauridine | 0 | low | 4 | 0 |
| penicillin g | 0 | low | 2 | 0 |
| idoxuridine | 0 | medium | 30 | 1 |
| metaraminol | 0 | low | 1 | 0 |
| triiodothyronine | 0 | low | 100 | 0 |
| diethylnitrosamine | 0 | low | 1,008 | 0 |
| methyldimethylaminoazobenzene | 0 | low | 115 | 0 |
| isoflurophate | 0 | low | 5 | 0 |
| biguanides | 0 | low | 2 | 0 |
| carbon tetrachloride | 0 | low | 163 | 0 |
| cantharidin | 0 | medium | 32 | 1 |
| alanine | 0 | medium | 85 | 9 |
| serine | 0 | low | 108 | 0 |
| desoxycorticosterone acetate | 0 | low | 2 | 0 |
| benz(a)anthracene | 0 | low | 9 | 0 |
| 4-nitroquinoline-1-oxide | 0 | low | 10 | 0 |
| chloramphenicol | 0 | low | 23 | 0 |
| aspartic acid | 0 | medium | 59 | 1 |
| glutamine | 0 | medium | 126 | 4 |
| lysine | 0 | low | 121 | 0 |
| allyl isothiocyanate | 0 | low | 5 | 0 |
| cyanides | 0 | low | 21 | 0 |
| physostigmine | 0 | low | 1 | 0 |
| sucrose | 0 | low | 39 | 0 |
| ethinyl estradiol | 0 | medium | 69 | 1 |
| chlordan | 0 | low | 6 | 0 |
| testosterone propionate | 0 | low | 3 | 0 |
| tubocurarine | 0 | low | 5 | 0 |
| 9,10-dimethyl-1,2-benzanthracene | 0 | low | 50 | 0 |
| apomorphine | 0 | low | 1 | 0 |
| aminopyrine | 0 | low | 25 | 0 |
| methyltestosterone | 0 | low | 26 | 0 |
| puromycin aminonucleoside | 0 | low | 2 | 0 |
| adenosine diphosphate | 0 | low | 30 | 0 |
| cephalothin | 0 | low | 1 | 0 |
| 2,3,4,6-tetrachlorophenol | 0 | low | 4 | 0 |
| uridine | 0 | low | 135 | 0 |
| uridine monophosphate | 0 | medium | 16 | 3 |
| uridine diphosphate | 0 | low | 4 | 0 |
| kanamycin a | 0 | low | 1 | 0 |
| bromodeoxyuridine | 0 | medium | 87 | 1 |
| galactose | 0 | medium | 152 | 3 |
| carbostyril | 0 | medium | 30 | 5 |
| phenylephrine | 0 | medium | 4 | 1 |
| n-nitrosomorpholine | 0 | low | 49 | 0 |
| levodopa | 0 | low | 3 | 0 |
| edetic acid | 0 | medium | 172 | 31 |
| tributyrin | 0 | low | 4 | 0 |
| p-aminoazobenzene | 0 | low | 13 | 0 |
| p-dimethylaminoazobenzene | 0 | low | 594 | 0 |
| phenylethyl alcohol | 0 | low | 13 | 0 |
| tyrosine | 0 | medium | 188 | 3 |
| cysteamine | 0 | low | 6 | 0 |
| monomethylhydrazine | 0 | low | 3 | 0 |
| veratramine | 0 | low | 1 | 0 |
| phlorhizin | 0 | low | 4 | 0 |
| methoxamine | 0 | low | 2 | 0 |
| adenosine monophosphate | 0 | low | 40 | 0 |
| cloxacillin | 0 | low | 1 | 0 |
| methylene blue | 0 | low | 11 | 0 |
| 4-toluenesulfonic acid | 0 | low | 1 | 0 |
| zoxazolamine | 0 | low | 2 | 0 |
| leucine | 0 | low | 173 | 0 |
| aniline | 0 | low | 6 | 0 |
| 2-aminoisobutyric acid | 0 | low | 2 | 0 |
| dimethylnitrosamine | 0 | low | 125 | 0 |
| androstenedione | 0 | low | 12 | 0 |
| carbaryl | 0 | low | 1 | 0 |
| cytidine monophosphate | 0 | medium | 4 | 2 |
| cytidine diphosphate | 0 | low | 1 | 0 |
| uridine triphosphate | 0 | low | 2 | 0 |
| lactose | 0 | low | 27 | 0 |
| methionine | 0 | medium | 195 | 2 |
| 1,2-dipalmitoylphosphatidylcholine | 0 | low | 2 | 0 |
| phenylalanine | 0 | medium | 87 | 4 |
| desoxycorticosterone | 0 | low | 14 | 0 |
| colchicine | 0 | medium | 48 | 1 |
| cytidine | 0 | low | 24 | 0 |
| cytidine triphosphate | 0 | low | 5 | 0 |
| uracil mustard | 0 | low | 2 | 0 |
| oxacillin | 0 | low | 1 | 0 |
| cycloheximide | 0 | low | 190 | 0 |
| ficusin | 0 | low | 3 | 0 |
| egtazic acid | 0 | low | 12 | 0 |
| barbituric acid | 0 | low | 5 | 0 |
| chloroform | 0 | low | 22 | 0 |
| dimethyl sulfone | 0 | low | 1 | 0 |
| hexachloroethane | 0 | low | 3 | 0 |
| gliotoxin | 0 | low | 1 | 0 |
| sodium citrate, anhydrous | 0 | low | 2 | 0 |
| dimethylformamide | 0 | low | 6 | 0 |
| norethindrone | 0 | low | 32 | 0 |
| norethynodrel | 0 | low | 18 | 0 |
| cycloserine | 0 | low | 1 | 0 |
| triaziquone | 0 | low | 3 | 0 |
| 17-alpha-hydroxyprogesterone | 0 | low | 2 | 0 |
| tubercidin | 0 | low | 5 | 0 |
| ampicillin | 0 | low | 7 | 0 |
| mannitol | 0 | medium | 15 | 1 |
| cytarabine | 0 | medium | 57 | 4 |
| dithionitrobenzoic acid | 0 | low | 1 | 0 |
| trifluridine | 0 | medium | 19 | 4 |
| ornithine | 0 | low | 39 | 0 |
| asparagine | 0 | low | 32 | 0 |
| 4-toluenesulfonamide | 0 | low | 1 | 0 |
| 4-hydroxypropiophenone | 0 | low | 3 | 0 |
| histidine | 0 | medium | 50 | 2 |
| 1,1,1-trichloroethane | 0 | low | 4 | 0 |
| medroxyprogesterone acetate | 0 | medium | 28 | 5 |
| valine | 0 | medium | 61 | 1 |
| threonine | 0 | low | 19 | 0 |
| mestranol | 0 | low | 55 | 0 |
| methaqualone | 0 | low | 1 | 0 |
| alizarin | 0 | low | 1 | 0 |
| dichlorodiphenyldichloroethane | 0 | medium | 13 | 1 |
| perthane | 0 | low | 1 | 0 |
| methandrostenolone | 0 | low | 4 | 0 |
| chlorquinaldol | 0 | medium | 1 | 1 |
| cordycepin | 0 | low | 8 | 0 |
| tryptophan | 0 | low | 118 | 0 |
| isoleucine | 0 | low | 20 | 0 |
| n,n'-diphenyl-4-phenylenediamine | 0 | low | 4 | 0 |
| arginine | 0 | medium | 119 | 5 |
| ethane | 0 | low | 5 | 0 |
| ethylene | 0 | medium | 4 | 2 |
| acetylene | 0 | low | 2 | 0 |
| methylamine | 0 | low | 1 | 0 |
| boranes | 0 | low | 3 | 0 |
| propane | 0 | low | 13 | 0 |
| ethyl chloride | 0 | low | 2 | 0 |
| vinyl chloride | 0 | medium | 237 | 1 |
| vinyl fluoride | 0 | low | 4 | 0 |
| acetonitrile | 0 | low | 2 | 0 |
| methylene chloride | 0 | low | 22 | 0 |
| carbon disulfide | 0 | low | 1 | 0 |
| ethylene oxide | 0 | low | 4 | 0 |
| bromodichloromethane | 0 | low | 2 | 0 |
| phosgene | 0 | low | 1 | 0 |
| fluorocarbon 22 | 0 | low | 1 | 0 |
| nitromethane | 0 | low | 1 | 0 |
| propylene oxide | 0 | low | 1 | 0 |
| trichlorofluoromethane | 0 | low | 1 | 0 |
| dichlorodifluoromethane | 0 | low | 1 | 0 |
| tert-butylhydroperoxide | 0 | low | 21 | 0 |
| trichloroacetic acid | 0 | low | 23 | 0 |
| perflutren | 0 | low | 14 | 0 |
| triamcinolone acetonide | 0 | low | 7 | 0 |
| fluoxymesterone | 0 | medium | 5 | 2 |
| bromcresol green | 0 | low | 1 | 0 |
| phencyclidine | 0 | medium | 14 | 1 |
| butobarbital | 0 | low | 1 | 0 |
| dimethyl sulfate | 0 | low | 1 | 0 |
| tromethamine | 0 | medium | 4 | 1 |
| quinic acid | 0 | low | 2 | 0 |
| tetraethoxysilane | 0 | low | 1 | 0 |
| triparanol | 0 | low | 4 | 0 |
| linalool | 0 | low | 1 | 0 |
| isoprene | 0 | low | 12 | 0 |
| methylethyl ketone | 0 | low | 1 | 0 |
| trichloroethylene | 0 | low | 39 | 0 |
| dichloroacetaldehyde | 0 | low | 1 | 0 |
| acrylamide | 0 | low | 6 | 0 |
| acrylic acid | 0 | medium | 3 | 1 |
| isobutyric acid | 0 | low | 1 | 0 |
| methacrylamide | 0 | low | 1 | 0 |
| dichloroacetic acid | 0 | low | 23 | 0 |
| dimethisterone | 0 | low | 2 | 0 |
| pantothenic acid | 0 | low | 1 | 0 |
| tetrabromobisphenol a | 0 | low | 3 | 0 |
| bisphenol a | 0 | low | 8 | 0 |
| bis(4-hydroxyphenyl)sulfone | 0 | low | 1 | 0 |
| cumene hydroperoxide | 0 | low | 1 | 0 |
| alpha-pinene | 0 | low | 4 | 0 |
| musk ketone | 0 | low | 1 | 0 |
| dehydrocholic acid | 0 | low | 1 | 0 |
| taurocholic acid | 0 | low | 22 | 0 |
| rhodamine b | 0 | medium | 8 | 1 |
| cyclizine | 0 | low | 1 | 0 |
| methylprednisolone | 0 | medium | 46 | 4 |
| musk ambrette (artificial) | 0 | low | 1 | 0 |
| vitamin k5 | 0 | low | 1 | 0 |
| rotenone | 0 | low | 24 | 0 |
| 2-methylanthraquinone | 0 | low | 1 | 0 |
| 9,10-anthraquinone | 0 | low | 2 | 0 |
| diethyl phthalate | 0 | low | 1 | 0 |
| benzo(f)quinoline | 0 | low | 1 | 0 |
| phthalimide | 0 | low | 1 | 0 |
| pyocyanine | 0 | low | 1 | 0 |
| fluorene | 0 | low | 15 | 0 |
| carbazole | 0 | low | 6 | 0 |
| isosorbide dinitrate | 0 | low | 2 | 0 |
| penicillanic acid | 0 | low | 3 | 0 |
| hexachlorobutadiene | 0 | low | 1 | 0 |
| xylitol | 0 | low | 1 | 0 |
| n-vinyl-2-pyrrolidinone | 0 | medium | 12 | 1 |
| 2-nitrotoluene | 0 | low | 1 | 0 |
| 2,3,5-triiodobenzoic acid | 0 | low | 2 | 0 |
| picryl chloride | 0 | low | 1 | 0 |
| picric acid | 0 | low | 1 | 0 |
| thymol | 0 | low | 14 | 0 |
| 1-naphthol | 0 | low | 2 | 0 |
| 2-aminodiphenyl | 0 | low | 1 | 0 |
| 2-phenylphenol | 0 | low | 1 | 0 |
| aminacrine | 0 | low | 4 | 0 |
| xanthone | 0 | low | 2 | 0 |
| beta-glucono-1,5-lactone | 0 | low | 1 | 0 |
| quinoxalines | 0 | medium | 39 | 2 |
| 1,2,3,4-tetrahydroisoquinoline | 0 | low | 1 | 0 |
| quinoline | 0 | low | 6 | 0 |
| 2-nitroanisole | 0 | low | 1 | 0 |
| isatin | 0 | low | 3 | 0 |
| 2-naphthylamine | 0 | medium | 18 | 1 |
| 2-methylquinoline | 0 | low | 1 | 0 |
| thenyldiamine | 0 | low | 2 | 0 |
| 3,3'-dichlorobenzidine | 0 | low | 1 | 0 |
| tolonium chloride | 0 | low | 5 | 0 |
| diphenyl | 0 | low | 3 | 0 |
| proflavine | 0 | low | 1 | 0 |
| 4-biphenylamine | 0 | low | 9 | 0 |
| xanthenes | 0 | low | 23 | 0 |
| benzidine | 0 | low | 5 | 0 |
| methyleugenol | 0 | low | 4 | 0 |
| 1-phenylpropanol | 0 | low | 1 | 0 |
| methyl benzoate | 0 | low | 1 | 0 |
| cdaa | 0 | low | 4 | 0 |
| fenoprop | 0 | low | 1 | 0 |
| propylparaben | 0 | low | 1 | 0 |
| 2-methyl-4-chlorophenoxyacetic acid | 0 | low | 3 | 0 |
| benzotriazole | 0 | low | 1 | 0 |
| benzothiophene | 0 | low | 1 | 0 |
| benzothiazole | 0 | low | 3 | 0 |
| 2-toluidine | 0 | low | 1 | 0 |
| 1,2-diaminobenzene | 0 | low | 2 | 0 |
| 2,4-diaminotoluene | 0 | low | 2 | 0 |
| 2,4,5-trichlorophenol | 0 | low | 1 | 0 |
| styrene oxide | 0 | low | 1 | 0 |
| 1,2-dibromo-3-chloropropane | 0 | low | 1 | 0 |
| 1,2,3-trichloropropane | 0 | low | 2 | 0 |
| diethyl ketone | 0 | low | 1 | 0 |
| methyl acrylate | 0 | medium | 1 | 1 |
| 4-butyrolactone | 0 | low | 9 | 0 |
| lactobionic acid | 0 | low | 18 | 0 |
| sulfosalicylic acid | 0 | low | 1 | 0 |
| phosphoribosyl pyrophosphate | 0 | low | 4 | 0 |
| o-aminoazotoluene | 0 | low | 27 | 0 |
| butyl methacrylate | 0 | low | 1 | 0 |
| ethylene dimethacrylate | 0 | low | 1 | 0 |
| furaldehyde | 0 | low | 3 | 0 |
| benzenearsonic acid | 0 | low | 1 | 0 |
| pyrrolidonecarboxylic acid | 0 | medium | 4 | 1 |
| cumene | 0 | low | 1 | 0 |
| alpha-methylstyrol | 0 | low | 1 | 0 |
| acetophenone | 0 | low | 1 | 0 |
| nitrobenzene | 0 | low | 1 | 0 |
| trehalose | 0 | low | 10 | 0 |
| methyl gallate | 0 | low | 1 | 0 |
| 1,2-dichloro-4-nitrobenzene | 0 | low | 1 | 0 |
| 4-bromophenacyl bromide | 0 | low | 1 | 0 |
| alpha phellandrene | 0 | low | 1 | 0 |
| 4-cymene | 0 | low | 1 | 0 |
| 4-hydroxyacetophenone | 0 | low | 1 | 0 |
| dimethyl-4-toluidine | 0 | low | 1 | 0 |
| 4-chloronitrobenzene | 0 | low | 1 | 0 |
| 4-(dimethylamino)benzaldehyde | 0 | low | 1 | 0 |
| ethylbenzene | 0 | medium | 1 | 1 |
| styrene | 0 | low | 2 | 0 |
| nicotinyl alcohol | 0 | low | 1 | 0 |
| n-nitrosopiperidine | 0 | low | 10 | 0 |
| quinuclidines | 0 | medium | 4 | 1 |
| cyclamic acid | 0 | low | 7 | 0 |
| 4-bromophenyl phenyl ether | 0 | low | 1 | 0 |
| n,n,n',n'-tetramethyl-4,4'-methylenedianiline | 0 | low | 1 | 0 |
| 4,4'-diphenylmethane diisocyanate | 0 | low | 1 | 0 |
| 4,4'-diaminodiphenylmethane | 0 | low | 3 | 0 |
| triethanolamine | 0 | low | 2 | 0 |
| boric acid | 0 | low | 10 | 0 |
| caprolactam | 0 | medium | 4 | 2 |
| 4-toluidine | 0 | low | 1 | 0 |
| 4-phenylenediamine | 0 | low | 2 | 0 |
| epichlorohydrin | 0 | low | 1 | 0 |
| ethylene dibromide | 0 | low | 2 | 0 |
| 1-bromopropane | 0 | low | 1 | 0 |
| 1,3-butadiene | 0 | low | 4 | 0 |
| acrolein | 0 | low | 8 | 0 |
| allylamine | 0 | low | 1 | 0 |
| propionitrile | 0 | low | 1 | 0 |
| acrylonitrile | 0 | low | 4 | 0 |
| chloroacetonitrile | 0 | low | 1 | 0 |
| allyl alcohol | 0 | low | 1 | 0 |
| glyoxal | 0 | low | 2 | 0 |
| chloromethyl methyl ether | 0 | low | 1 | 0 |
| 2-methylpentane | 0 | low | 6 | 0 |
| 1-nitropropane | 0 | low | 1 | 0 |
| methyl isobutyl ketone | 0 | low | 1 | 0 |
| succinic anhydride | 0 | low | 1 | 0 |
| maleic anhydride | 0 | medium | 99 | 10 |
| bromobenzene | 0 | low | 2 | 0 |
| chlorobenzene | 0 | low | 2 | 0 |
| thiophenol | 0 | low | 2 | 0 |
| 2-aminopyrimidine | 0 | low | 2 | 0 |
| pentane | 0 | low | 2 | 0 |
| diethylamine | 0 | low | 2 | 0 |
| pyrroles | 0 | medium | 239 | 33 |
| tetrahydrofuran | 0 | low | 2 | 0 |
| furan | 0 | low | 6 | 0 |
| thiophenes | 0 | medium | 81 | 18 |
| di-tert-butyl peroxide | 0 | low | 2 | 0 |
| isopropyl myristate | 0 | medium | 2 | 2 |
| n-hexane | 0 | low | 3 | 0 |
| morpholine | 0 | low | 1 | 0 |
| diethylenetriamine | 0 | low | 1 | 0 |
| diethanolamine | 0 | low | 4 | 0 |
| bis(2-chloroethyl)ether | 0 | low | 1 | 0 |
| diethylene glycol | 0 | low | 1 | 0 |
| dipropyl sulfide | 0 | low | 1 | 0 |
| n-butoxyethanol | 0 | low | 1 | 0 |
| methyl palmitate | 0 | low | 4 | 0 |
| dodecanol | 0 | low | 1 | 0 |
| behenic acid | 0 | low | 1 | 0 |
| estradiol dipropionate | 0 | low | 1 | 0 |
| phenformin | 0 | low | 3 | 0 |
| oxyphenisatin acetate | 0 | low | 2 | 0 |
| bromcresol purple | 0 | low | 1 | 0 |
| triphenyl phosphate | 0 | low | 3 | 0 |
| tetrafluoroethylene | 0 | low | 1 | 0 |
| 2-aminoanthraquinone | 0 | low | 1 | 0 |
| diethylhexyl phthalate | 0 | low | 22 | 0 |
| dimethoxyethyl phthalate | 0 | low | 1 | 0 |
| hexachlorobenzene | 0 | low | 15 | 0 |
| trinitrotoluene | 0 | low | 3 | 0 |
| framycetin | 0 | medium | 15 | 1 |
| 1-hydroxyphthalazine | 0 | low | 1 | 0 |
| 2,2'-methylenebis(4-methyl-6-tert-butylphenol) | 0 | low | 1 | 0 |
| isoquinoline | 0 | low | 1 | 0 |
| anthracene | 0 | low | 3 | 0 |
| clorophene | 0 | low | 1 | 0 |
| cyclopentanone | 0 | low | 1 | 0 |
| 2,4-dinitrotoluene | 0 | low | 4 | 0 |
| vanillic acid | 0 | low | 1 | 0 |
| triethylamine | 0 | low | 1 | 0 |
| cyclonite | 0 | low | 2 | 0 |
| sulfan blue | 0 | low | 2 | 0 |
| 1-hydroxyanthraquinone | 0 | low | 1 | 0 |
| pyrazolanthrone | 0 | low | 30 | 0 |
| iodoantipyrine | 0 | low | 1 | 0 |
| 1,4-naphthoquinone | 0 | low | 3 | 0 |
| dimethyl phthalate | 0 | low | 1 | 0 |
| diatrizoate meglumine | 0 | medium | 24 | 1 |
| meglumine | 0 | medium | 182 | 21 |
| captan | 0 | low | 3 | 0 |
| iodohippuric acid | 0 | low | 4 | 0 |
| neoprontosil | 0 | low | 1 | 0 |
| uridine diphosphate glucose | 0 | low | 4 | 0 |
| 1-naphthylamine | 0 | low | 8 | 0 |
| fluorodeoxyuridylate | 0 | low | 8 | 0 |
| 2-naphthol | 0 | low | 15 | 0 |
| neozone | 0 | low | 1 | 0 |
| dextrothyroxine | 0 | low | 1 | 0 |
| n-butyl lactate | 0 | low | 1 | 0 |
| shikimic acid | 0 | medium | 1 | 1 |
| 4-nitrosodimethylaniline | 0 | low | 1 | 0 |
| nitrilotriacetic acid | 0 | low | 8 | 0 |
| 4,4'-thiodianiline | 0 | low | 1 | 0 |
| protocatechualdehyde | 0 | low | 1 | 0 |
| benzyl acetate | 0 | low | 1 | 0 |
| sulfurous acid, 2-(p-tert-butylphenoxy)-1-methylethyl 2-chloroethyl ester | 0 | low | 1 | 0 |
| estragole | 0 | low | 8 | 0 |
| n,n'-dinitrosopiperazine | 0 | low | 2 | 0 |
| n-butyl acrylate | 0 | low | 1 | 0 |
| ethyl acetate | 0 | low | 20 | 0 |
| iminodiacetic acid | 0 | low | 5 | 0 |
| monomethylarsonic acid | 0 | low | 1 | 0 |
| pregnenolone | 0 | low | 8 | 0 |
| yohimbine | 0 | low | 1 | 0 |
| 3-o-methylglucose | 0 | low | 1 | 0 |
| 2-chloroadenosine | 0 | low | 3 | 0 |
| ditiocarb | 0 | low | 7 | 0 |
| ic 140 | 0 | medium | 1 | 1 |
| potassium cyanide | 0 | low | 3 | 0 |
| methohexital | 0 | low | 2 | 0 |
| dydrogesterone | 0 | low | 1 | 0 |
| catechin | 0 | medium | 96 | 1 |
| thiamine pyrophosphate | 0 | low | 1 | 0 |
| homoarginine | 0 | low | 1 | 0 |
| diazooxonorleucine | 0 | low | 3 | 0 |
| dibenzo(a,i)pyrene | 0 | low | 1 | 0 |
| dibenzo(a,l)pyrene | 0 | low | 4 | 0 |
| benzo(e)pyrene | 0 | low | 2 | 0 |
| 7h-dibenzo(c,g)carbazole | 0 | low | 4 | 0 |
| benzo(c)phenanthrene | 0 | low | 1 | 0 |
| perylene | 0 | low | 12 | 0 |
| benzo(b)fluoranthene | 0 | low | 1 | 0 |
| fluoranthene | 0 | low | 3 | 0 |
| benzo(k)fluoranthene | 0 | low | 2 | 0 |
| chrysene | 0 | low | 2 | 0 |
| benz(c)acridine | 0 | low | 1 | 0 |
| quinazolines | 0 | medium | 249 | 40 |
| acridines | 0 | low | 22 | 0 |
| indazoles | 0 | medium | 58 | 11 |
| benzoxazoles | 0 | medium | 12 | 2 |
| adamantane | 0 | low | 6 | 0 |
| cyclopentane | 0 | low | 24 | 0 |
| isoxazoles | 0 | medium | 34 | 5 |
| oxazoles | 0 | low | 17 | 0 |
| thiazoles | 0 | medium | 167 | 8 |
| 1,2,4-triazole | 0 | low | 2 | 0 |
| pyrimidine | 0 | low | 12 | 0 |
| pyrazines | 0 | medium | 75 | 13 |
| ethynodiol diacetate | 0 | low | 6 | 0 |
| nitroblue tetrazolium | 0 | low | 1 | 0 |
| triphenyltetrazolium | 0 | low | 1 | 0 |
| calcium gluconate | 0 | medium | 2 | 1 |
| ephedrine | 0 | low | 3 | 0 |
| allylisopropylacetamide | 0 | low | 1 | 0 |
| hydrazine | 0 | medium | 68 | 2 |
| chlormadinone acetate | 0 | low | 3 | 0 |
| 2,2-dichloro-1,1,1-trifluoroethane | 0 | low | 1 | 0 |
| hemicholinium 3 | 0 | low | 1 | 0 |
| evans blue | 0 | low | 5 | 0 |
| monocrotaline | 0 | low | 5 | 0 |
| testosterone enanthate | 0 | low | 7 | 0 |
| 5-fluorouridine | 0 | low | 5 | 0 |
| azacitidine | 0 | medium | 130 | 1 |
| diazomethane | 0 | low | 1 | 0 |
| perfluorooctanoic acid | 0 | low | 14 | 0 |
| perfluorodecanoic acid | 0 | low | 1 | 0 |
| methylthioinosine | 0 | low | 1 | 0 |
| perfluorobutane | 0 | medium | 157 | 14 |
| perflexane | 0 | low | 4 | 0 |
| nandrolone decanoate | 0 | low | 1 | 0 |
| aminoimidazole carboxamide | 0 | low | 11 | 0 |
| methysergide | 0 | low | 7 | 0 |
| phenylbenzoquinone | 0 | low | 1 | 0 |
| thymidine monophosphate | 0 | low | 6 | 0 |
| trans-1,4-bis(2-chlorobenzaminomethyl)cyclohexane dihydrochloride | 0 | low | 1 | 0 |
| citrulline | 0 | low | 8 | 0 |
| betamethasone | 0 | low | 5 | 0 |
| cyanamide | 0 | low | 1 | 0 |
| perflubron | 0 | low | 7 | 0 |
| cyproterone acetate | 0 | medium | 26 | 2 |
| beta-cyclocitral | 0 | low | 1 | 0 |
| lithocholic acid | 0 | low | 10 | 0 |
| nandrolone | 0 | low | 8 | 0 |
| thiazolidine-4-carboxylic acid | 0 | low | 1 | 0 |
| 2-aminopurine | 0 | low | 8 | 0 |
| hydantoins | 0 | medium | 6 | 1 |
| fluorobenzenes | 0 | low | 5 | 0 |
| homocystine | 0 | low | 1 | 0 |
| n-pentyl nitrite | 0 | low | 1 | 0 |
| dextropropoxyphene | 0 | low | 2 | 0 |
| methylguanidine | 0 | low | 1 | 0 |
| limestone | 0 | low | 3 | 0 |
| oxamide | 0 | low | 1 | 0 |
| glycyrrhetinic acid | 0 | low | 1 | 0 |
| chenodeoxycholic acid | 0 | low | 36 | 0 |
| glycocholic acid | 0 | low | 12 | 0 |
| isocorydine | 0 | low | 4 | 0 |
| liriodenine | 0 | low | 1 | 0 |
| fusarium | 0 | low | 15 | 0 |
| funiculosin (anthraquinone) | 0 | low | 1 | 0 |
| boldine | 0 | low | 3 | 0 |
| rhein | 0 | low | 7 | 0 |
| berbamine | 0 | low | 3 | 0 |
| indirubin | 0 | low | 3 | 0 |
| lucanthone | 0 | low | 3 | 0 |
| epitestosterone | 0 | low | 1 | 0 |
| plumbagin | 0 | low | 11 | 0 |
| cepharanthine | 0 | low | 5 | 0 |
| chrysophanic acid | 0 | low | 2 | 0 |
| imperatorin | 0 | low | 2 | 0 |
| phosphoadenosine phosphosulfate | 0 | low | 1 | 0 |
| emetine | 0 | low | 4 | 0 |
| osthol | 0 | low | 7 | 0 |
| dihydralazine | 0 | low | 1 | 0 |
| reticulin | 0 | low | 13 | 0 |
| cytisine | 0 | low | 1 | 0 |
| flavanone | 0 | low | 1 | 0 |
| thymoquinone | 0 | low | 17 | 0 |
| 4-methylquinoline | 0 | low | 1 | 0 |
| 1,4-benzodioxan | 0 | low | 1 | 0 |
| methaphenilene | 0 | low | 1 | 0 |
| chlornaphazin | 0 | low | 1 | 0 |
| melarsoprol | 0 | low | 1 | 0 |
| carvacrol | 0 | low | 3 | 0 |
| 4-hydroxyphenylethanol | 0 | low | 1 | 0 |
| caprolactone | 0 | low | 2 | 0 |
| orcinol | 0 | low | 1 | 0 |
| alpha-aminopyridine | 0 | medium | 41 | 3 |
| thiazolidines | 0 | low | 12 | 0 |
| mustard gas | 0 | low | 2 | 0 |
| cyanogen bromide | 0 | low | 4 | 0 |
| oleanolic acid | 0 | low | 77 | 0 |
| chlorobenzilate | 0 | low | 1 | 0 |
| dihydroergotamine | 0 | low | 1 | 0 |
| periplogenin | 0 | low | 1 | 0 |
| elemene | 0 | low | 1 | 0 |
| hematoxylin | 0 | low | 10 | 0 |
| podophyllotoxin | 0 | medium | 29 | 4 |
| hesperidin | 0 | low | 11 | 0 |
| medroxyprogesterone | 0 | medium | 18 | 1 |
| dihydrotestosterone | 0 | low | 20 | 0 |
| luminol | 0 | medium | 5 | 1 |
| physcione | 0 | low | 4 | 0 |
| angelicin | 0 | low | 1 | 0 |
| flavone | 0 | low | 5 | 0 |
| tryptophol | 0 | low | 1 | 0 |
| copper gluconate | 0 | medium | 8 | 1 |
| thiophene-2-carboxylate | 0 | low | 2 | 0 |
| azomycin | 0 | low | 12 | 0 |
| uridine diphosphate n-acetylglucosamine | 0 | low | 2 | 0 |
| cellobiose | 0 | low | 1 | 0 |
| 3',5'-dichloromethotrexate | 0 | low | 6 | 0 |
| syringic acid | 0 | low | 1 | 0 |
| chrysoidine | 0 | low | 2 | 0 |
| chlormethiazole | 0 | low | 1 | 0 |
| tropolone | 0 | low | 1 | 0 |
| 4,6-dinitro-o-cresol | 0 | low | 2 | 0 |
| perillyl alcohol | 0 | low | 3 | 0 |
| methamphetamine | 0 | low | 2 | 0 |
| dicyclohexylcarbodiimide | 0 | low | 1 | 0 |
| 1,2-ethanedithiol | 0 | low | 1 | 0 |
| uranyl acetate | 0 | low | 1 | 0 |
| maleimide | 0 | low | 1 | 0 |
| muscone | 0 | medium | 3 | 2 |
| malondialdehyde | 0 | medium | 80 | 5 |
| ethyl isothiocyanate | 0 | low | 1 | 0 |
| bis(chloromethyl) ether | 0 | low | 1 | 0 |
| myristic acid | 0 | low | 5 | 0 |
| trichloroacetonitrile | 0 | low | 1 | 0 |
| magnesium carbonate | 0 | low | 1 | 0 |
| trinitrobenzenesulfonic acid | 0 | low | 1 | 0 |
| eosine yellowish-(ys) | 0 | low | 13 | 0 |
| violacein | 0 | low | 2 | 0 |
| lucanthone hydrochloride | 0 | low | 6 | 0 |
| 1-naphthylisothiocyanate | 0 | low | 3 | 0 |
| paeonol | 0 | low | 4 | 0 |
| hematoporphyrin | 0 | low | 10 | 0 |
| neutral red | 0 | low | 10 | 0 |
| aniline mustard | 0 | low | 2 | 0 |
| lithium carbonate | 0 | medium | 8 | 1 |
| linamarin | 0 | low | 1 | 0 |
| 4-chloromercuribenzenesulfonate | 0 | low | 3 | 0 |
| beta-phellandrene | 0 | low | 1 | 0 |
| tristearin | 0 | low | 2 | 0 |
| tripalmitin | 0 | low | 1 | 0 |
| glycyl-glycyl-glycine | 0 | low | 1 | 0 |
| glycylglycine | 0 | low | 1 | 0 |
| glycerylphosphorylcholine | 0 | low | 1 | 0 |
| formestane | 0 | low | 2 | 0 |
| 3-hydroxyflavone | 0 | low | 25 | 0 |
| diphenylamine | 0 | medium | 8 | 2 |
| angelica lactone | 0 | low | 1 | 0 |
| methyl n-butyl ketone | 0 | low | 1 | 0 |
| butylurea | 0 | low | 1 | 0 |
| butyl isothiocyanate | 0 | low | 1 | 0 |
| allyl sulfide | 0 | low | 15 | 0 |
| vinyl bromide | 0 | low | 2 | 0 |
| megestrol acetate | 0 | medium | 9 | 4 |
| methylurea | 0 | low | 1 | 0 |
| diisopropylnitrosamine | 0 | low | 1 | 0 |
| alpha-naphthoflavone | 0 | low | 10 | 0 |
| 2,6-dinitrotoluene | 0 | low | 4 | 0 |
| toyocamycin | 0 | low | 1 | 0 |
| 2-nitrofluorene | 0 | low | 1 | 0 |
| galactitol | 0 | low | 1 | 0 |
| 2,4-dichloro-1-nitrobenzene | 0 | low | 1 | 0 |
| 8-methylquinoline | 0 | low | 1 | 0 |
| 2-anthramine | 0 | low | 1 | 0 |
| benzoylhydrazine | 0 | low | 1 | 0 |
| n-methyl-n-nitrosoaniline | 0 | low | 2 | 0 |
| 4-methoxy-3-phenylenediamine | 0 | low | 1 | 0 |
| n-ethyl-n-nitrosourethane | 0 | low | 1 | 0 |
| nitrosomethylurethane | 0 | low | 2 | 0 |
| 2-benzylmalonate | 0 | low | 1 | 0 |
| acetylcysteine | 0 | medium | 111 | 5 |
| ethyl pyruvate | 0 | low | 2 | 0 |
| 2,6-dichloro-4-nitrophenol | 0 | low | 2 | 0 |
| 4-hydrazinobenzoic acid | 0 | low | 1 | 0 |
| 3-hydroxybenzeneacetic acid | 0 | low | 1 | 0 |
| 3-hydroxyacetanilide | 0 | low | 1 | 0 |
| n-nitroso(di-n-propyl)amine | 0 | low | 3 | 0 |
| n-methyl-4-aminoazobenzene | 0 | low | 1 | 0 |
| ethyl palmitate | 0 | low | 1 | 0 |
| n-propyl disulfide | 0 | low | 2 | 0 |
| dibromoacetic acid | 0 | low | 2 | 0 |
| dicarbethoxydihydrocollidine | 0 | low | 5 | 0 |
| c.i. 42510 | 0 | low | 13 | 0 |
| brilliant green | 0 | low | 1 | 0 |
| Berberine chloride (TN) | 0 | low | 1 | 0 |
| ethyl tert-butyl ether | 0 | low | 2 | 0 |
| glycochenodeoxycholic acid | 0 | low | 14 | 0 |
| erythromycin | 0 | low | 3 | 0 |
| dehydroepiandrosterone sulfate | 0 | low | 6 | 0 |
| nitrosoguanidines | 0 | low | 12 | 0 |
| 2-piperidone | 0 | medium | 16 | 2 |
| perfluoropentane | 0 | medium | 3 | 1 |
| hempa | 0 | low | 1 | 0 |
| methylnitrosourea | 0 | low | 38 | 0 |
| 2-methylimidazole | 0 | low | 2 | 0 |
| n-methyl-n-formylhydrazine | 0 | low | 3 | 0 |
| ethylnitrosourea | 0 | low | 26 | 0 |
| 2,3-dimethylmaleic anhydride | 0 | low | 1 | 0 |
| 4,4'-biphenyldicarboxylic acid | 0 | low | 1 | 0 |
| o,p'-ddt | 0 | low | 1 | 0 |
| levonorgestrel | 0 | medium | 4 | 1 |
| porfiromycin | 0 | low | 1 | 0 |
| 1,6-hexamethylene diisocyanate | 0 | low | 1 | 0 |
| tempidon | 0 | low | 1 | 0 |
| 1-phenylazo-2-naphthol | 0 | low | 3 | 0 |
| boldenone | 0 | low | 2 | 0 |
| norgestrienone | 0 | low | 1 | 0 |
| turinabol | 0 | low | 1 | 0 |
| vinblastine | 0 | low | 2 | 0 |
| alpha-fluoro-beta-alanine | 0 | low | 5 | 0 |
| n-nitrosobutylurea | 0 | low | 3 | 0 |
| amaranth dye | 0 | low | 1 | 0 |
| 2-hydroxypropyl methacrylate | 0 | low | 1 | 0 |
| dibutylnitrosamine | 0 | low | 11 | 0 |
| cyclopentenone | 0 | low | 1 | 0 |
| n-nitrosopyrrolidine | 0 | low | 8 | 0 |
| 1-methylpyridinium | 0 | low | 1 | 0 |
| n-nitrosoperhydroazepine | 0 | low | 2 | 0 |
| 5-aminobenzimidazole | 0 | low | 1 | 0 |
| 2-aminobenzimidazole | 0 | low | 1 | 0 |
| nitrosobenzylmethylamine | 0 | low | 3 | 0 |
| methidathion | 0 | low | 2 | 0 |
| deoxycytidine | 0 | medium | 710 | 160 |
| deoxyuridine | 0 | medium | 28 | 1 |
| 2,6-dichloroindophenol | 0 | low | 1 | 0 |
| testolactone | 0 | low | 1 | 0 |
| rhodamine 6g | 0 | low | 2 | 0 |
| methylphosphonic acid | 0 | low | 1 | 0 |
| heptachlor epoxide | 0 | low | 2 | 0 |
| deoxycytidine monophosphate | 0 | low | 3 | 0 |
| trimethyltin chloride | 0 | low | 1 | 0 |
| bucrylate | 0 | low | 4 | 0 |
| ethambutol | 0 | low | 4 | 0 |
| 1,3-diphenylpropane | 0 | low | 1 | 0 |
| nicotinamide mononucleotide | 0 | low | 4 | 0 |
| n-nitrosodiethanolamine | 0 | low | 4 | 0 |
| pyridine-2-carboxaldehyde | 0 | low | 1 | 0 |
| tetramethylpyrazine | 0 | medium | 5 | 1 |
| decabromobiphenyl ether | 0 | low | 1 | 0 |
| 4-aminothiophenol | 0 | low | 1 | 0 |
| ethidium bromide | 0 | low | 1 | 0 |
| testosterone 17-phenylpropionate | 0 | low | 1 | 0 |
| carmine | 0 | medium | 3 | 1 |
| calcium peroxide | 0 | medium | 1 | 1 |
| durapatite | 0 | medium | 22 | 1 |
| cadmium sulfide | 0 | low | 2 | 0 |
| sodium hydroxide | 0 | low | 3 | 0 |
| manganese dioxide | 0 | medium | 3 | 1 |
| zinc oxide | 0 | medium | 17 | 2 |
| thorium dioxide | 0 | low | 292 | 0 |
| lead sulfide | 0 | low | 1 | 0 |
| molybdenum disulfide | 0 | low | 3 | 0 |
| cupric sulfide | 0 | low | 1 | 0 |
| arsenic trioxide | 0 | medium | 120 | 9 |
| chromium trioxide | 0 | low | 1 | 0 |
| vancomycin | 0 | low | 5 | 0 |
| glycyrrhizic acid | 0 | medium | 33 | 1 |
| d-alpha tocopherol | 0 | medium | 130 | 6 |
| tocopherols | 0 | low | 11 | 0 |
| trifenmorph | 0 | low | 1 | 0 |
| pregnenolone carbonitrile | 0 | low | 4 | 0 |
| 1,2-epoxyhexane | 0 | medium | 2 | 2 |
| pseudouridine | 0 | low | 8 | 0 |
| n-nitroso-2,6-dimethylmorpholine | 0 | low | 7 | 0 |
| selenomethionine | 0 | low | 19 | 0 |
| selenocystine | 0 | low | 2 | 0 |
| n-(1-naphthyl)ethylenediamine | 0 | low | 1 | 0 |
| n-methylcarbazole | 0 | low | 1 | 0 |
| methyl tert-butyl ether | 0 | low | 2 | 0 |
| digoxigenin | 0 | low | 6 | 0 |
| 1,1-dichloro-1-fluoroethane | 0 | low | 1 | 0 |
| decane | 0 | low | 2 | 0 |
| nitrofen | 0 | low | 1 | 0 |
| stearylamine | 0 | low | 2 | 0 |
| ethyldimethylaminopropyl carbodiimide | 0 | low | 1 | 0 |
| tetrachloroisophthalonitrile | 0 | medium | 1 | 1 |
| paraquat | 0 | low | 6 | 0 |
| pristane | 0 | low | 1 | 0 |
| s,n,n'-tripropylthiocarbamate | 0 | low | 1 | 0 |
| nitrapyrin | 0 | low | 2 | 0 |
| 2-tert-butylhydroquinone | 0 | low | 6 | 0 |
| dronabinol | 0 | low | 4 | 0 |
| methionine sulfoximine | 0 | low | 4 | 0 |
| amiloride | 0 | low | 10 | 0 |
| 3,3'-dichlorobiphenyl | 0 | low | 1 | 0 |
| diallyl trisulfide | 0 | low | 4 | 0 |
| 3'-methyl-4-methylaminoazobenzene | 0 | low | 3 | 0 |
| pimozide | 0 | low | 4 | 0 |
| 2,4,5-trichlorophenoxyethanol | 0 | low | 2 | 0 |
| azetidyl-2-carboxylic acid | 0 | low | 1 | 0 |
| diallyl disulfide | 0 | low | 6 | 0 |
| n-isopropylacrylamide | 0 | low | 3 | 0 |
| 1,5-naphthalenediamine | 0 | low | 2 | 0 |
| phenethyl isothiocyanate | 0 | low | 9 | 0 |
| oxyclozanide | 0 | low | 1 | 0 |
| fluorescein | 0 | low | 17 | 0 |
| methylprednisolone hemisuccinate | 0 | medium | 1 | 1 |
| 1-methylpyrene | 0 | low | 1 | 0 |
| nile blue | 0 | low | 1 | 0 |
| mirex | 0 | low | 4 | 0 |
| thioflavin t | 0 | low | 1 | 0 |
| flupenthixol | 0 | low | 1 | 0 |
| captafol | 0 | low | 3 | 0 |
| fucose | 0 | medium | 118 | 2 |
| benzophenoneidum | 0 | low | 1 | 0 |
| sulfur hexafluoride | 0 | medium | 280 | 26 |
| victoria blue b | 0 | low | 3 | 0 |
| direct blue 6 | 0 | low | 1 | 0 |
| c.i. direct blue 1 | 0 | low | 1 | 0 |
| uridine diphosphate glucuronic acid | 0 | low | 2 | 0 |
| acadesine | 0 | low | 2 | 0 |
| thiocholchicine | 0 | low | 2 | 0 |
| 2-(dimethylamino)ethyl methacrylate | 0 | low | 1 | 0 |
| uridine diphosphate galactose | 0 | low | 1 | 0 |
| benzyl thiocyanate | 0 | low | 1 | 0 |
| dichloroacetonitrile | 0 | low | 1 | 0 |
| glycidyl trimethylammonium chloride | 0 | low | 1 | 0 |
| stavudine | 0 | low | 1 | 0 |
| doxifluridine | 0 | medium | 81 | 15 |
| dibromoacetonitrile | 0 | low | 1 | 0 |
| 2,2-bis(bromomethyl)-1,3-propanediol | 0 | low | 1 | 0 |
| fluorescein-5-isothiocyanate | 0 | low | 40 | 0 |
| sabinene | 0 | low | 13 | 0 |
| mannose | 0 | low | 35 | 0 |
| thiamine triphosphate | 0 | medium | 2 | 2 |
| dithiothreitol | 0 | medium | 32 | 1 |
| 3-methoxy-4-aminoazobenzene | 0 | low | 1 | 0 |
| megestrol | 0 | medium | 9 | 3 |
| ponceau 3r | 0 | low | 2 | 0 |
| azo rubin s | 0 | low | 1 | 0 |
| ecdysone | 0 | low | 1 | 0 |
| cyclic cmp | 0 | low | 3 | 0 |
| diheptyl phthalate | 0 | low | 2 | 0 |
| dimethyl trisulfide | 0 | low | 1 | 0 |
| chlorophacinone | 0 | low | 1 | 0 |
| 5-methylchrysene | 0 | low | 1 | 0 |
| tranylcypromine | 0 | low | 1 | 0 |
| 3-phenoxybenzoic acid | 0 | low | 1 | 0 |
| nafenopin | 0 | low | 17 | 0 |
| streptomycin | 0 | low | 5 | 0 |
| carbonates | 0 | low | 6 | 0 |
| butylhydroxybutylnitrosamine | 0 | low | 7 | 0 |
| 2-amino-1,3,4-thiadiazole | 0 | low | 1 | 0 |
| nitroxoline | 0 | low | 1 | 0 |
| pentaethylenehexamine | 0 | low | 2 | 0 |
| 4-acetylaminobiphenyl | 0 | low | 1 | 0 |
| dideoxyadenosine | 0 | low | 4 | 0 |
| pn 401 | 0 | low | 2 | 0 |
| 2-acetamidophenanthrene | 0 | low | 2 | 0 |
| dimethylnitramine | 0 | low | 3 | 0 |
| cladribine | 0 | low | 4 | 0 |
| mono-(2-ethylhexyl)phthalate | 0 | low | 1 | 0 |
| chlorophenol red | 0 | low | 1 | 0 |
| n-hydroxy-4-acetylaminobiphenyl | 0 | low | 1 | 0 |
| 2,2'-diamino-1,1'-dinaphthyl | 0 | low | 1 | 0 |
| nitracrine | 0 | low | 1 | 0 |
| diphenylarsinic acid | 0 | low | 3 | 0 |
| carbenicillin | 0 | low | 1 | 0 |
| metanephrine | 0 | low | 3 | 0 |
| buthionine sulfoximine | 0 | low | 24 | 0 |
| metocurine | 0 | low | 1 | 0 |
| norleucine | 0 | low | 2 | 0 |
| 1'-hydroxysafrole | 0 | low | 4 | 0 |
| floxacillin | 0 | low | 1 | 0 |
| 1-hydroxypyrene | 0 | low | 1 | 0 |
| n-nitrosodibenzylamine | 0 | low | 1 | 0 |
| 2,7-dinitrofluorene | 0 | low | 1 | 0 |
| 3-benzoylpyridine | 0 | low | 1 | 0 |
| 1-nitropyrene | 0 | low | 3 | 0 |
| vidarabine | 0 | medium | 15 | 1 |
| diadenosine tetraphosphate | 0 | low | 1 | 0 |
| iodinated glycerol | 0 | low | 14 | 0 |
| maleic hydrazide | 0 | low | 1 | 0 |
| limonene | 0 | low | 5 | 0 |
| acetoxyacetylaminofluorene | 0 | low | 1 | 0 |
| diazoline | 0 | low | 1 | 0 |
| 4-(4-dimethylaminophenylazo)benzoic acid | 0 | low | 1 | 0 |
| n-methylaspartate | 0 | low | 1 | 0 |
| enbucrilate | 0 | medium | 53 | 5 |
| 3-deazaadenosine | 0 | low | 2 | 0 |
| helenalin | 0 | low | 1 | 0 |
| nitrosomethyl-n-butylamine | 0 | low | 2 | 0 |
| n-nitrodiethylamine | 0 | low | 4 | 0 |
| trimethaphan | 0 | low | 1 | 0 |
| 1-(4-carboxyphenyl)-3,3-dimethyltriazene | 0 | medium | 2 | 1 |
| 1-phenyl-3,3-dimethyltriazene | 0 | low | 1 | 0 |
| methylglucamine metrizoate | 0 | medium | 2 | 1 |
| hepes | 0 | low | 1 | 0 |
| dysprosium | 0 | low | 1 | 0 |
| einsteinium | 0 | low | 1 | 0 |
| iridium | 0 | medium | 8 | 1 |
| lanthanum | 0 | low | 6 | 0 |
| lutetium | 0 | medium | 23 | 2 |
| manganese | 0 | medium | 107 | 17 |
| mercury | 0 | medium | 20 | 3 |
| molybdenum | 0 | medium | 14 | 1 |
| neptunium | 0 | low | 1 | 0 |
| neodymium | 0 | low | 8 | 0 |
| neon | 0 | low | 3 | 0 |
| niobium | 0 | low | 1 | 0 |
| osmium | 0 | low | 1 | 0 |
| palladium | 0 | low | 12 | 0 |
| platinum | 0 | medium | 55 | 6 |
| plutonium | 0 | low | 20 | 0 |
| praseodymium | 0 | low | 3 | 0 |
| rhenium | 0 | medium | 60 | 11 |
| rhodium | 0 | low | 5 | 0 |
| ruthenium | 0 | low | 19 | 0 |
| samarium | 0 | low | 2 | 0 |
| scandium | 0 | medium | 4 | 1 |
| silver | 0 | medium | 80 | 5 |
| tantalum | 0 | low | 7 | 0 |
| technetium | 0 | medium | 678 | 9 |
| terbium | 0 | low | 1 | 0 |
| thorium | 0 | low | 30 | 0 |
| thulium | 0 | medium | 2 | 2 |
| titanium | 0 | medium | 37 | 5 |
| tungsten | 0 | low | 5 | 0 |
| actinium | 0 | low | 2 | 0 |
| americium | 0 | low | 5 | 0 |
| argon | 0 | low | 15 | 0 |
| cadmium | 0 | medium | 63 | 2 |
| cerium | 0 | low | 10 | 0 |
| chromium | 0 | medium | 16 | 2 |
| curium | 0 | low | 3 | 0 |
| erbium | 0 | low | 1 | 0 |
| europium | 0 | medium | 5 | 1 |
| gadolinium | 0 | medium | 249 | 20 |
| gold | 0 | medium | 203 | 4 |
| hafnium | 0 | low | 1 | 0 |
| helium | 0 | medium | 19 | 1 |
| holmium | 0 | medium | 53 | 13 |
| uranium | 0 | medium | 7 | 2 |
| vanadium | 0 | low | 5 | 0 |
| xenon | 0 | low | 10 | 0 |
| ytterbium | 0 | low | 7 | 0 |
| yttrium | 0 | medium | 44 | 3 |
| zirconium | 0 | low | 15 | 0 |
| californium | 0 | low | 1 | 0 |
| aluminum chloride | 0 | low | 2 | 0 |
| cupric chloride | 0 | low | 2 | 0 |
| zalcitabine | 0 | low | 9 | 0 |
| magnesium sulfate | 0 | low | 1 | 0 |
| mercuric chloride | 0 | low | 4 | 0 |
| selenium disulfide | 0 | low | 2 | 0 |
| 6-nitrochrysene | 0 | low | 2 | 0 |
| acetylglucosamine | 0 | low | 29 | 0 |
| meladrazine | 0 | low | 2 | 0 |
| galactosamine | 0 | medium | 45 | 3 |
| perchloric acid | 0 | low | 2 | 0 |
| palladium chloride | 0 | low | 1 | 0 |
| cesium chloride | 0 | low | 2 | 0 |
| hypochlorous acid | 0 | low | 7 | 0 |
| camptothecin | 0 | medium | 892 | 168 |
| ferric chloride | 0 | low | 3 | 0 |
| nickel chloride | 0 | low | 4 | 0 |
| ferrous sulfate | 0 | low | 2 | 0 |
| phosphine | 0 | low | 2 | 0 |
| isopentenyladenosine | 0 | low | 1 | 0 |
| bromine | 0 | medium | 6 | 1 |
| barium sulfate | 0 | low | 27 | 0 |
| monoethylglycinexylidide | 0 | medium | 8 | 1 |
| s-methylcysteine | 0 | low | 2 | 0 |
| zinc sulfate | 0 | medium | 6 | 1 |
| potassium nitrate | 0 | low | 1 | 0 |
| sodium sulfate | 0 | medium | 2 | 1 |
| calcium phosphate, dibasic, anhydrous | 0 | low | 2 | 0 |
| calcium phosphate, monobasic, anhydrous | 0 | low | 2 | 0 |
| tricalcium phosphate | 0 | medium | 19 | 2 |
| chromates | 0 | low | 2 | 0 |
| copper sulfate | 0 | medium | 6 | 1 |
| silver nitrate | 0 | low | 11 | 0 |
| sodium thiosulfate | 0 | medium | 17 | 2 |
| calcium sulfate | 0 | low | 2 | 0 |
| potassium dichromate | 0 | low | 1 | 0 |
| deuterium | 0 | low | 11 | 0 |
| fluorine | 0 | low | 33 | 0 |
| chlorine | 0 | medium | 15 | 1 |
| nitrous acid | 0 | low | 1 | 0 |
| silver iodide | 0 | low | 1 | 0 |
| fluorosulfonic acid | 0 | low | 1 | 0 |
| thallium chloride | 0 | low | 3 | 0 |
| glycerol 1-stearate | 0 | low | 1 | 0 |
| ethinyl estradiol-norgestrel combination | 0 | low | 8 | 0 |
| galactose | 0 | medium | 35 | 3 |
| poloxalene | 0 | low | 3 | 0 |
| sizofiran | 0 | low | 1 | 0 |
| antimony trichloride | 0 | low | 1 | 0 |
| ozone | 0 | medium | 7 | 2 |
| aluminum sulfate | 0 | low | 1 | 0 |
| radon | 0 | low | 5 | 0 |
| 1,3-dichloro-1-propene | 0 | low | 3 | 0 |
| lead nitrate | 0 | low | 5 | 0 |
| sodium selenite | 0 | medium | 15 | 2 |
| tellurous acid | 0 | low | 1 | 0 |
| cadmium chloride | 0 | low | 15 | 0 |
| 4-chloro-7-nitrobenzofurazan | 0 | low | 6 | 0 |
| ancitabine | 0 | low | 2 | 0 |
| chlormerodrin | 0 | low | 4 | 0 |
| trolamine salicylate | 0 | low | 23 | 0 |
| stanozolol | 0 | low | 5 | 0 |
| rhamnose | 0 | low | 5 | 0 |
| methylethylnitrosamine | 0 | low | 2 | 0 |
| clodronic acid | 0 | low | 6 | 0 |
| chrysotile | 0 | low | 1 | 0 |
| ammonium chloride | 0 | low | 19 | 0 |
| chloropeptide | 0 | low | 1 | 0 |
| ethionine | 0 | low | 104 | 0 |
| n-ethyl-n-hydroxyethylnitrosamine | 0 | low | 13 | 0 |
| arabinofuranosylcytosine triphosphate | 0 | low | 2 | 0 |
| 3-hydroxybenzo(a)pyrene | 0 | low | 1 | 0 |
| benzo(a)pyrene 7,8-dihydrodiol | 0 | low | 2 | 0 |
| 2',3-dimethyl-4-aminobiphenyl | 0 | low | 2 | 0 |
| manganese chloride | 0 | medium | 2 | 2 |
| titanium dioxide | 0 | medium | 18 | 4 |
| misonidazole | 0 | medium | 7 | 2 |
| mopidamol | 0 | low | 1 | 0 |
| tri-(2-chloroisopropyl)phosphate | 0 | low | 1 | 0 |
| technetium 99m | 0 | low | 1 | 0 |
| salen | 0 | low | 1 | 0 |
| tiletamine hydrochloride | 0 | low | 41 | 0 |
| selegiline | 0 | low | 1 | 0 |
| urobilinogen | 0 | low | 4 | 0 |
| levamisole | 0 | medium | 21 | 4 |
| cycasin | 0 | low | 7 | 0 |
| trimethylolpropane triacrylate | 0 | low | 1 | 0 |
| cephalexin | 0 | low | 1 | 0 |
| 1-methyladenosine | 0 | low | 2 | 0 |
| isosorbide-5-mononitrate | 0 | low | 1 | 0 |
| pentamethylmelamine | 0 | medium | 1 | 1 |
| diallylnitrosamine | 0 | low | 1 | 0 |
| ferric nitrilotriacetate | 0 | low | 3 | 0 |
| n'-nitrosonornicotine | 0 | low | 1 | 0 |
| tetradecanoylphorbol acetate | 0 | low | 148 | 0 |
| tocopheryl nicotinate | 0 | low | 1 | 0 |
| sodium bisulfide | 0 | low | 1 | 0 |
| showdomycin | 0 | low | 1 | 0 |
| fluorides | 0 | medium | 32 | 1 |
| danazol | 0 | low | 21 | 0 |
| tomatine | 0 | low | 1 | 0 |
| n-nitrosoephedrine | 0 | low | 1 | 0 |
| stilbene oxide | 0 | low | 3 | 0 |
| stannic oxide | 0 | low | 2 | 0 |
| n,n-dimethyl-4-(6-benzothiazolylazo)aniline | 0 | low | 1 | 0 |
| chromium | 0 | low | 3 | 0 |
| keracyanin | 0 | low | 1 | 0 |
| molybdenum dioxide | 0 | low | 1 | 0 |
| 1-deoxynojirimycin | 0 | low | 12 | 0 |
| taurolidine | 0 | low | 5 | 0 |
| isoamyl 2-cyanoacrylate | 0 | low | 1 | 0 |
| oxadiazon | 0 | low | 1 | 0 |
| geosmin | 0 | low | 1 | 0 |
| iodine | 0 | low | 7 | 0 |
| osmium tetroxide | 0 | low | 1 | 0 |
| daunorubicin | 0 | medium | 47 | 4 |
| razoxane | 0 | low | 6 | 0 |
| diftalone | 0 | low | 1 | 0 |
| fludarabine phosphate | 0 | low | 1 | 0 |
| phosphotyrosine | 0 | low | 35 | 0 |
| luteoskyrin | 0 | low | 1 | 0 |
| carbimazole | 0 | low | 1 | 0 |
| bromocriptine | 0 | low | 5 | 0 |
| indium phosphide | 0 | low | 1 | 0 |
| fenitrothion | 0 | low | 1 | 0 |
| zingerone | 0 | low | 3 | 0 |
| phenyl acetate | 0 | medium | 194 | 5 |
| cetylpyridinium chloride anhydrous | 0 | low | 11 | 0 |
| myrcene | 0 | low | 2 | 0 |
| pyrrolidine | 0 | low | 2 | 0 |
| dioctyl adipate | 0 | low | 1 | 0 |
| 1,4-dioxane | 0 | low | 6 | 0 |
| chlorodibromomethane | 0 | low | 3 | 0 |
| triamcinolone | 0 | medium | 7 | 1 |
| tris(2,3-dibromopropyl)phosphate | 0 | low | 1 | 0 |
| tributyl phosphate | 0 | low | 1 | 0 |
| dimedone | 0 | low | 1 | 0 |
| methacrylonitrile | 0 | low | 1 | 0 |
| chloroprene | 0 | low | 5 | 0 |
| tetrachloroethylene | 0 | low | 10 | 0 |
| fludrocortisone | 0 | low | 1 | 0 |
| ursodeoxycholic acid | 0 | medium | 58 | 4 |
| pyrene | 0 | low | 2 | 0 |
| isothiuronium | 0 | low | 1 | 0 |
| rafoxanide | 0 | low | 1 | 0 |
| silybin | 0 | low | 1 | 0 |
| 4-methoxyamphetamine | 0 | low | 27 | 0 |
| prospidium | 0 | low | 1 | 0 |
| 8-bromo cyclic adenosine monophosphate | 0 | low | 16 | 0 |
| pronamide | 0 | low | 2 | 0 |
| transferrin | 0 | medium | 170 | 3 |
| fanft | 0 | low | 1 | 0 |
| tridemorph | 0 | low | 14 | 0 |
| 9,10-dihydro-9,10-dihydroxybenzo(a)pyrene | 0 | low | 1 | 0 |
| alkenes | 0 | low | 5 | 0 |
| calcium oxalate | 0 | low | 1 | 0 |
| glutamic acid | 0 | low | 30 | 0 |
| glucaric acid | 0 | low | 7 | 0 |
| alovudine | 0 | medium | 9 | 2 |
| adenylyl imidodiphosphate | 0 | low | 1 | 0 |
| azoxymethane | 0 | low | 23 | 0 |
| cefazolin | 0 | medium | 3 | 3 |
| sodium azide | 0 | low | 5 | 0 |
| azides | 0 | low | 14 | 0 |
| adenosine diphosphate ribose | 0 | low | 10 | 0 |
| amoxicillin | 0 | low | 4 | 0 |
| timolol | 0 | low | 1 | 0 |
| n-methyl-7h-dibenzo(c,g)carbazole | 0 | low | 2 | 0 |
| tramadol | 0 | low | 2 | 0 |
| oxovanadium iv | 0 | low | 1 | 0 |
| gallium citrate | 0 | low | 4 | 0 |
| 4-acetylaminofluorene | 0 | low | 2 | 0 |
| nigericin | 0 | low | 1 | 0 |
| oxcarbazepine | 0 | low | 1 | 0 |
| prednimustine | 0 | low | 1 | 0 |
| octachlorostyrene | 0 | low | 1 | 0 |
| ioxitalamic acid | 0 | medium | 4 | 1 |
| s-adenosylmethionine | 0 | low | 10 | 0 |
| vidarabine phosphate | 0 | low | 6 | 0 |
| zidovudine | 0 | medium | 16 | 2 |
| 7-ethoxycoumarin | 0 | low | 2 | 0 |
| acetylgalactosamine | 0 | low | 16 | 0 |
| b 10610 | 0 | low | 1 | 0 |
| flubendazole | 0 | low | 1 | 0 |
| pcb 118 | 0 | low | 3 | 0 |
| 3,4,3',4'-tetrachlorobiphenyl | 0 | low | 5 | 0 |
| 2,3,3',4,4'-pentachlorobiphenyl | 0 | low | 1 | 0 |
| 3,4,5,3',4',5'-hexachlorobiphenyl | 0 | low | 1 | 0 |
| 4-ipomeanol | 0 | medium | 3 | 1 |
| proroxan | 0 | low | 1 | 0 |
| paclitaxel | 0 | medium | 492 | 77 |
| 2,3,4,5-tetrachlorobiphenyl | 0 | low | 1 | 0 |
| etoposide | 0 | medium | 303 | 26 |
| substance p | 0 | low | 13 | 0 |
| promegestone | 0 | low | 2 | 0 |
| dobutamine | 0 | low | 5 | 0 |
| 1'-acetoxysafrole | 0 | low | 1 | 0 |
| ticarcillin | 0 | low | 1 | 0 |
| 5,6-dihydroxy-2-dimethylaminotetralin | 0 | low | 1 | 0 |
| 2,4,5,2',4',5'-hexachlorobiphenyl | 0 | low | 4 | 0 |
| enilconazole | 0 | low | 2 | 0 |
| iprodione | 0 | low | 1 | 0 |
| ribavirin | 0 | medium | 274 | 18 |
| lentinan | 0 | medium | 24 | 2 |
| amikacin | 0 | medium | 3 | 1 |
| phorbol 12,13-dibutyrate | 0 | low | 3 | 0 |
| benzo(a)pyrene 4,5-epoxide | 0 | low | 1 | 0 |
| 2,3,4,2',3',4'-hexachlorobiphenyl | 0 | low | 1 | 0 |
| aroclor 1016 | 0 | low | 1 | 0 |
| agent orange | 0 | low | 3 | 0 |
| 1,2,3,7,8-pentachlorodibenzo-p-dioxin | 0 | low | 1 | 0 |
| n-(2-hydroxypropyl)methacrylamide | 0 | low | 5 | 0 |
| methyldopa | 0 | low | 6 | 0 |
| bezafibrate | 0 | medium | 5 | 1 |
| 1,6-dinitropyrene | 0 | low | 2 | 0 |
| 1,8-dinitropyrene | 0 | low | 1 | 0 |
| diltiazem | 0 | low | 6 | 0 |
| nimustine | 0 | low | 12 | 0 |
| lonidamine | 0 | medium | 4 | 1 |
| diethylmethylnitrosourea | 0 | low | 1 | 0 |
| vinclozolin | 0 | low | 1 | 0 |
| 2,3,7,8-tetrabromodibenzo-4-dioxin | 0 | low | 1 | 0 |
| n-acetyl-4-benzoquinoneimine | 0 | low | 1 | 0 |
| vecuronium bromide | 0 | low | 1 | 0 |
| vx | 0 | low | 1 | 0 |
| ng-nitroarginine methyl ester | 0 | low | 10 | 0 |
| 2,3,7,8-tetrachlorodibenzofuran | 0 | low | 1 | 0 |
| buthiobate | 0 | low | 1 | 0 |
| 1'-hydroxyestragole | 0 | low | 3 | 0 |
| deoxynivalenol | 0 | low | 4 | 0 |
| permethrin | 0 | low | 4 | 0 |
| chlorodiphenyl (54% chlorine) | 0 | low | 13 | 0 |
| pirfenidone | 0 | low | 7 | 0 |
| 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid | 0 | low | 5 | 0 |
| 1-carboxyglutamic acid | 0 | low | 5 | 0 |
| dh 990 | 0 | low | 1 | 0 |
| diisopropanolnitrosamine | 0 | low | 20 | 0 |
| vindesine | 0 | medium | 14 | 2 |
| 3,3',5,5'-tetramethylbenzidine | 0 | low | 1 | 0 |
| meglitinide | 0 | low | 1 | 0 |
| 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 0 | low | 5 | 0 |
| nitazoxanide | 0 | low | 1 | 0 |
| sufentanil | 0 | low | 2 | 0 |
| epirubicin | 0 | medium | 521 | 116 |
| eg 626 | 0 | low | 1 | 0 |
| cefmetazole | 0 | low | 1 | 0 |
| methyl(acetoxymethyl)nitrosamine | 0 | low | 4 | 0 |
| desflurane | 0 | low | 1 | 0 |
| 2,3,4,7,8-pentachlorodibenzofuran | 0 | low | 3 | 0 |
| diaziquone | 0 | low | 1 | 0 |
| s-2678 | 0 | low | 1 | 0 |
| elliptinium | 0 | medium | 4 | 2 |
| enkephalin, methionine | 0 | low | 1 | 0 |
| idarubicin | 0 | medium | 27 | 8 |
| 2,4,5,2',4',5'-hexabromobiphenyl | 0 | low | 1 | 0 |
| eniluracil | 0 | medium | 6 | 4 |
| fenarimol | 0 | low | 1 | 0 |
| propiconazole | 0 | low | 15 | 0 |
| nitrosobis(2-oxopropyl)amine | 0 | low | 23 | 0 |
| piperacillin | 0 | low | 3 | 0 |
| n-nitroso(2-hydroxypropyl)(2-oxopropyl)amine | 0 | low | 5 | 0 |
| paroxetine | 0 | low | 2 | 0 |
| acifluorfen | 0 | low | 2 | 0 |
| captopril | 0 | low | 10 | 0 |
| cefoperazone | 0 | low | 2 | 0 |
| staurosporine | 0 | low | 6 | 0 |
| yttrium citrate | 0 | medium | 2 | 2 |
| cetaben | 0 | low | 1 | 0 |
| 4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone | 0 | low | 9 | 0 |
| oltipraz | 0 | medium | 17 | 6 |
| atracurium | 0 | low | 4 | 0 |
| lidamidine | 0 | low | 1 | 0 |
| nicorandil | 0 | medium | 1 | 1 |
| colforsin | 0 | low | 28 | 0 |
| dioxadet | 0 | low | 2 | 0 |
| glu-p-2 | 0 | low | 2 | 0 |
| 2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole | 0 | low | 2 | 0 |
| iso-sulfan blue | 0 | low | 2 | 0 |
| buserelin | 0 | medium | 3 | 1 |
| triclabendazole | 0 | low | 1 | 0 |
| fialuridine | 0 | low | 3 | 0 |
| amonafide | 0 | low | 3 | 0 |
| pimonidazole | 0 | low | 4 | 0 |
| pefloxacin | 0 | low | 2 | 0 |
| daurisoline | 0 | low | 2 | 0 |
| n-3-methylbutyl-n-1-methylacetonylnitrosamine | 0 | low | 1 | 0 |
| bisantrene | 0 | low | 5 | 0 |
| fomesafen | 0 | low | 4 | 0 |
| fenoxycarb | 0 | low | 5 | 0 |
| zami 1305 | 0 | low | 1 | 0 |
| swainsonine | 0 | low | 8 | 0 |
| 9-(4-methylanilino)-acridine | 0 | low | 1 | 0 |
| tripamide | 0 | low | 1 | 0 |
| 1,3-dinitropyrene | 0 | low | 1 | 0 |
| lovastatin | 0 | low | 42 | 0 |
| 2-amino-3-methylimidazo(4,5-f)quinoline | 0 | low | 22 | 0 |
| n-nitrosobis(2-oxobutyl)amine | 0 | low | 1 | 0 |
| mebrofenin | 0 | low | 5 | 0 |
| piritrexim | 0 | medium | 1 | 1 |
| castanospermine | 0 | low | 2 | 0 |
| simvastatin | 0 | medium | 36 | 2 |
| pravastatin | 0 | medium | 18 | 4 |
| cabergoline | 0 | low | 2 | 0 |
| raloxifene hydrochloride | 0 | low | 6 | 0 |
| ilmofosine | 0 | medium | 2 | 1 |
| mifepristone | 0 | medium | 12 | 2 |
| itraconazole | 0 | low | 5 | 0 |
| gusperimus | 0 | low | 2 | 0 |
| 1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea | 0 | low | 1 | 0 |
| flavone acetic acid | 0 | low | 2 | 0 |
| 5,9-dimethyldibenzo(c,g)carbazole | 0 | low | 2 | 0 |
| iopentol | 0 | low | 2 | 0 |
| antineoplaston a10 | 0 | medium | 4 | 1 |
| fluorodopa f 18 | 0 | low | 14 | 0 |
| salmeterol xinafoate | 0 | medium | 1 | 1 |
| bmy 25067 | 0 | low | 1 | 0 |
| atamestane | 0 | low | 1 | 0 |
| fura-2 | 0 | low | 6 | 0 |
| crisnatol | 0 | low | 1 | 0 |
| 1,2-dihydroxy-epoxy-1,2,3,4-tetrahydro-5-methylchrysene | 0 | low | 1 | 0 |
| imiquimod | 0 | low | 2 | 0 |
| n 0437, (-)-isomer | 0 | low | 1 | 0 |
| fadrozole | 0 | low | 5 | 0 |
| esmolol | 0 | medium | 2 | 1 |
| adapalene | 0 | low | 1 | 0 |
| adefovir | 0 | medium | 34 | 3 |
| loxiglumide | 0 | low | 2 | 0 |
| aromasil | 0 | medium | 14 | 5 |
| zileuton | 0 | low | 2 | 0 |
| clopidogrel | 0 | low | 10 | 0 |
| cidofovir anhydrous | 0 | low | 1 | 0 |
| mibefradil | 0 | low | 1 | 0 |
| risotilide | 0 | low | 1 | 0 |
| topotecan | 0 | medium | 25 | 8 |
| tenidap | 0 | low | 1 | 0 |
| gemcitabine | 0 | medium | 429 | 90 |
| temoporfin | 0 | low | 3 | 0 |
| lufironil | 0 | low | 1 | 0 |
| remifentanil | 0 | medium | 9 | 6 |
| atorvastatin | 0 | medium | 24 | 1 |
| lamivudine | 0 | medium | 175 | 13 |
| duloxetine hydrochloride | 0 | low | 2 | 0 |
| irinotecan | 0 | medium | 688 | 146 |
| valsartan | 0 | low | 1 | 0 |
| zolmitriptan | 0 | low | 1 | 0 |
| 3-iodobenzylguanidine | 0 | medium | 91 | 4 |
| adefovir dipivoxil | 0 | medium | 16 | 2 |
| emtricitabine | 0 | low | 3 | 0 |
| capecitabine | 0 | medium | 374 | 101 |
| adenosine | 0 | medium | 143 | 3 |
| safranal | 0 | low | 1 | 0 |
| 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone | 0 | low | 1 | 0 |
| octyl gallate | 0 | low | 1 | 0 |
| ferric citrate | 0 | low | 2 | 0 |
| 3-n-butylphthalide | 0 | low | 1 | 0 |
| gadolinium chloride | 0 | low | 9 | 0 |
| vanadates | 0 | low | 8 | 0 |
| cupric nitrilotriacetate | 0 | low | 2 | 0 |
| dimethylhydrazines | 0 | medium | 46 | 1 |
| dehydroabietylamine | 0 | low | 2 | 0 |
| 3-(methylnitrosamino)propionitrile | 0 | low | 1 | 0 |
| 2-amino-3,4-dimethylimidazo(4,5-f)quinoline | 0 | low | 8 | 0 |
| 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline | 0 | low | 14 | 0 |
| musk xylene | 0 | low | 1 | 0 |
| scarlet red | 0 | low | 1 | 0 |
| sudan iii | 0 | low | 2 | 0 |
| acridine orange | 0 | low | 6 | 0 |
| isothiocyanic acid | 0 | low | 5 | 0 |
| cuprous chloride | 0 | low | 1 | 0 |
| chromic phosphate | 0 | medium | 3 | 1 |
| carbogen | 0 | medium | 7 | 1 |
| caloreen | 0 | low | 1 | 0 |
| 2-amino-9h-pyrido(2,3-b)indole | 0 | low | 1 | 0 |
| octyl glucoside | 0 | low | 1 | 0 |
| cisatracurium | 0 | low | 2 | 0 |
| halofuginone | 0 | low | 3 | 0 |
| trazodone hydrochloride | 0 | low | 12 | 0 |
| dexamethasone 21-methanesulfonate | 0 | low | 1 | 0 |
| dexamethasone 21-palmitate | 0 | medium | 2 | 2 |
| 3,4,5,3',4'-pentachlorobiphenyl | 0 | low | 11 | 0 |
| efavirenz | 0 | low | 2 | 0 |
| nelfinavir | 0 | low | 3 | 0 |
| 2',3'-dideoxycytidinene | 0 | low | 1 | 0 |
| methionine methyl ester | 0 | low | 1 | 0 |
| glucose, (beta-d)-isomer | 0 | medium | 60 | 3 |
| anisodamine | 0 | low | 1 | 0 |
| mevastatin | 0 | low | 7 | 0 |
| simvastatin acid | 0 | low | 3 | 0 |
| chloroquine diphosphate | 0 | low | 1 | 0 |
| fenofibric acid | 0 | low | 1 | 0 |
| 2',7'-dichlorofluorescein | 0 | low | 3 | 0 |
| ursolic acid | 0 | low | 33 | 0 |
| norharman | 0 | low | 4 | 0 |
| thiazolyl blue | 0 | medium | 71 | 2 |
| thymidine 5'-triphosphate | 0 | low | 2 | 0 |
| betulinic acid | 0 | low | 10 | 0 |
| dexelvucitabine | 0 | low | 1 | 0 |
| 2'3'-didehydro-2'3'-dideoxyadenosine | 0 | low | 2 | 0 |
| arctigenin | 0 | low | 5 | 0 |
| baicalin | 0 | medium | 12 | 2 |
| plerixafor | 0 | low | 10 | 0 |
| amprenavir | 0 | low | 1 | 0 |
| oseltamivir | 0 | low | 3 | 0 |
| allicin | 0 | low | 5 | 0 |
| 5-methylcytosine | 0 | low | 31 | 0 |
| guanidine thiocyanate | 0 | low | 1 | 0 |
| ibacitabine | 0 | low | 1 | 0 |
| epigallocatechin gallate | 0 | low | 71 | 0 |
| cholesteryl succinate | 0 | low | 2 | 0 |
| gallocatechol | 0 | medium | 5 | 1 |
| 2'-deoxycytidine 5'-triphosphate | 0 | low | 1 | 0 |
| 25-hydroxycholesterol | 0 | low | 20 | 0 |
| phosphoramidic acid | 0 | low | 2 | 0 |
| 1,2-dipalmitoyl-3-phosphatidylethanolamine | 0 | low | 2 | 0 |
| aica ribonucleotide | 0 | low | 8 | 0 |
| thomsen-friedenreich antigen | 0 | low | 9 | 0 |
| salvin | 0 | low | 5 | 0 |
| 1,2-dipalmitoylphosphatidylglycerol | 0 | low | 1 | 0 |
| 1,2-distearoyllecithin | 0 | low | 1 | 0 |
| bathocuproine | 0 | low | 1 | 0 |
| 1-beta-d-arabinofuranosylcytosine 5'-monophosphate | 0 | low | 1 | 0 |
| 5-bromo-4-chloro-3-indolyl beta-galactoside | 0 | low | 3 | 0 |
| nile red | 0 | low | 1 | 0 |
| metaperiodate | 0 | low | 10 | 0 |
| lissamine rhodamine b | 0 | low | 3 | 0 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | 0 | low | 1 | 0 |
| tris(2,2'-bipyridine)ruthenium(II) | 0 | low | 2 | 0 |
| fructose-1-phosphate | 0 | low | 1 | 0 |
| 2-oxothiazolidine-4-carboxylic acid | 0 | low | 1 | 0 |
| aspartate-beta-hydroxamate | 0 | low | 1 | 0 |
| o-(6)-methylguanine | 0 | low | 9 | 0 |
| pyrrolidine dithiocarbamate | 0 | medium | 8 | 1 |
| o-4-methylthymine | 0 | low | 1 | 0 |
| peroxynitric acid | 0 | low | 1 | 0 |
| glutathione disulfide | 0 | low | 12 | 0 |
| bathophenanthroline disulfonic acid | 0 | low | 1 | 0 |
| triptonide | 0 | low | 1 | 0 |
| iopamidol | 0 | medium | 134 | 24 |
| histamine phosphate | 0 | low | 1 | 0 |
| cephalosporin c | 0 | medium | 6 | 3 |
| tetraiodothyroacetic acid | 0 | low | 2 | 0 |
| 5-dihydrocortisone | 0 | low | 1 | 0 |
| 5-methylnicotinamide | 0 | low | 2 | 0 |
| 3'-deoxyadenosine 5'-triphosphate | 0 | low | 1 | 0 |
| trofosfamide | 0 | medium | 3 | 1 |
| lathosterol | 0 | low | 1 | 0 |
| tretoquinol | 0 | low | 1 | 0 |
| milnacipran | 0 | low | 1 | 0 |
| flomoxef | 0 | medium | 2 | 2 |
| methoxy-morpholinyl-doxorubicin | 0 | low | 2 | 0 |
| bepafant | 0 | low | 1 | 0 |
| iobitridol | 0 | medium | 9 | 1 |
| telmisartan | 0 | low | 6 | 0 |
| methacycline | 0 | low | 2 | 0 |
| bergenin | 0 | low | 1 | 0 |
| boron nitride | 0 | low | 2 | 0 |
| iridium radioisotopes | 0 | medium | 17 | 4 |
| xenon radioisotopes | 0 | low | 13 | 0 |
| 2-methoxyestradiol | 0 | low | 11 | 0 |
| ovosiston | 0 | low | 2 | 0 |
| perylenediimide | 0 | low | 1 | 0 |
| naphthalimides | 0 | low | 17 | 0 |
| toxoflavin | 0 | low | 1 | 0 |
| benzeneboronic acid | 0 | low | 3 | 0 |
| porphine | 0 | low | 1 | 0 |
| moskene | 0 | low | 1 | 0 |
| acetoxime | 0 | low | 2 | 0 |
| bromosuccinimide | 0 | low | 2 | 0 |
| leucomalachite green | 0 | low | 1 | 0 |
| musk tibetine | 0 | low | 1 | 0 |
| 1,7-phenanthroline | 0 | low | 23 | 0 |
| pyrazolo(3,4-d)pyrimidine | 0 | low | 1 | 0 |
| triazoles | 0 | medium | 81 | 5 |
| diazobenzenesulfonic acid | 0 | low | 1 | 0 |
| perfluorododecanoic acid | 0 | low | 1 | 0 |
| iodophthalein | 0 | low | 1 | 0 |
| dabi | 0 | low | 1 | 0 |
| 6-methyladenine | 0 | low | 8 | 0 |
| lupulon | 0 | low | 1 | 0 |
| atranorin | 0 | low | 1 | 0 |
| tangeretin | 0 | low | 5 | 0 |
| isoimperatorin | 0 | low | 2 | 0 |
| isocoumarins | 0 | low | 2 | 0 |
| 1-piperideine | 0 | low | 1 | 0 |
| delphinidin | 0 | low | 22 | 0 |
| sesamol | 0 | low | 1 | 0 |
| 1,2-dithiol-3-thione | 0 | low | 2 | 0 |
| 4-aminoquinoline | 0 | low | 1 | 0 |
| ethinylestradiol-3-sulfate | 0 | low | 1 | 0 |
| 1,3-bis(4-carboxyphenoxy)propane | 0 | low | 1 | 0 |
| fluorodeoxyglucose f18 | 0 | medium | 1,060 | 64 |
| sertraline | 0 | low | 6 | 0 |
| zoledronic acid | 0 | medium | 24 | 1 |
| glutaurine | 0 | low | 1 | 0 |
| schizandrol b | 0 | low | 1 | 0 |
| elmustine | 0 | low | 1 | 0 |
| artemisinin | 0 | low | 9 | 0 |
| propildazine | 0 | low | 1 | 0 |
| pirinixil | 0 | low | 3 | 0 |
| propacetamol | 0 | medium | 1 | 1 |
| tianeptine | 0 | low | 1 | 0 |
| artemether | 0 | low | 2 | 0 |
| 1,2,3,4-tetrahydroquinoline | 0 | low | 1 | 0 |
| fructose-6-phosphate | 0 | low | 2 | 0 |
| acefylline | 0 | low | 2 | 0 |
| 5-fluoropyrimidine | 0 | low | 4 | 0 |
| 5-iodouracil | 0 | low | 1 | 0 |
| tyrosyltyrosine | 0 | low | 1 | 0 |
| 5-hydroxymethylcytosine | 0 | low | 22 | 0 |
| 2-hydroxychavicol | 0 | low | 1 | 0 |
| acamprosate | 0 | low | 1 | 0 |
| dapoxetine | 0 | medium | 2 | 2 |
| dexrazoxane | 0 | low | 1 | 0 |
| masoprocol | 0 | low | 2 | 0 |
| tocophersolan | 0 | low | 25 | 0 |
| 7-methyladenine | 0 | low | 1 | 0 |
| voriconazole | 0 | medium | 5 | 2 |
| tazolol | 0 | low | 1 | 0 |
| enocitabine | 0 | medium | 1 | 1 |
| ranimustine | 0 | low | 2 | 0 |
| mitozolomide | 0 | low | 1 | 0 |
| aceclofenac | 0 | low | 1 | 0 |
| olaquindox | 0 | low | 1 | 0 |
| pheneturide | 0 | low | 1 | 0 |
| terlipressin | 0 | medium | 4 | 1 |
| losoxantrone | 0 | medium | 1 | 1 |
| bw 12c79 | 0 | medium | 1 | 1 |
| ubenimex | 0 | low | 6 | 0 |
| avarone | 0 | low | 1 | 0 |
| oxetanocin a | 0 | low | 1 | 0 |
| sulfolithocholylglycine | 0 | low | 1 | 0 |
| 7-hydroxystaurosporine | 0 | low | 1 | 0 |
| hesperetin | 0 | low | 2 | 0 |
| 4-o-methyl-12-o-tetradecanoylphorbol 13-acetate | 0 | low | 2 | 0 |
| magnolol | 0 | low | 4 | 0 |
| honokiol | 0 | low | 9 | 0 |
| sesamin | 0 | low | 2 | 0 |
| columbamine | 0 | low | 2 | 0 |
| coptisine | 0 | low | 4 | 0 |
| jatrorrhizine | 0 | low | 1 | 0 |
| betulin | 0 | low | 5 | 0 |
| hernandezine | 0 | low | 1 | 0 |
| nobiletin | 0 | low | 5 | 0 |
| narciclasine | 0 | low | 1 | 0 |
| lycorine | 0 | low | 2 | 0 |
| neamine | 0 | low | 1 | 0 |
| teleocidin b-4 | 0 | low | 5 | 0 |
| leupeptin | 0 | low | 4 | 0 |
| picropodophyllin | 0 | low | 5 | 0 |
| alkannin | 0 | low | 1 | 0 |
| pacein | 0 | medium | 15 | 1 |
| berberrubine | 0 | low | 2 | 0 |
| alantolactone | 0 | low | 2 | 0 |
| 3-aminophenoxazone | 0 | low | 1 | 0 |
| juncusol | 0 | low | 1 | 0 |
| nsc 361456 | 0 | medium | 1 | 1 |
| 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide | 0 | low | 1 | 0 |
| 7-bromobenzanthracene | 0 | low | 1 | 0 |
| indole-2-carboxylic acid | 0 | low | 1 | 0 |
| tetrandrine | 0 | low | 12 | 0 |
| 3-deazaneplanocin | 0 | low | 4 | 0 |
| tosyllysine chloromethyl ketone | 0 | low | 1 | 0 |
| dehydrocostus lactone | 0 | low | 3 | 0 |
| xanthomicrol | 0 | low | 1 | 0 |
| isoalantolactone | 0 | low | 2 | 0 |
| fascaplysine | 0 | low | 1 | 0 |
| pulsatilla saponin a | 0 | low | 1 | 0 |
| hederagenin | 0 | low | 1 | 0 |
| fr 109615 | 0 | low | 1 | 0 |
| jacaranone | 0 | low | 1 | 0 |
| o(6)-methyl-2'-deoxyguanosine | 0 | low | 1 | 0 |
| calpeptin | 0 | low | 1 | 0 |
| gliclazide | 0 | low | 5 | 0 |
| dauricine | 0 | low | 1 | 0 |
| brusatol | 0 | low | 3 | 0 |
| panaxadiol | 0 | low | 3 | 0 |
| corilagin | 0 | low | 5 | 0 |
| glycyl-histidyl-lysine | 0 | low | 1 | 0 |
| maslinic acid | 0 | low | 2 | 0 |
| clofentezine | 0 | low | 1 | 0 |
| carbohydrazide | 0 | low | 2 | 0 |
| oxazolidin-2-one | 0 | low | 5 | 0 |
| ceric oxide | 0 | low | 6 | 0 |
| bis(diphenylphosphine)ethane | 0 | low | 1 | 0 |
| perfluorooctane sulfonic acid | 0 | low | 10 | 0 |
| triphenylmethylphosphonium | 0 | low | 1 | 0 |
| atovaquone | 0 | low | 2 | 0 |
| 1-(2-chloroethyl)-1-nitrosourea | 0 | low | 1 | 0 |
| 2-(methylamino)isobutyric acid | 0 | low | 1 | 0 |
| c.i. direct red 80 | 0 | low | 1 | 0 |
| methylimidazoleacetic acid | 0 | low | 1 | 0 |
| 2-chlorodiazepam | 0 | medium | 1 | 1 |
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 0 | low | 1 | 0 |
| 6-carboxyfluorescein | 0 | low | 1 | 0 |
| 7-methylbenz(c)acridine | 0 | low | 1 | 0 |
| isoguanine | 0 | low | 1 | 0 |
| 6-methoxy-2-naphthalaldehyde | 0 | low | 1 | 0 |
| bendamustine hydrochloride | 0 | medium | 4 | 1 |
| sofosbuvir | 0 | low | 1 | 0 |
| 2',7'-dichlorodihydrofluorescein diacetate | 0 | low | 2 | 0 |
| tris(2-aminoethyl)amine | 0 | low | 2 | 0 |
| ribose-5-phosphate | 0 | low | 1 | 0 |
| rosiglitazone | 0 | low | 27 | 0 |
| erucin | 0 | low | 3 | 0 |
| 3,7-diazanonane-1,9-diamine | 0 | low | 2 | 0 |
| 3,7-dimethyl-7-octen-1-ol | 0 | low | 1 | 0 |
| benzylphosphonic acid | 0 | low | 1 | 0 |
| gamma-glutamine-4-nitroanilide | 0 | low | 1 | 0 |
| cryptolepine | 0 | low | 1 | 0 |
| 2-bromopalmitate | 0 | low | 1 | 0 |
| bexarotene | 0 | medium | 3 | 1 |
| noracycline | 0 | low | 2 | 0 |
| bisecurin i | 0 | low | 1 | 0 |
| 3,4-dihydroxyphenylethanol | 0 | low | 4 | 0 |
| 4-phenylbutylamine | 0 | low | 2 | 0 |
| eriocitrin | 0 | low | 2 | 0 |
| 1-(2-hydroxyethyl)-1-nitrosourea | 0 | low | 1 | 0 |
| n-acryloyl-tris(hydroxymethyl)aminomethane | 0 | low | 1 | 0 |
| biotinyl-n-hydroxysulfosuccinimide ester | 0 | low | 1 | 0 |
| 5-(biotinamido)pentylamine | 0 | low | 1 | 0 |
| adriamycinol | 0 | low | 5 | 0 |
| clarithromycin | 0 | medium | 2 | 1 |
| ferroin | 0 | low | 1 | 0 |
| gadolinium edta | 0 | low | 3 | 0 |
| 4-methoxy-1-naphthalaldehyde | 0 | low | 1 | 0 |
| 1-nitroso-5,6-dihydrouracil | 0 | low | 1 | 0 |
| epidepride | 0 | low | 1 | 0 |
| tebuconazole | 0 | low | 2 | 0 |
| 4-(4-chlorophenyl)-2-phenyl-2-(1,2,4-triazol-1-ylmethyl)butanenitrile | 0 | low | 1 | 0 |
| difenoconazole | 0 | low | 1 | 0 |
| cp094 | 0 | low | 1 | 0 |
| fenazaquin | 0 | low | 1 | 0 |
| fludioxonil | 0 | low | 1 | 0 |
| coenzyme a | 0 | low | 20 | 0 |
| 5-aminoindazole | 0 | low | 1 | 0 |
| 7-chlorobenz(a)anthracene | 0 | low | 1 | 0 |
| gentiopicroside | 0 | low | 1 | 0 |
| 5,7-dimethoxyflavone | 0 | low | 4 | 0 |
| tretazicar | 0 | medium | 3 | 1 |
| mebeverine | 0 | low | 2 | 0 |
| o-desmethylangolensin | 0 | low | 1 | 0 |
| nicotine | 0 | medium | 11 | 2 |
| nsc-172755 | 0 | low | 2 | 0 |
| loganic acid | 0 | low | 1 | 0 |
| 1-aminocyclobutanecarboxylic acid | 0 | low | 2 | 0 |
| fibrinogen | 0 | medium | 211 | 10 |
| terreic acid | 0 | low | 1 | 0 |
| 17-alpha-hydroxypregnenolone | 0 | low | 3 | 0 |
| matrine | 0 | low | 1 | 0 |
| equol | 0 | low | 4 | 0 |
| 7-ketocholesterol | 0 | low | 1 | 0 |
| cadmium telluride | 0 | low | 13 | 0 |
| goethite | 0 | medium | 1 | 1 |
| glycidamide | 0 | low | 2 | 0 |
| homocysteine | 0 | medium | 27 | 1 |
| 4-methylumbelliferyl glucuronide | 0 | low | 1 | 0 |
| 4-hydroxypropranolol | 0 | low | 2 | 0 |
| 8-((4-chlorophenyl)thio)cyclic-3',5'-amp | 0 | low | 3 | 0 |
| hydroxyflutamide | 0 | low | 1 | 0 |
| 2,2',4,6,6'-pentachlorobiphenyl | 0 | low | 1 | 0 |
| n-nitrosobis(2-acetoxypropyl)amine | 0 | low | 1 | 0 |
| lyngbyatoxin a | 0 | low | 1 | 0 |
| delta-tocopherol | 0 | low | 1 | 0 |
| sarsasapogenin | 0 | low | 3 | 0 |
| tylophorine | 0 | low | 2 | 0 |
| fluoromisonidazole | 0 | low | 1 | 0 |
| levobupivacaine | 0 | medium | 1 | 1 |
| mci 9038 | 0 | low | 1 | 0 |
| lopinavir | 0 | medium | 2 | 2 |
| gamma-tocopherol | 0 | low | 3 | 0 |
| zymosterol | 0 | low | 1 | 0 |
| allotetrahydrocortisol | 0 | low | 1 | 0 |
| propionyl-coenzyme a | 0 | low | 2 | 0 |
| annatto | 0 | low | 1 | 0 |
| methylarsine oxide | 0 | low | 1 | 0 |
| glycyltyrosine | 0 | low | 1 | 0 |
| firefly luciferin | 0 | low | 1 | 0 |
| norcantharidin | 0 | low | 48 | 0 |
| cortisol 21-mesylate | 0 | low | 1 | 0 |
| xanthorrhizol | 0 | low | 1 | 0 |
| dithiobis(succinimidylpropionate) | 0 | low | 1 | 0 |
| dehydroabietic acid | 0 | low | 2 | 0 |
| malvidin 3-galactoside | 0 | low | 1 | 0 |
| alpha-tocopherol phosphate | 0 | low | 1 | 0 |
| glucuronic acid | 0 | low | 25 | 0 |
| 4-mercaptobenzoate | 0 | low | 1 | 0 |
| 2,2-dimethyl-beta-alanine | 0 | low | 2 | 0 |
| 6-ethylguanine | 0 | low | 3 | 0 |
| 4',5,6,7-tetramethoxyflavone | 0 | low | 1 | 0 |
| phosphoramide mustard | 0 | low | 2 | 0 |
| dipin | 0 | low | 3 | 0 |
| carbobenzoxyglycylphenylalanine amide | 0 | low | 1 | 0 |
| 10-hydroxycamptothecin | 0 | medium | 22 | 1 |
| hexylglutathione | 0 | low | 1 | 0 |
| 2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine | 0 | low | 1 | 0 |
| 3-methoxybenzamide | 0 | low | 1 | 0 |
| 4-hydroxyantipyrine | 0 | low | 2 | 0 |
| cholest-5-ene-3 beta,26-diol | 0 | low | 2 | 0 |
| diosgenin | 0 | low | 16 | 0 |
| o(6)-ethyl-2'-deoxyguanosine | 0 | low | 1 | 0 |
| 4-hydroxycyclophosphamide | 0 | low | 1 | 0 |
| 4-methoxydalbergione | 0 | low | 2 | 0 |
| phorbolol myristate acetate | 0 | low | 1 | 0 |
| dianhydro-3,4-diacetylgalactitol | 0 | low | 2 | 0 |
| pyrimidin-2-one beta-ribofuranoside | 0 | low | 5 | 0 |
| nimbolide | 0 | low | 3 | 0 |
| foxes | 0 | low | 5 | 0 |
| kemptide | 0 | low | 1 | 0 |
| benzylidene glucose | 0 | low | 1 | 0 |
| alpha-glutamyltryptophan | 0 | medium | 1 | 1 |
| combretastatin | 0 | low | 2 | 0 |
| beta-hydroxyisovalerylshikonin | 0 | low | 1 | 0 |
| fangchinoline | 0 | low | 3 | 0 |
| rfcnu | 0 | low | 1 | 0 |
| 8-chloro-cyclic adenosine monophosphate | 0 | low | 1 | 0 |
| loliolide | 0 | low | 1 | 0 |
| coumarin 6 | 0 | low | 4 | 0 |
| 10-deazaaminopterin | 0 | low | 1 | 0 |
| arctiin | 0 | low | 3 | 0 |
| 7-amino-4-trifluoromethylcoumarin | 0 | low | 1 | 0 |
| n-hydroxysuccinimide suberic acid ester | 0 | low | 1 | 0 |
| cyclic dtpa anhydride | 0 | low | 1 | 0 |
| tingenone | 0 | low | 1 | 0 |
| becatecarin | 0 | medium | 1 | 1 |
| cycloleucalenol | 0 | low | 1 | 0 |
| tetrahydrodeoxycorticosterone | 0 | low | 1 | 0 |
| methyl mannoside, (alpha-d)-isomer | 0 | low | 1 | 0 |
| meldola blue | 0 | low | 1 | 0 |
| pregnanetriol | 0 | medium | 1 | 1 |
| n-methyladenosine | 0 | medium | 57 | 1 |
| 1,2-distearoylphosphatidylethanolamine | 0 | low | 3 | 0 |
| 4'-methoxyflavanone | 0 | low | 1 | 0 |
| lanthionine | 0 | low | 1 | 0 |
| 4-(methylthio)-3-butenyl isothiocyanate | 0 | low | 1 | 0 |
| cobalt | 0 | medium | 61 | 1 |
| p-methoxy-n-methylphenethylamine | 0 | low | 1 | 0 |
| fulvestrant | 0 | medium | 9 | 2 |
| aflatoxicol | 0 | low | 1 | 0 |
| uftoral | 0 | medium | 58 | 6 |
| hydrogen sulfite | 0 | low | 9 | 0 |
| 1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid | 0 | low | 1 | 0 |
| aflatoxin b1-2,3-oxide | 0 | low | 3 | 0 |
| yttrium radioisotopes | 0 | medium | 1,268 | 109 |
| mizoribine | 0 | low | 1 | 0 |
| chlorates | 0 | low | 2 | 0 |
| desethylamiodarone | 0 | low | 2 | 0 |
| carbidopa, levodopa drug combination | 0 | low | 1 | 0 |
| u 73122 | 0 | low | 1 | 0 |
| fotemustine | 0 | medium | 28 | 9 |
| arginyl-glycyl-aspartic acid | 0 | low | 42 | 0 |
| wr 1065 | 0 | medium | 2 | 1 |
| vitamin b 6 | 0 | medium | 12 | 1 |
| imipenem, anhydrous | 0 | low | 4 | 0 |
| cremophor el | 0 | low | 2 | 0 |
| 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol | 0 | low | 1 | 0 |
| s-nitrosoglutathione | 0 | low | 2 | 0 |
| n-nitrosomethyl-2-oxopropylamine | 0 | low | 2 | 0 |
| diacetyldichlorofluorescein | 0 | low | 1 | 0 |
| o-methylsterigmatocystin | 0 | low | 1 | 0 |
| 3,3',4,4',5,5'-hexabromobiphenyl | 0 | low | 3 | 0 |
| 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole | 0 | low | 1 | 0 |
| 1-hydroxymethylpyrene | 0 | low | 1 | 0 |
| 1,n(6)-ethenoadenine | 0 | medium | 3 | 2 |
| paxilline | 0 | low | 22 | 0 |
| prolinedithiocarbamate | 0 | low | 5 | 0 |
| beauvericin | 0 | low | 2 | 0 |
| artesunic acid | 0 | low | 16 | 0 |
| cyanates | 0 | low | 7 | 0 |
| dehydroretronecine | 0 | low | 2 | 0 |
| pyridinoline | 0 | low | 1 | 0 |
| deoxypyridinoline | 0 | low | 1 | 0 |
| 1,n(6)-ethenodeoxyadenosine | 0 | low | 2 | 0 |
| ambrox | 0 | low | 1 | 0 |
| thiamethoxam | 0 | medium | 2 | 2 |
| s-ethyl glutathione | 0 | low | 3 | 0 |
| 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate | 0 | low | 1 | 0 |
| pentoxyresorufin | 0 | low | 1 | 0 |
| cyproterone acetate, ethinyl estradiol drug combination | 0 | medium | 1 | 1 |
| sivelestat | 0 | medium | 2 | 2 |
| bismuth nitrate | 0 | low | 1 | 0 |
| n-nitrosomethyl-2-hydroxypropylamine | 0 | low | 1 | 0 |
| 22-hydroxycholesterol | 0 | low | 2 | 0 |
| propionylcarnitine | 0 | low | 1 | 0 |
| aldophosphamide | 0 | low | 2 | 0 |
| inositol-1,3,4,5-tetrakisphosphate | 0 | low | 2 | 0 |
| dimyristoylphosphatidylglycerol | 0 | low | 1 | 0 |
| arginyl-glycyl-aspartyl-serine | 0 | low | 2 | 0 |
| 4-ethylthymine | 0 | low | 2 | 0 |
| saikosaponin d | 0 | low | 16 | 0 |
| perindopril | 0 | medium | 7 | 2 |
| geniposide | 0 | low | 3 | 0 |
| procyanidin | 0 | low | 16 | 0 |
| n-nitroso-2-hydroxymorpholine | 0 | low | 1 | 0 |
| epicatechin gallate | 0 | low | 3 | 0 |
| deguelin | 0 | low | 2 | 0 |
| benzanthracene-3,4-dihydrodiol | 0 | low | 1 | 0 |
| fingolimod hydrochloride | 0 | low | 18 | 0 |
| daidzin | 0 | low | 2 | 0 |
| dihydrocapsaicin | 0 | low | 1 | 0 |
| triptolide | 0 | low | 16 | 0 |
| 4-(5-nitro-2-furyl)thiazole | 0 | low | 1 | 0 |
| o(4)-ethylthymidine | 0 | low | 1 | 0 |
| 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide | 0 | medium | 1 | 1 |
| n-nitroso-n(2)-fluorenylacetamide | 0 | low | 1 | 0 |
| cobaltiprotoporphyrin | 0 | low | 3 | 0 |
| plutonium nitrate | 0 | low | 1 | 0 |
| vinyl carbamate epoxide | 0 | low | 1 | 0 |
| cafestol | 0 | low | 3 | 0 |
| asiaticoside | 0 | low | 1 | 0 |
| proanthocyanidin | 0 | low | 3 | 0 |
| diazan | 0 | low | 1 | 0 |
| parthenolide | 0 | low | 10 | 0 |
| schizandrin b | 0 | low | 3 | 0 |
| tamibarotene | 0 | low | 2 | 0 |
| carboxyamido-triazole | 0 | low | 1 | 0 |
| ecteinascidin 743 | 0 | medium | 4 | 2 |
| kt 6149 | 0 | medium | 1 | 1 |
| kt 5823 | 0 | low | 2 | 0 |
| 1-hexadecyl-2-acetyl-glycero-3-phosphocholine | 0 | medium | 9 | 1 |
| 4'-deoxy-4'-iododoxorubicin | 0 | low | 2 | 0 |
| 3'-hydroxymethyl-4-(dimethylamino)azobenzene | 0 | low | 2 | 0 |
| bifendate | 0 | low | 2 | 0 |
| deoxyglucose | 0 | medium | 75 | 4 |
| tadalafil | 0 | low | 4 | 0 |
| bauerenol | 0 | low | 1 | 0 |
| precirol | 0 | low | 1 | 0 |
| 1-phenyl-2-decanoylamino-3-morpholino-1-propanol | 0 | low | 2 | 0 |
| 6-phenylhexyl isothiocyanate | 0 | low | 1 | 0 |
| 7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride | 0 | low | 1 | 0 |
| indolo(3,2-b)carbazole | 0 | low | 1 | 0 |
| 9-(2,3-dihydroxypropyl)adenine | 0 | low | 1 | 0 |
| homoorientin | 0 | medium | 5 | 1 |
| kahweol | 0 | low | 4 | 0 |
| valerates | 0 | low | 2 | 0 |
| 4-n-pyrrolidinylazobenzene | 0 | low | 1 | 0 |
| monobromobimane | 0 | low | 2 | 0 |
| liquiritigenin | 0 | low | 3 | 0 |
| selenomethylselenocysteine | 0 | low | 4 | 0 |
| 3-deoxyglucosone | 0 | low | 1 | 0 |
| 16-hydroxyestrone | 0 | low | 2 | 0 |
| n-(1-methyl-2-phenylethyl)adenosine | 0 | low | 1 | 0 |
| aluminum phthalocyanine | 0 | low | 5 | 0 |
| thromboxanes | 0 | low | 2 | 0 |
| monochlorobimane | 0 | low | 1 | 0 |
| 6-methyl-1,3,8-trichlorodibenzofuran | 0 | low | 1 | 0 |
| tanshinone | 0 | low | 30 | 0 |
| 1-(carboxymethylthio)tetradecane | 0 | low | 1 | 0 |
| 4,6-diamino-5-n-formamidopyrimidine | 0 | low | 3 | 0 |
| protoberberine | 0 | low | 2 | 0 |
| soyasapogenol b | 0 | low | 1 | 0 |
| toosendanin | 0 | low | 4 | 0 |
| amarogentin | 0 | low | 3 | 0 |
| ifosfamide | 0 | low | 1 | 0 |
| metadoxine | 0 | medium | 2 | 1 |
| 3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate | 0 | low | 1 | 0 |
| 3beta-(n-(n',n'-dimethylaminoethane)carbamoyl)cholesterol | 0 | low | 1 | 0 |
| stachydrine | 0 | low | 2 | 0 |
| glycolithocholic acid | 0 | low | 1 | 0 |
| taraxasterol | 0 | low | 1 | 0 |
| 4'-phosphopantetheine | 0 | low | 1 | 0 |
| s-methyl glutathione | 0 | low | 1 | 0 |
| sophocarpine | 0 | low | 2 | 0 |
| 15-hydroxyeicosanoic acid | 0 | low | 1 | 0 |
| glycyl-arginyl-glycyl-aspartyl-seryl-proline | 0 | low | 1 | 0 |
| nitisinone | 0 | low | 23 | 0 |
| bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) | 0 | low | 1 | 0 |
| me 2303 | 0 | low | 2 | 0 |
| marimastat | 0 | medium | 5 | 1 |
| nitroaspirin | 0 | low | 1 | 0 |
| asiatic acid | 0 | low | 3 | 0 |
| 1'-acetoxychavicol acetate | 0 | low | 2 | 0 |
| ak 2123 | 0 | low | 2 | 0 |
| clofarabine | 0 | low | 1 | 0 |
| silicon phthalocyanine pc4 | 0 | low | 4 | 0 |
| 2-pyrrolino-dox | 0 | low | 1 | 0 |
| 6-fluoromevalonolactone | 0 | low | 1 | 0 |
| dioscin | 0 | low | 4 | 0 |
| astilbin | 0 | low | 1 | 0 |
| 2-aminomethyl-4-t-butyl-6-iodophenol | 0 | low | 1 | 0 |
| cucurbitacins | 0 | low | 4 | 0 |
| benzo(a)pyrene-3,6-quinol | 0 | low | 1 | 0 |
| ginsenoside rh2 | 0 | low | 21 | 0 |
| ar 12463 | 0 | low | 1 | 0 |
| 5-fluoromethylornithine | 0 | low | 1 | 0 |
| elacridar | 0 | low | 3 | 0 |
| aminopentol | 0 | low | 1 | 0 |
| nitroflurbiprofen | 0 | low | 1 | 0 |
| caprylates | 0 | low | 20 | 0 |
| 1,3,4-thiadiazole | 0 | low | 2 | 0 |
| 4,5-dioxovaleric acid | 0 | low | 2 | 0 |
| zami 1327 | 0 | low | 1 | 0 |
| pramipexole | 0 | low | 1 | 0 |
| ru 39411 | 0 | low | 1 | 0 |
| dt 5461 | 0 | low | 1 | 0 |
| parecoxib | 0 | medium | 7 | 4 |
| perimidine | 0 | low | 1 | 0 |
| disodium cantharidin | 0 | low | 2 | 0 |
| hydroquinidine | 0 | low | 1 | 0 |
| 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | 0 | low | 7 | 0 |
| egta acetoxymethyl ester | 0 | low | 1 | 0 |
| rges peptide | 0 | low | 1 | 0 |
| (20s)-20-hydroxycholesterol | 0 | low | 2 | 0 |
| thymidine 3',5'-diphosphate | 0 | low | 1 | 0 |
| 5-fluorodihydrouracil | 0 | low | 1 | 0 |
| dl 111-it | 0 | low | 1 | 0 |
| selenonorcholesterol | 0 | low | 1 | 0 |
| 6-bromoconduritol | 0 | low | 1 | 0 |
| soyasaponin bb | 0 | low | 1 | 0 |
| phytosphingosine | 0 | low | 1 | 0 |
| rc 3095 | 0 | low | 1 | 0 |
| dx 9065a | 0 | low | 1 | 0 |
| pd 142893 | 0 | low | 1 | 0 |
| gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate | 0 | low | 17 | 0 |
| benzoyl-coenzyme a | 0 | low | 1 | 0 |
| (3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium | 0 | medium | 1 | 1 |
| inositol 2,4,5-trisphosphate | 0 | low | 1 | 0 |
| san 58035 | 0 | low | 1 | 0 |
| 5-fluorodopamine | 0 | low | 2 | 0 |
| 3-deoxy-3-fluoro-d-glucose | 0 | low | 1 | 0 |
| saccharolactone | 0 | low | 2 | 0 |
| 3,7,12-trihydroxycholestan-26-oic acid | 0 | low | 2 | 0 |
| astragaloside a | 0 | low | 10 | 0 |
| celastrol | 0 | low | 20 | 0 |
| bruceine d | 0 | low | 2 | 0 |
| aaptamine | 0 | low | 1 | 0 |
| betulonic acid | 0 | low | 2 | 0 |
| carbene | 0 | low | 2 | 0 |
| peroxynitrous acid | 0 | medium | 9 | 2 |
| perchlorate | 0 | low | 1 | 0 |
| fullerene c60 | 0 | low | 10 | 0 |
| imatinib mesylate | 0 | medium | 222 | 13 |
| mk 0663 | 0 | low | 1 | 0 |
| tazobactam | 0 | low | 3 | 0 |
| gefitinib | 0 | medium | 76 | 6 |
| ethylene glycolylbis(succinimidyl succinate) | 0 | low | 1 | 0 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | 0 | low | 1 | 0 |
| cholesterol hydroperoxide | 0 | low | 1 | 0 |
| 7 alpha-hydroxy-4-cholesten-3-one | 0 | medium | 2 | 1 |
| 4-carboxyfluorescein | 0 | low | 2 | 0 |
| galactosyl-(1-3)galactose | 0 | low | 2 | 0 |
| n(6)-carboxymethyllysine | 0 | low | 1 | 0 |
| technetium tc 99m hydroxymethylene diphosphonate | 0 | low | 18 | 0 |
| angiotensin ii, des-phe(8)- | 0 | low | 4 | 0 |
| glycyl-arginyl-glycyl-aspartyl-serine | 0 | low | 3 | 0 |
| technetium tc 99m etidronate | 0 | low | 1 | 0 |
| n,n-dimethylarginine | 0 | low | 1 | 0 |
| htr composite | 0 | low | 2 | 0 |
| 3-tyr-octreotide | 0 | low | 4 | 0 |
| antibiotic g 418 | 0 | low | 4 | 0 |
| 4-iodoamphetamine | 0 | low | 2 | 0 |
| glycerophosphoethanolamine | 0 | low | 2 | 0 |
| f-chemotactic peptide | 0 | low | 1 | 0 |
| 1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone | 0 | low | 1 | 0 |
| hydroxycitric acid | 0 | low | 2 | 0 |
| lysyl-aspartyl-glutamyl-leucine | 0 | low | 1 | 0 |
| phosphohistidine | 0 | low | 1 | 0 |
| 3-hydroxymethylantipyrine | 0 | low | 2 | 0 |
| vadimezan | 0 | medium | 3 | 1 |
| 27-hydroxycholesterol | 0 | low | 2 | 0 |
| tyrosyl-isoleucyl-glycyl-seryl-arginine | 0 | low | 1 | 0 |
| e 64 | 0 | low | 1 | 0 |
| glabridin | 0 | low | 4 | 0 |
| rubiadin | 0 | low | 1 | 0 |
| soranjidiol | 0 | low | 1 | 0 |
| tetrahydrocurcumin | 0 | low | 2 | 0 |
| desloratadine | 0 | low | 1 | 0 |
| amdoxovir | 0 | low | 1 | 0 |
| 1-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid | 0 | low | 2 | 0 |
| genkwadaphnin | 0 | low | 1 | 0 |
| rubimaillin | 0 | low | 1 | 0 |
| 1,4,7-triazacyclononane-n,n',n''-triacetic acid | 0 | low | 2 | 0 |
| s-tubercidinylhomocysteine | 0 | low | 1 | 0 |
| 5-hexyl-2'-deoxyuridine | 0 | low | 1 | 0 |
| nsc 224070 | 0 | low | 1 | 0 |
| 7-hydroxy-7'-methoxy-4,4'-bis(1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester | 0 | low | 1 | 0 |
| 6-methoxypurine arabinoside | 0 | low | 2 | 0 |
| glycerophosphoinositol 4,5-bisphosphate | 0 | low | 2 | 0 |
| n-acetylneuraminosyl(alpha2-6)lactosamine | 0 | low | 1 | 0 |
| dibutyryl cyclic-3',5'-cytidine monophosphate | 0 | low | 3 | 0 |
| adenosine triphosphate adenosine monophosphate adenosine monophosphate | 0 | low | 1 | 0 |
| n-(4-(2-chlorophenyl)-6,7-dimethyl-3-quinolyl)-n'-(2,4-difluorophenyl)urea | 0 | low | 1 | 0 |
| 502u83 | 0 | medium | 1 | 1 |
| 7-hydroxycoumarin glucuronide | 0 | low | 1 | 0 |
| beta-ethylstyrene oxide | 0 | low | 1 | 0 |
| anthglutin | 0 | low | 1 | 0 |
| neominophagen c | 0 | low | 3 | 0 |
| alteichin | 0 | low | 2 | 0 |
| 1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene | 0 | low | 2 | 0 |
| 7-(gamma-glutamyl)-4-methylcoumarylamide | 0 | low | 2 | 0 |
| panaxydol | 0 | low | 2 | 0 |
| disialosyl galactosyl globoside | 0 | low | 1 | 0 |
| 5-aza-2'-deoxycytidine-5'-triphosphate | 0 | low | 1 | 0 |
| l 012 | 0 | low | 1 | 0 |
| methotrexate | 0 | medium | 335 | 33 |
| gsk peptide | 0 | low | 1 | 0 |
| guanidinopropylsuccinic acid | 0 | low | 1 | 0 |
| ar 12456 | 0 | low | 1 | 0 |
| 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone | 0 | low | 1 | 0 |
| schisanhenol b | 0 | low | 2 | 0 |
| 3-methyl-4',6-dihydroxy-3',5'-dibromoflavone | 0 | low | 1 | 0 |
| 4-(3-trifluoromethyldiazirino)benzoic acid | 0 | low | 1 | 0 |
| delphinidin | 0 | low | 3 | 0 |
| cyanidin | 0 | low | 1 | 0 |
| ovothiol c | 0 | low | 1 | 0 |
| clitocine | 0 | low | 1 | 0 |
| cki 7 | 0 | low | 1 | 0 |
| n-(2-(diethylamino)ethyl)-4-iodobenzamide | 0 | medium | 3 | 3 |
| antiprimod | 0 | low | 2 | 0 |
| 4-hydroxy-25-desoxyneorollinicin | 0 | low | 2 | 0 |
| dioctadecylamidoglycylspermine | 0 | low | 1 | 0 |
| esterbut-3 | 0 | low | 1 | 0 |
| 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine | 0 | low | 1 | 0 |
| 2',2'-difluorodeoxycytidine 5'-triphosphate | 0 | low | 1 | 0 |
| talotrexin | 0 | low | 1 | 0 |
| 1,3-bis(4-amidinophenoxy)-2-(4-amidinophenoxymethyl)ethylpropane | 0 | medium | 1 | 1 |
| ym 529 | 0 | low | 2 | 0 |
| e 5880 | 0 | medium | 1 | 1 |
| 2-amino-1-(4-chlorophenyl)-3-fluoropropane | 0 | low | 1 | 0 |
| cercosporamide | 0 | low | 1 | 0 |
| umifenovir | 0 | low | 1 | 0 |
| 10-methyl spiro(4.5)dec-6-en-6-carboxylic acid | 0 | medium | 1 | 1 |
| sk&f 104976 | 0 | low | 2 | 0 |
| c 1311 | 0 | low | 1 | 0 |
| n',n''-diacetylspermine | 0 | low | 2 | 0 |
| osw 1 | 0 | low | 2 | 0 |
| omega-n-methylarginine | 0 | low | 3 | 0 |
| abiraterone | 0 | low | 2 | 0 |
| kw 2189 | 0 | medium | 1 | 1 |
| n-hydroxysulfosuccinimide | 0 | low | 1 | 0 |
| carbapenems | 0 | medium | 2 | 1 |
| 1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea | 0 | low | 1 | 0 |
| cholesteryl iopanoate | 0 | low | 2 | 0 |
| aspartame | 0 | low | 1 | 0 |
| calcium borate | 0 | medium | 2 | 2 |
| pomalidomide | 0 | low | 1 | 0 |
| xylose | 0 | medium | 8 | 1 |
| d-apv | 0 | low | 1 | 0 |
| cd 437 | 0 | low | 3 | 0 |
| perrhenate | 0 | low | 1 | 0 |
| phytol | 0 | low | 1 | 0 |
| sinensetin | 0 | low | 2 | 0 |
| proline | 0 | medium | 65 | 1 |
| cucurbitaceae | 0 | low | 5 | 0 |
| escitalopram | 0 | low | 2 | 0 |
| procyanidin b3 | 0 | low | 1 | 0 |
| 8-chloroadenosine | 0 | low | 1 | 0 |
| 10-propargyl-10-deazaaminopterin | 0 | low | 2 | 0 |
| docetaxel | 0 | low | 1 | 0 |
| docetaxel anhydrous | 0 | medium | 231 | 62 |
| perifosine | 0 | medium | 3 | 1 |
| lonafarnib | 0 | medium | 4 | 1 |
| tariquidar | 0 | medium | 1 | 1 |
| 3-nitroso-2-oxazolidone | 0 | low | 2 | 0 |
| nitrosocarbamate | 0 | low | 1 | 0 |
| peptide elongation factor 2 | 0 | low | 1 | 0 |
| 3,4-epithiobutanenitrile | 0 | low | 1 | 0 |
| levofloxacin | 0 | medium | 3 | 2 |
| aclacinomycin | 0 | low | 3 | 0 |
| ezetimibe | 0 | low | 1 | 0 |
| 4-boronophenylalanine | 0 | medium | 8 | 3 |
| 2'-deoxycytidine diphosphate | 0 | low | 1 | 0 |
| 5-methoxytryptophan | 0 | low | 1 | 0 |
| dx 8951 | 0 | low | 1 | 0 |
| vatalanib | 0 | medium | 13 | 6 |
| alpha-fluoro-beta-ureidopropionic acid | 0 | low | 1 | 0 |
| evodiamine | 0 | low | 14 | 0 |
| 3,3,5,5-tetramethyl-1-pyrroline n-oxide | 0 | low | 1 | 0 |
| copper bis(histidinate) | 0 | low | 1 | 0 |
| phosphorodithioic acid | 0 | low | 1 | 0 |
| prolyl-tyrosine | 0 | low | 2 | 0 |
| moxifloxacin | 0 | medium | 4 | 1 |
| tyramine o-sulfate | 0 | low | 1 | 0 |
| thiobenzyl benzyloxycarbonyl-l-lysinate | 0 | low | 1 | 0 |
| mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin | 0 | low | 2 | 0 |
| cyc 682 | 0 | low | 1 | 0 |
| borneo | 0 | low | 1 | 0 |
| diamminebis(ursodeoxycholate(o,o'))platinum(ii) | 0 | low | 1 | 0 |
| 9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole | 0 | low | 3 | 0 |
| bazedoxifene | 0 | low | 3 | 0 |
| phorbols | 0 | low | 4 | 0 |
| tomentosin | 0 | low | 1 | 0 |
| schizandrin a | 0 | low | 1 | 0 |
| omeprazole sulfide | 0 | low | 1 | 0 |
| 10-deacetyltaxol | 0 | low | 1 | 0 |
| atractylenolide iii | 0 | low | 1 | 0 |
| dehydrocrotonin | 0 | low | 1 | 0 |
| naproxen | 0 | medium | 3 | 1 |
| canertinib | 0 | low | 1 | 0 |
| cinacalcet | 0 | low | 3 | 0 |
| echinoside a | 0 | low | 1 | 0 |
| hydroxyl radical | 0 | medium | 13 | 1 |
| 1-(2'-deoxy-2'-fluoro-beta-arabinofuranosyl)-5-methylcytosine triphosphate | 0 | low | 1 | 0 |
| gemcabene | 0 | low | 1 | 0 |
| gelsenicine | 0 | low | 1 | 0 |
| edotreotide | 0 | medium | 12 | 3 |
| versicolorins | 0 | low | 1 | 0 |
| telbivudine | 0 | medium | 24 | 2 |
| jte 522 | 0 | low | 2 | 0 |
| rhodioloside | 0 | low | 5 | 0 |
| malvidin | 0 | low | 1 | 0 |
| apigeninidin | 0 | low | 1 | 0 |
| dysprosium oxide | 0 | low | 1 | 0 |
| gadolinium oxide | 0 | low | 2 | 0 |
| atrasentan | 0 | low | 1 | 0 |
| resiquimod | 0 | low | 2 | 0 |
| indium trichloride | 0 | low | 6 | 0 |
| singlet oxygen | 0 | low | 10 | 0 |
| carcinolipin | 0 | low | 2 | 0 |
| justicidin a | 0 | low | 1 | 0 |
| miltirone | 0 | low | 1 | 0 |
| cryptotanshinone | 0 | low | 10 | 0 |
| fenton's reagent | 0 | low | 3 | 0 |
| cyc 202 | 0 | low | 5 | 0 |
| carbodiimides | 0 | low | 1 | 0 |
| cycloartane | 0 | low | 1 | 0 |
| abrine | 0 | low | 1 | 0 |
| ar-turmerone | 0 | low | 2 | 0 |
| vanillactic acid | 0 | low | 1 | 0 |
| isoflavanone | 0 | low | 1 | 0 |
| 2-deoxy-lyxo-hexose | 0 | low | 1 | 0 |
| nevadensin | 0 | low | 4 | 0 |
| sweroside | 0 | low | 1 | 0 |
| salvigenin | 0 | low | 1 | 0 |
| maprounic acid | 0 | low | 1 | 0 |
| ampelopsin | 0 | low | 13 | 0 |
| methylselenic acid | 0 | low | 1 | 0 |
| myricanone | 0 | low | 1 | 0 |
| dihydroguaiaretic acid | 0 | low | 1 | 0 |
| 8-aminohexylamino camp | 0 | low | 1 | 0 |
| aloenin | 0 | low | 1 | 0 |
| isovitexin | 0 | low | 3 | 0 |
| 2-deoxy-2-fluorogalactose | 0 | medium | 6 | 1 |
| cyclodrine | 0 | low | 1 | 0 |
| lhrh, lys(6)- | 0 | low | 1 | 0 |
| (sulfobromophthalein)glutathione conjugate | 0 | low | 1 | 0 |
| platycodin d | 0 | low | 8 | 0 |
| gingerdione | 0 | low | 1 | 0 |
| tac 278 | 0 | low | 1 | 0 |
| sclareol | 0 | low | 1 | 0 |
| schizandrer a | 0 | low | 1 | 0 |
| sialyl-le(a) oligosaccharide | 0 | low | 1 | 0 |
| crambescidin 816 | 0 | low | 1 | 0 |
| butrin | 0 | low | 1 | 0 |
| enniatin b | 0 | low | 2 | 0 |
| calcium pyrophosphate | 0 | low | 2 | 0 |
| 2-phenyl-1,2-benzisothiazol-3-(2h)-one | 0 | low | 1 | 0 |
| matrine, (5beta)-isomer | 0 | low | 1 | 0 |
| technetium tc 99m pentetate | 0 | medium | 87 | 11 |
| diethylenetriaminetetraacetic acid | 0 | low | 1 | 0 |
| thiophosphoric acid | 0 | low | 1 | 0 |
| anacardic acid | 0 | low | 1 | 0 |
| peiminine | 0 | low | 1 | 0 |
| ardisiacrispin a | 0 | low | 1 | 0 |
| nordihydrocapsaicin | 0 | low | 1 | 0 |
| bisdechlorogeodin | 0 | low | 1 | 0 |
| beta-solamarine | 0 | low | 5 | 0 |
| isophorone diisocyanate | 0 | low | 1 | 0 |
| symmetric dimethylarginine | 0 | low | 1 | 0 |
| aminopterin | 0 | medium | 8 | 2 |
| 4-(2-aminoethyl)benzenesulfonamide | 0 | low | 1 | 0 |
| bradykinin, hydroxy-pro(3)- | 0 | low | 1 | 0 |
| 2-fluoro-2-deoxy-d-glucose | 0 | low | 2 | 0 |
| threonyl-lysyl-proline | 0 | low | 1 | 0 |
| angiotensin ii, sar(1)-val(5)- | 0 | low | 1 | 0 |
| copper tetrabenzo(b,f,j,n)-1,5,9,13-tetraazacyclohexadecine | 0 | low | 1 | 0 |
| 2-hydroxyhemopyrroline-5-one | 0 | low | 1 | 0 |
| methyl protodioscin | 0 | low | 2 | 0 |
| biotin | 0 | medium | 43 | 1 |
| isofuranodiene | 0 | low | 2 | 0 |
| angiotensin ii | 0 | medium | 92 | 10 |
| campesterol | 0 | low | 3 | 0 |
| carboline-3-carboxylic acid | 0 | low | 1 | 0 |
| 1-nitrohydroxyphenyl-n-benzoylalanine | 0 | low | 1 | 0 |
| atropine | 0 | medium | 8 | 1 |
| stronger neominophagen c | 0 | low | 2 | 0 |
| anemodeanin a | 0 | low | 1 | 0 |
| lignin | 0 | medium | 4 | 1 |
| ropivacaine | 0 | medium | 9 | 4 |
| oleanolic acid 3-o-monoglucuronide | 0 | low | 1 | 0 |
| dendrophenol | 0 | low | 2 | 0 |
| sb 203580 | 0 | low | 24 | 0 |
| sb 216763 | 0 | low | 1 | 0 |
| enzastaurin | 0 | medium | 2 | 1 |
| erlotinib | 0 | low | 3 | 0 |
| erlotinib hydrochloride | 0 | medium | 95 | 19 |
| 4'-o-methylepigallocatechin | 0 | low | 1 | 0 |
| organophosphonates | 0 | medium | 69 | 6 |
| ly 353381 | 0 | low | 1 | 0 |
| isoxanthochymol | 0 | low | 1 | 0 |
| limonin | 0 | low | 3 | 0 |
| nickel monoxide | 0 | low | 1 | 0 |
| psyllium | 0 | low | 1 | 0 |
| scutellarin | 0 | low | 4 | 0 |
| aflatoxin b1 | 0 | medium | 372 | 4 |
| 5'-deoxy-5'-iodouridine | 0 | low | 1 | 0 |
| o-(4-ethoxybutyl)berbamine | 0 | low | 1 | 0 |
| deflazacort | 0 | low | 1 | 0 |
| maltotriose | 0 | low | 1 | 0 |
| eudesmane | 0 | low | 1 | 0 |
| 6-dodecyl-2-methoxy-1,4-benzoquinone | 0 | low | 1 | 0 |
| n-acetylgalactosamine 6-sulfate | 0 | low | 1 | 0 |
| 3-(2'-pyridyldithio)benzyldiazoacetate | 0 | low | 1 | 0 |
| cohumulone | 0 | low | 1 | 0 |
| araloside a | 0 | low | 1 | 0 |
| fe(iii)-edta | 0 | low | 1 | 0 |
| troleandomycin | 0 | low | 2 | 0 |
| purine n-oxide | 0 | low | 1 | 0 |
| lapatinib | 0 | medium | 25 | 6 |
| 2-(4-morpholinoanilino)-6-cyclohexylaminopurine | 0 | low | 1 | 0 |
| darunavir | 0 | low | 1 | 0 |
| deferasirox | 0 | low | 3 | 0 |
| taspine | 0 | low | 3 | 0 |
| dabigatran | 0 | low | 3 | 0 |
| tolvaptan | 0 | low | 4 | 0 |
| sorafenib | 0 | medium | 3,013 | 273 |
| lenalidomide | 0 | medium | 12 | 4 |
| 1-methylpropyl-2-imidazolyl disulfide | 0 | low | 1 | 0 |
| cellobial | 0 | low | 1 | 0 |
| demecolcine | 0 | low | 5 | 0 |
| santonin | 0 | low | 1 | 0 |
| cholic acid | 0 | low | 14 | 0 |
| deoxycholic acid | 0 | low | 36 | 0 |
| cortisone | 0 | low | 51 | 0 |
| adrenosterone | 0 | low | 1 | 0 |
| lithium fluoride | 0 | low | 1 | 0 |
| vacquinol-1 | 0 | low | 1 | 0 |
| gossypol acetic acid | 0 | low | 1 | 0 |
| nandrolone phenpropionate | 0 | low | 1 | 0 |
| 3-nitrotyrosine | 0 | low | 8 | 0 |
| stigmastanol | 0 | low | 1 | 0 |
| lanosterol | 0 | low | 5 | 0 |
| 2-hydroxyestradiol | 0 | low | 2 | 0 |
| methenolone enanthate | 0 | low | 1 | 0 |
| vincristine sulfate | 0 | low | 1 | 0 |
| nogalamycin | 0 | low | 1 | 0 |
| mibolerone | 0 | low | 1 | 0 |
| n,n-diamylnitrosamine | 0 | low | 2 | 0 |
| nsc 74859 | 0 | low | 8 | 0 |
| pheophorbide a | 0 | low | 9 | 0 |
| anisomycin | 0 | low | 6 | 0 |
| benzofurans | 0 | medium | 55 | 1 |
| chondocurine (1beta)-(+-)-isomer | 0 | low | 1 | 0 |
| potassium bromide | 0 | low | 1 | 0 |
| 1,3,6,8-tetrabromocarbazole | 0 | low | 1 | 0 |
| estramustine | 0 | low | 2 | 0 |
| hellebrigenin | 0 | low | 2 | 0 |
| cinobufotalin | 0 | low | 7 | 0 |
| Gamabufogenin | 0 | low | 2 | 0 |
| lupeol | 0 | low | 11 | 0 |
| telocinobufagin | 0 | low | 1 | 0 |
| cyclovirobuxine d | 0 | low | 1 | 0 |
| calendula | 0 | low | 1 | 0 |
| metribolone | 0 | low | 3 | 0 |
| arsenic trioxide | 0 | low | 1 | 0 |
| solanine | 0 | low | 7 | 0 |
| withaferin a | 0 | low | 6 | 0 |
| 6-methylpurine 2'-deoxyriboside | 0 | low | 1 | 0 |
| phenesterin | 0 | low | 1 | 0 |
| noscapine | 0 | low | 1 | 0 |
| Harringtonine | 0 | low | 2 | 0 |
| glaucarubinone | 0 | low | 1 | 0 |
| homoharringtonine | 0 | low | 5 | 0 |
| acivicin | 0 | medium | 6 | 1 |
| elesclomol | 0 | low | 4 | 0 |
| wortmannin | 0 | low | 31 | 0 |
| menogaril | 0 | medium | 2 | 1 |
| 2-oxindole | 0 | low | 3 | 0 |
| 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one | 0 | low | 1 | 0 |
| withanolides | 0 | low | 7 | 0 |
| rocaglamide | 0 | low | 1 | 0 |
| lariciresinol | 0 | low | 1 | 0 |
| nsc 348884 | 0 | low | 1 | 0 |
| anthricin | 0 | low | 1 | 0 |
| 2'-fluorothymidine | 0 | low | 8 | 0 |
| erianin | 0 | low | 7 | 0 |
| trimethoprim, sulfamethoxazole drug combination | 0 | low | 2 | 0 |
| phyllanthin | 0 | low | 1 | 0 |
| demethyleneberberine | 0 | low | 1 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | 0 | low | 34 | 0 |
| colupulone | 0 | low | 1 | 0 |
| pomolic acid | 0 | low | 1 | 0 |
| taurochenodeoxycholic acid | 0 | low | 8 | 0 |
| bortezomib | 0 | medium | 46 | 5 |
| chamaejasmin | 0 | low | 1 | 0 |
| neocryptolepine | 0 | low | 1 | 0 |
| ritonavir | 0 | medium | 15 | 3 |
| acetogenins | 0 | low | 5 | 0 |
| cap1-6d | 0 | low | 1 | 0 |
| Bardoxolone | 0 | low | 2 | 0 |
| bardoxolone methyl | 0 | low | 1 | 0 |
| fluorocholine | 0 | medium | 14 | 4 |
| n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium | 0 | medium | 11 | 1 |
| nexavar | 0 | low | 1 | 0 |
| dihydropyridines | 0 | low | 6 | 0 |
| lanatosides | 0 | low | 2 | 0 |
| gant 61 | 0 | low | 5 | 0 |
| nsc 141537 | 0 | low | 1 | 0 |
| permanganate | 0 | medium | 2 | 2 |
| secalonic acid | 0 | low | 3 | 0 |
| leupeptins | 0 | low | 35 | 0 |
| carboplatin | 0 | medium | 226 | 43 |
| lithium chloride | 0 | low | 5 | 0 |
| leptomycin b | 0 | low | 2 | 0 |
| s-adenosylhomocysteine | 0 | low | 19 | 0 |
| 5'-methylthioadenosine | 0 | low | 6 | 0 |
| glycogen | 0 | medium | 142 | 1 |
| arabinose | 0 | low | 3 | 0 |
| n-acetylneuraminic acid | 0 | medium | 44 | 1 |
| mannose-6-phosphate | 0 | low | 7 | 0 |
| fibrin | 0 | low | 20 | 0 |
| bradykinin | 0 | medium | 27 | 1 |
| canavanine | 0 | low | 8 | 0 |
| glucosamine | 0 | low | 58 | 0 |
| elastin | 0 | low | 9 | 0 |
| carnosine | 0 | low | 4 | 0 |
| mevalonic acid | 0 | medium | 48 | 1 |
| ribose 1-phosphate | 0 | low | 1 | 0 |
| raffinose | 0 | low | 5 | 0 |
| naringenin | 0 | low | 10 | 0 |
| epiglucan | 0 | low | 11 | 0 |
| oxytocin | 0 | low | 1 | 0 |
| laminaran | 0 | low | 1 | 0 |
| pantetheine | 0 | low | 1 | 0 |
| theanine | 0 | low | 3 | 0 |
| inositol 1,4,5-trisphosphate | 0 | low | 9 | 0 |
| ouabain | 0 | low | 14 | 0 |
| allose | 0 | low | 4 | 0 |
| scopolin | 0 | low | 1 | 0 |
| puromycin | 0 | low | 42 | 0 |
| taxifolin | 0 | low | 2 | 0 |
| desmosterol | 0 | low | 1 | 0 |
| tosylphenylalanyl chloromethyl ketone | 0 | low | 1 | 0 |
| tartaric acid | 0 | low | 1 | 0 |
| pentostatin | 0 | low | 7 | 0 |
| n-formylmethionine | 0 | low | 1 | 0 |
| taurolithocholic acid | 0 | low | 3 | 0 |
| n-glycolylneuraminic acid | 0 | low | 5 | 0 |
| nitroarginine | 0 | low | 1 | 0 |
| 5-methyldeoxycytidine | 0 | low | 4 | 0 |
| inositol 3-phosphate | 0 | medium | 2 | 1 |
| 3,7-dihydroxycholestan-26-oic acid | 0 | low | 2 | 0 |
| dehydroascorbic acid | 0 | low | 2 | 0 |
| cortodoxone | 0 | low | 1 | 0 |
| eriodictyol | 0 | low | 1 | 0 |
| pelargonidin | 0 | low | 2 | 0 |
| nivalenol | 0 | low | 1 | 0 |
| arbutin | 0 | low | 1 | 0 |
| fructans | 0 | low | 2 | 0 |
| strychnine | 0 | low | 7 | 0 |
| quinidine | 0 | low | 4 | 0 |
| meropenem | 0 | medium | 1 | 1 |
| griseofulvin | 0 | low | 11 | 0 |
| monensin | 0 | low | 15 | 0 |
| digitoxin | 0 | low | 4 | 0 |
| saquinavir | 0 | low | 2 | 0 |
| pentazocine | 0 | medium | 3 | 1 |
| rocuronium | 0 | low | 3 | 0 |
| hyperforin | 0 | low | 1 | 0 |
| miglitol | 0 | low | 1 | 0 |
| phalloidine | 0 | low | 6 | 0 |
| ranunculin | 0 | low | 1 | 0 |
| taccalonolide a | 0 | low | 1 | 0 |
| buclizine | 0 | low | 1 | 0 |
| neriifolin | 0 | low | 1 | 0 |
| ruscogenin | 0 | low | 1 | 0 |
| cyclamin | 0 | low | 2 | 0 |
| ginsenoside rg1 | 0 | low | 3 | 0 |
| beta-hederin | 0 | low | 1 | 0 |
| notoginsenoside r1 | 0 | low | 1 | 0 |
| brucine | 0 | low | 7 | 0 |
| ferruginol | 0 | low | 1 | 0 |
| ingenol | 0 | low | 1 | 0 |
| decursin | 0 | low | 1 | 0 |
| genipin | 0 | low | 6 | 0 |
| naringin | 0 | low | 4 | 0 |
| swertiamarin | 0 | low | 1 | 0 |
| pulegone | 0 | low | 1 | 0 |
| ochratoxin a | 0 | low | 14 | 0 |
| theasinensin a | 0 | low | 1 | 0 |
| xanthochymol | 0 | low | 1 | 0 |
| cajanol | 0 | low | 1 | 0 |
| Hircinol | 0 | low | 1 | 0 |
| gingerol | 0 | low | 5 | 0 |
| alpha bitter acid | 0 | low | 1 | 0 |
| alpha-chaconine | 0 | low | 2 | 0 |
| cyclopamine | 0 | low | 9 | 0 |
| lignans | 0 | low | 35 | 0 |
| acriflavine | 0 | low | 1 | 0 |
| acetylleucyl-leucyl-norleucinal | 0 | low | 6 | 0 |
| bq 123 | 0 | low | 1 | 0 |
| n-formylmethionine leucyl-phenylalanine | 0 | low | 3 | 0 |
| sodium arsenite | 0 | low | 13 | 0 |
| soyasaponin ii | 0 | low | 1 | 0 |
| petunidin-3-glucoside | 0 | low | 1 | 0 |
| malvidin-3-glucoside | 0 | low | 1 | 0 |
| difluprednate | 0 | low | 1 | 0 |
| doxorubicin hydrochloride | 0 | low | 3 | 0 |
| sultamicillin | 0 | medium | 1 | 1 |
| betadex | 0 | low | 18 | 0 |
| maleic acid | 0 | low | 2 | 0 |
| acetyl coenzyme a | 0 | low | 28 | 0 |
| e-z cinnamic acid | 0 | low | 3 | 0 |
| ergosterol | 0 | low | 5 | 0 |
| trichostatin a | 0 | low | 53 | 0 |
| tretinoin | 0 | medium | 207 | 8 |
| equilenin | 0 | low | 1 | 0 |
| arachidonic acid | 0 | medium | 44 | 3 |
| fumaric acid | 0 | low | 1 | 0 |
| farnesol | 0 | low | 13 | 0 |
| 3-hydroxy-3-methylglutaryl-coenzyme a | 0 | low | 3 | 0 |
| resveratrol | 0 | medium | 89 | 3 |
| retinol | 0 | medium | 88 | 1 |
| latrunculin a | 0 | low | 4 | 0 |
| cyanoginosin lr | 0 | low | 33 | 0 |
| palmitoleic acid | 0 | low | 2 | 0 |
| oleic acid | 0 | low | 75 | 0 |
| tacrolimus | 0 | medium | 106 | 12 |
| ferric hydroxide | 0 | low | 1 | 0 |
| farnesyl pyrophosphate | 0 | low | 1 | 0 |
| ferulic acid | 0 | low | 6 | 0 |
| pectins | 0 | low | 10 | 0 |
| (3R,5S)-fluvastatin | 0 | low | 2 | 0 |
| cerivastatin | 0 | low | 1 | 0 |
| cocaine | 0 | low | 2 | 0 |
| eicosapentaenoic acid | 0 | medium | 26 | 7 |
| sr 12813 | 0 | low | 1 | 0 |
| thapsigargin | 0 | low | 28 | 0 |
| mycophenolic acid | 0 | medium | 23 | 2 |
| clindamycin | 0 | low | 2 | 0 |
| keratan sulfate | 0 | low | 1 | 0 |
| brivudine | 0 | low | 1 | 0 |
| gw 6471 | 0 | low | 1 | 0 |
| lycopene | 0 | medium | 23 | 1 |
| zithromax | 0 | low | 3 | 0 |
| adenylosuccinate | 0 | low | 1 | 0 |
| cefoxitin | 0 | low | 3 | 0 |
| 2-butenal | 0 | low | 1 | 0 |
| obeticholic acid | 0 | low | 8 | 0 |
| gw 3965 | 0 | low | 3 | 0 |
| t0901317 | 0 | low | 10 | 0 |
| epothilone b | 0 | medium | 5 | 2 |
| n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea | 0 | low | 1 | 0 |
| y 27632 | 0 | low | 8 | 0 |
| methylproamine | 0 | low | 1 | 0 |
| cytidine monophosphate n-acetylneuraminic acid | 0 | low | 2 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | 0 | low | 2 | 0 |
| n(1)-guanyl-1,7-diaminoheptane | 0 | low | 3 | 0 |
| prostaglandin d2 | 0 | low | 14 | 0 |
| diethylstilbestrol | 0 | low | 49 | 0 |
| epothilone a | 0 | medium | 15 | 6 |
| alitretinoin | 0 | low | 11 | 0 |
| h 89 | 0 | low | 3 | 0 |
| afimoxifene | 0 | low | 4 | 0 |
| imidazolidines | 0 | medium | 3 | 1 |
| carbon-11 acetate | 0 | medium | 13 | 2 |
| fluciclovine f-18 | 0 | low | 2 | 0 |
| n-succinimidyl-4-fluorobenzoate | 0 | low | 1 | 0 |
| aclarubicin | 0 | medium | 20 | 2 |
| thymopentin | 0 | medium | 3 | 2 |
| taribavirin | 0 | low | 3 | 0 |
| decitabine | 0 | medium | 84 | 1 |
| d-glucaro-delta-lactam | 0 | low | 1 | 0 |
| colfosceril palmitate | 0 | low | 1 | 0 |
| phorbol-12,13-didecanoate | 0 | low | 2 | 0 |
| iridoids | 0 | low | 18 | 0 |
| lamivudine triphosphate | 0 | low | 1 | 0 |
| troxacitabine | 0 | low | 2 | 0 |
| ketoconazole | 0 | low | 2 | 0 |
| dactinomycin | 0 | low | 261 | 0 |
| gamma-sitosterol | 0 | low | 9 | 0 |
| tiazofurin | 0 | low | 1 | 0 |
| aphidicolin | 0 | low | 2 | 0 |
| arsphenamine | 0 | low | 1 | 0 |
| azaserine | 0 | low | 10 | 0 |
| melphalan | 0 | medium | 130 | 31 |
| bgugaine | 0 | low | 1 | 0 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | 0 | low | 22 | 0 |
| tenofovir | 0 | medium | 204 | 7 |
| posaconazole | 0 | low | 1 | 0 |
| ganoderiol f | 0 | low | 1 | 0 |
| 5-ethynyl-2'-deoxyuridine | 0 | low | 1 | 0 |
| bromodeoxycytidine | 0 | low | 1 | 0 |
| rubitecan | 0 | medium | 4 | 1 |
| terameprocol | 0 | low | 1 | 0 |
| micafungin | 0 | low | 2 | 0 |
| acetylshikonin | 0 | low | 3 | 0 |
| shikonin | 0 | low | 17 | 0 |
| dehydroglyasperin c | 0 | low | 1 | 0 |
| kazinol b | 0 | low | 1 | 0 |
| riboflavin | 0 | low | 40 | 0 |
| n-nonyl-1-deoxynojirimycin | 0 | low | 1 | 0 |
| likviriton | 0 | low | 1 | 0 |
| evp 4593 | 0 | low | 3 | 0 |
| 2,3-bis(bromomethyl)quinoxaline-1,4-dioxide | 0 | medium | 2 | 2 |
| tyrosine o-sulfate | 0 | low | 4 | 0 |
| 5-fluoro-2'-deoxycytidine | 0 | medium | 1 | 1 |
| potassium permanganate | 0 | low | 2 | 0 |
| sodium bicarbonate | 0 | low | 7 | 0 |
| sodium benzoate | 0 | low | 1 | 0 |
| ammonium acetate | 0 | low | 1 | 0 |
| zn(ii)-phthalocyanine | 0 | low | 8 | 0 |
| triacetoneamine-n-oxyl | 0 | low | 1 | 0 |
| spathulenol | 0 | low | 1 | 0 |
| dipyrone | 0 | low | 1 | 0 |
| sodium perchlorate | 0 | low | 1 | 0 |
| bromochloroacetic acid | 0 | medium | 311 | 2 |
| tolfenamic acid | 0 | low | 1 | 0 |
| artemisin | 0 | low | 1 | 0 |
| carbenoxolone sodium | 0 | low | 1 | 0 |
| meglumine iodipamide | 0 | low | 1 | 0 |
| hectochlorin | 0 | low | 1 | 0 |
| alpha-asarone | 0 | low | 1 | 0 |
| nemorosone | 0 | low | 1 | 0 |
| rhapontin | 0 | low | 1 | 0 |
| cinnamaldehyde | 0 | low | 1 | 0 |
| elaidic acid | 0 | low | 2 | 0 |
| trans-4-coumaric acid | 0 | low | 1 | 0 |
| anethole | 0 | low | 3 | 0 |
| geraniol | 0 | low | 5 | 0 |
| glycosides | 0 | medium | 54 | 1 |
| benzylideneacetone | 0 | low | 1 | 0 |
| chalcone | 0 | low | 27 | 0 |
| isomethyleugenol | 0 | medium | 344 | 2 |
| piplartine | 0 | low | 4 | 0 |
| citral | 0 | low | 1 | 0 |
| beta-ionone | 0 | low | 8 | 0 |
| retinaldehyde | 0 | low | 1 | 0 |
| piperine | 0 | low | 6 | 0 |
| retinol acetate | 0 | low | 1 | 0 |
| squalene | 0 | low | 4 | 0 |
| stilbenes | 0 | medium | 124 | 2 |
| 2'-hydroxychalcone | 0 | low | 1 | 0 |
| isoliquiritigenin | 0 | low | 2 | 0 |
| versicolorin a | 0 | low | 1 | 0 |
| phenyl-n-tert-butylnitrone | 0 | low | 1 | 0 |
| xanthohumol | 0 | low | 9 | 0 |
| 4-dimethylaminostilbene | 0 | low | 2 | 0 |
| picibanil | 0 | medium | 100 | 11 |
| 2-methoxycinnamaldehyde | 0 | low | 2 | 0 |
| cardamonin | 0 | low | 1 | 0 |
| 4'-methoxychalcone | 0 | low | 1 | 0 |
| hirsutanol a | 0 | low | 2 | 0 |
| xanthoangelol | 0 | low | 3 | 0 |
| sorbic acid | 0 | low | 1 | 0 |
| floxuridine | 0 | medium | 3 | 1 |
| flavin-adenine dinucleotide | 0 | low | 9 | 0 |
| cannabidiol | 0 | low | 2 | 0 |
| malonyl coenzyme a | 0 | low | 1 | 0 |
| buprenorphine | 0 | low | 4 | 0 |
| lypressin | 0 | medium | 3 | 1 |
| arginine vasopressin | 0 | low | 3 | 0 |
| pyrophosphate | 0 | low | 24 | 0 |
| palmitoyl coenzyme a | 0 | low | 5 | 0 |
| gw9662 | 0 | low | 7 | 0 |
| s 1033 | 0 | low | 8 | 0 |
| dihydrosphingosine 1-phosphate | 0 | low | 1 | 0 |
| acetyl-aspartyl-glutamyl-valyl-aspartal | 0 | low | 1 | 0 |
| azidopine | 0 | low | 1 | 0 |
| amygdalin | 0 | low | 7 | 0 |
| glucobrassicin | 0 | low | 1 | 0 |
| trilostane | 0 | low | 1 | 0 |
| bucillamine | 0 | low | 1 | 0 |
| canrenoic acid | 0 | low | 1 | 0 |
| lanatoside c | 0 | low | 2 | 0 |
| polidocanol | 0 | low | 5 | 0 |
| iothalamate meglumine | 0 | medium | 17 | 5 |
| tropisetron | 0 | medium | 1 | 1 |
| sodium metabisulfite | 0 | medium | 1 | 1 |
| tram 34 | 0 | low | 2 | 0 |
| isopropyl thiogalactoside | 0 | low | 3 | 0 |
| leuprolide | 0 | medium | 5 | 1 |
| fludarabine | 0 | medium | 9 | 1 |
| propylthiouracil | 0 | low | 2 | 0 |
| nsc 4347 | 0 | low | 2 | 0 |
| n(6)-cyclopentyladenosine | 0 | low | 1 | 0 |
| sesquiterpenes | 0 | low | 111 | 0 |
| chlorprothixene | 0 | low | 2 | 0 |
| dienestrol | 0 | low | 1 | 0 |
| etomidate | 0 | low | 1 | 0 |
| mercaptopurine | 0 | low | 37 | 0 |
| methylthiouracil | 0 | low | 5 | 0 |
| ag-213 | 0 | low | 2 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | 0 | low | 4 | 0 |
| thioinosine | 0 | low | 1 | 0 |
| jrf 12 | 0 | low | 1 | 0 |
| thiobenzamide | 0 | low | 5 | 0 |
| caffeic acid | 0 | low | 9 | 0 |
| 4-methoxycinnamic acid | 0 | low | 1 | 0 |
| 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose | 0 | low | 1 | 0 |
| stf 62247 | 0 | low | 1 | 0 |
| 3,6-dibenzyl-1,2-dihydro-1,2,4,5-tetraazine | 0 | low | 1 | 0 |
| 1-(2-hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione | 0 | low | 1 | 0 |
| urocanic acid | 0 | low | 1 | 0 |
| 4-acetylaminostilbene | 0 | low | 3 | 0 |
| cotinine | 0 | low | 1 | 0 |
| heliotrine | 0 | low | 1 | 0 |
| parthenolide, (1ar-(1ar*,4e,7as*,10as*,10br*))-isomer | 0 | low | 1 | 0 |
| tetrahydropalmatine | 0 | low | 3 | 0 |
| dieldrin | 0 | low | 29 | 0 |
| curcumin | 0 | medium | 198 | 2 |
| cct018159 | 0 | low | 1 | 0 |
| hypocrellin b | 0 | low | 3 | 0 |
| ptc-209 | 0 | low | 1 | 0 |
| rhodanine | 0 | low | 1 | 0 |
| thiouracil | 0 | low | 8 | 0 |
| 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one | 0 | low | 1 | 0 |
| thiohydantoins | 0 | medium | 1 | 1 |
| methimazole | 0 | low | 3 | 0 |
| cinnarizine | 0 | low | 1 | 0 |
| sulindac | 0 | low | 8 | 0 |
| capsaicin | 0 | low | 19 | 0 |
| enclomiphene | 0 | low | 6 | 0 |
| terbinafine | 0 | low | 1 | 0 |
| aurapten | 0 | low | 1 | 0 |
| caryophyllene oxide | 0 | low | 2 | 0 |
| chlorogenic acid | 0 | medium | 23 | 1 |
| fatostatin | 0 | low | 1 | 0 |
| thioguanine anhydrous | 0 | low | 7 | 0 |
| neotetrazolium | 0 | low | 2 | 0 |
| thiobarbituric acid | 0 | low | 2 | 0 |
| thiourea | 0 | medium | 14 | 1 |
| indigo carmine | 0 | medium | 6 | 1 |
| 3-amino-5-mercapto-1,2,4-triazole | 0 | low | 1 | 0 |
| D-fructopyranose | 0 | medium | 62 | 1 |
| thioacetamide | 0 | low | 71 | 0 |
| tempo | 0 | low | 1 | 0 |
| ferric ferrocyanide | 0 | low | 8 | 0 |
| succimer | 0 | low | 5 | 0 |
| aflatoxin b | 0 | low | 1 | 0 |
| aflatoxin g2 | 0 | low | 1 | 0 |
| digoxin | 0 | low | 8 | 0 |
| fumonisin b1 | 0 | medium | 20 | 1 |
| fumonisin b2 | 0 | low | 2 | 0 |
| tamoxifen | 0 | medium | 234 | 46 |
| sodium taurodeoxycholate | 0 | low | 4 | 0 |
| 1-dodecyl-3-methylimidazolium | 0 | low | 1 | 0 |
| nadp | 0 | low | 66 | 0 |
| 1,1-diphenyl-2-picrylhydrazyl | 0 | low | 7 | 0 |
| 2-mercapto-5-benzimidazolesulfonic acid | 0 | low | 1 | 0 |
| yoda 1 | 0 | low | 1 | 0 |
| 5-carboxytetramethylrhodamine | 0 | low | 1 | 0 |
| 5-cyano-2,3-ditolyltetrazolium chloride | 0 | low | 2 | 0 |
| 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium | 0 | low | 2 | 0 |
| t 0070907 | 0 | low | 3 | 0 |
| stattic | 0 | low | 6 | 0 |
| nitrobenzanthrone | 0 | low | 3 | 0 |
| krn 7000 | 0 | low | 11 | 0 |
| sirtinol | 0 | low | 1 | 0 |
| methyl-thiohydantoin-tryptophan | 0 | low | 2 | 0 |
| 10074-g5 | 0 | low | 1 | 0 |
| hlm006474 | 0 | low | 1 | 0 |
| monastrol | 0 | low | 2 | 0 |
| zeranol | 0 | low | 2 | 0 |
| fusidic acid | 0 | low | 1 | 0 |
| rhyncophylline | 0 | low | 1 | 0 |
| valinomycin | 0 | low | 6 | 0 |
| thiopental | 0 | low | 6 | 0 |
| ranitidine | 0 | medium | 9 | 1 |
| maraviroc | 0 | low | 3 | 0 |
| toremifene | 0 | low | 11 | 0 |
| u 0126 | 0 | low | 28 | 0 |
| rwj 67657 | 0 | low | 1 | 0 |
| dieckol | 0 | low | 2 | 0 |
| telaprevir | 0 | low | 13 | 0 |
| laccase | 0 | low | 1 | 0 |
| pica | 0 | low | 1 | 0 |
| 5-hydroxycytosine | 0 | low | 1 | 0 |
| 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol | 0 | low | 3 | 0 |
| 6-methyl-2-(phenylethynyl)pyridine | 0 | low | 1 | 0 |
| bms 387032 | 0 | low | 2 | 0 |
| lithium | 0 | medium | 18 | 1 |
| fosfestrol | 0 | low | 1 | 0 |
| cobaltous chloride | 0 | medium | 28 | 1 |
| nitrogen dioxide | 0 | medium | 8 | 3 |
| dermatan sulfate | 0 | low | 6 | 0 |
| dezocine | 0 | medium | 1 | 1 |
| nizatidine | 0 | low | 1 | 0 |
| orlistat | 0 | low | 7 | 0 |
| quinine | 0 | low | 2 | 0 |
| kaurenoic acid | 0 | low | 2 | 0 |
| 1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester | 0 | low | 4 | 0 |
| 15,16-dihydro-11-methylcyclopenta(a)phenanthren-17-one | 0 | low | 1 | 0 |
| indium oxine | 0 | low | 5 | 0 |
| 3-hydroxy-1-nitrosopyrrolidine | 0 | low | 1 | 0 |
| amrubicin | 0 | medium | 4 | 2 |
| glycodeoxycholic acid | 0 | low | 1 | 0 |
| rtki cpd | 0 | low | 7 | 0 |
| brassinin | 0 | low | 1 | 0 |
| didimethylsulfoxide dichloroplatinum(ii) | 0 | medium | 3 | 1 |
| 2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | 0 | medium | 4 | 1 |
| cystine | 0 | low | 21 | 0 |
| alpha-hydroxytamoxifen | 0 | low | 2 | 0 |
| diethylstilbestrol monophosphate | 0 | low | 2 | 0 |
| methenolone | 0 | low | 1 | 0 |
| 3-aminolevamisole | 0 | low | 2 | 0 |
| prucalopride | 0 | low | 1 | 0 |
| safingol | 0 | low | 6 | 0 |
| dasatinib | 0 | medium | 30 | 1 |
| kw 2170 | 0 | low | 1 | 0 |
| erysolin | 0 | low | 1 | 0 |
| bigelovin | 0 | low | 2 | 0 |
| oxalylglycine | 0 | low | 1 | 0 |
| atractylon | 0 | low | 1 | 0 |
| ct 2584 | 0 | low | 1 | 0 |
| zd 6474 | 0 | medium | 15 | 1 |
| dicyclanil | 0 | low | 1 | 0 |
| glutaryl-coenzyme a | 0 | low | 2 | 0 |
| ferrocenium | 0 | low | 1 | 0 |
| 2-fluoro-2-deoxyglucose-6-phosphate | 0 | medium | 3 | 1 |
| nitinol | 0 | low | 7 | 0 |
| ki 8110 | 0 | low | 1 | 0 |
| calixarenes | 0 | low | 2 | 0 |
| dryocrassin | 0 | low | 1 | 0 |
| heparin | 0 | low | 1 | 0 |
| olivomycins | 0 | low | 1 | 0 |
| amanitins | 0 | low | 8 | 0 |
| cytellin | 0 | low | 13 | 0 |
| verticillins | 0 | low | 1 | 0 |
| phosphonic acid | 0 | low | 1 | 0 |
| n-(2-naphthalene)sulfonyl-dl-tryptophan | 0 | low | 1 | 0 |
| salinomycin | 0 | low | 16 | 0 |
| gnidimacrin | 0 | low | 1 | 0 |
| gigantol | 0 | low | 3 | 0 |
| ginsenosides | 0 | medium | 74 | 5 |
| 2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | 0 | low | 2 | 0 |
| compound 968 | 0 | low | 1 | 0 |
| chromeceptin | 0 | low | 1 | 0 |
| phosphothreonine | 0 | low | 5 | 0 |
| cambinol | 0 | low | 3 | 0 |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | 0 | low | 1 | 0 |
| ovalbumin | 0 | low | 7 | 0 |
| sw033291 | 0 | low | 1 | 0 |
| n-acetylgalactosaminyl-1-4-n-acetylglucosamine | 0 | low | 1 | 0 |
| sodium dodecyl sulfate | 0 | low | 24 | 0 |
| fh535 | 0 | low | 6 | 0 |
| blister | 0 | low | 2 | 0 |
| bromohydrin pyrophosphate | 0 | low | 1 | 0 |
| crocin | 0 | low | 6 | 0 |
| galactomannan | 0 | medium | 3 | 1 |
| mtt formazan | 0 | low | 12 | 0 |
| l 663536 | 0 | low | 5 | 0 |
| flavan-3-ol | 0 | low | 1 | 0 |
| 6-hydrazinopyridine-3-carboxylic acid | 0 | low | 1 | 0 |
| zinc protoporphyrin ix | 0 | low | 3 | 0 |
| 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone | 0 | low | 4 | 0 |
| ocotillol | 0 | low | 1 | 0 |
| metanil yellow | 0 | low | 1 | 0 |
| alpha-chymotrypsin | 0 | low | 25 | 0 |
| alpinetin | 0 | low | 1 | 0 |
| ferrostatin-1 | 0 | low | 4 | 0 |
| tetramethylrhodamine isothiocyanate | 0 | low | 2 | 0 |
| sb 415286 | 0 | low | 1 | 0 |
| 17-ketosteroids | 0 | low | 14 | 0 |
| naphthoquinones | 0 | medium | 56 | 2 |
| jhw 015 | 0 | low | 2 | 0 |
| sc 560 | 0 | low | 1 | 0 |
| sodium borohydride | 0 | low | 2 | 0 |
| alpha-carotene | 0 | medium | 7 | 1 |
| digitoxigenin | 0 | low | 3 | 0 |
| osteoprotegerin | 0 | low | 7 | 0 |
| 1,1-dimethyl-4-acetylpiperazinium | 0 | low | 1 | 0 |
| 4-mercaptophenylboronic acid | 0 | low | 1 | 0 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide | 0 | low | 4 | 0 |
| rhodamine 123 | 0 | low | 23 | 0 |
| tolcapone | 0 | low | 1 | 0 |
| myelin basic protein | 0 | low | 2 | 0 |
| tx 402 | 0 | low | 1 | 0 |
| merbarone | 0 | medium | 2 | 2 |
| imd 0354 | 0 | low | 1 | 0 |
| ex 527 | 0 | low | 2 | 0 |
| iodoazomycin arabinoside | 0 | low | 1 | 0 |
| tetrathiomolybdate | 0 | low | 2 | 0 |
| diethyl maleate | 0 | low | 3 | 0 |
| ginkgetin | 0 | low | 1 | 0 |
| resveratrol-4'-o-glucuronide | 0 | low | 1 | 0 |
| cinnamamide | 0 | low | 1 | 0 |
| eupatilin | 0 | low | 1 | 0 |
| isoliensinine | 0 | low | 2 | 0 |
| farnesoic acid | 0 | low | 2 | 0 |
| geranylgeranic acid | 0 | low | 8 | 0 |
| catechin gallate | 0 | low | 1 | 0 |
| ku 55933 | 0 | low | 3 | 0 |
| sphingosine | 0 | low | 48 | 0 |
| quercetin | 0 | low | 98 | 0 |
| ubiquinone q2 | 0 | low | 1 | 0 |
| bilirubin | 0 | medium | 828 | 51 |
| dinoprostone | 0 | medium | 115 | 2 |
| dinoprost | 0 | low | 6 | 0 |
| biochanin a | 0 | low | 1 | 0 |
| formononetin | 0 | low | 2 | 0 |
| sterigmatocystin | 0 | low | 13 | 0 |
| vitexin | 0 | low | 7 | 0 |
| acacetin | 0 | low | 2 | 0 |
| apigenin | 0 | low | 49 | 0 |
| luteolin | 0 | medium | 32 | 1 |
| 7,3'-dihydroxy-4'-methoxyisoflavone | 0 | low | 5 | 0 |
| linoleic acid | 0 | medium | 37 | 1 |
| calcitriol | 0 | medium | 35 | 2 |
| pinosylvin | 0 | low | 1 | 0 |
| scopoletin | 0 | low | 1 | 0 |
| ubiquinone 9 | 0 | medium | 1 | 1 |
| vitamin k semiquinone radical | 0 | medium | 95 | 2 |
| beta carotene | 0 | medium | 34 | 3 |
| leukotriene b4 | 0 | low | 7 | 0 |
| thromboxane a2 | 0 | low | 1 | 0 |
| retinol palmitate | 0 | low | 2 | 0 |
| coniferaldehyde | 0 | low | 1 | 0 |
| feruloyltyramine | 0 | low | 1 | 0 |
| hymecromone | 0 | low | 12 | 0 |
| daphnetin | 0 | low | 1 | 0 |
| 8,11,14-eicosatrienoic acid | 0 | low | 4 | 0 |
| luteolin-7-glucoside | 0 | low | 3 | 0 |
| apigetrin | 0 | low | 3 | 0 |
| 15-ketoprostaglandin e2 | 0 | low | 1 | 0 |
| alprostadil | 0 | medium | 32 | 4 |
| vitamin d 2 | 0 | low | 2 | 0 |
| stigmasterol | 0 | low | 4 | 0 |
| cholecalciferol | 0 | medium | 12 | 2 |
| rutin | 0 | low | 9 | 0 |
| vitamin k1 oxide | 0 | low | 1 | 0 |
| kaempferol | 0 | low | 8 | 0 |
| leukotriene d4 | 0 | low | 2 | 0 |
| leukotriene e4 | 0 | low | 1 | 0 |
| prostaglandin a2 | 0 | low | 3 | 0 |
| 9-deoxy-delta-9-prostaglandin d2 | 0 | low | 3 | 0 |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | 0 | low | 2 | 0 |
| 6-ketoprostaglandin f1 alpha | 0 | medium | 7 | 1 |
| zeaxanthin | 0 | low | 2 | 0 |
| senecionine | 0 | low | 1 | 0 |
| lipoxin a4 | 0 | medium | 5 | 1 |
| gamma-linolenic acid | 0 | medium | 10 | 2 |
| alpha-linolenic acid | 0 | low | 16 | 0 |
| prostaglandin e3 | 0 | low | 1 | 0 |
| prostaglandin f1 | 0 | low | 1 | 0 |
| harmine | 0 | low | 4 | 0 |
| naringenin chalcone | 0 | low | 1 | 0 |
| genistein | 0 | medium | 54 | 1 |
| amphotericin b | 0 | low | 13 | 0 |
| pulmicort | 0 | low | 1 | 0 |
| oxymetholone | 0 | low | 31 | 0 |
| pyrvinium | 0 | low | 2 | 0 |
| mivacurium | 0 | low | 1 | 0 |
| kava | 0 | low | 1 | 0 |
| entacapone | 0 | low | 1 | 0 |
| trovafloxacin | 0 | low | 1 | 0 |
| butein | 0 | low | 8 | 0 |
| astaxanthine | 0 | low | 4 | 0 |
| canthaxanthin | 0 | low | 2 | 0 |
| cryptoxanthins | 0 | medium | 3 | 1 |
| fucoxanthin | 0 | low | 3 | 0 |
| lutein | 0 | low | 4 | 0 |
| norbixin | 0 | low | 1 | 0 |
| isobavachalcone | 0 | low | 1 | 0 |
| cucurbitacin b | 0 | low | 5 | 0 |
| cucurbitacin c | 0 | low | 1 | 0 |
| cucurbitacin d | 0 | low | 1 | 0 |
| nsc 106399 | 0 | low | 3 | 0 |
| cucurbitacin i | 0 | low | 5 | 0 |
| geranylgeraniol | 0 | low | 3 | 0 |
| mezerein | 0 | low | 1 | 0 |
| strigol | 0 | low | 1 | 0 |
| toxiferine | 0 | low | 1 | 0 |
| esculetin | 0 | low | 1 | 0 |
| 7-hydroxycoumarin | 0 | low | 2 | 0 |
| trilobolide | 0 | low | 1 | 0 |
| xanthatin | 0 | low | 3 | 0 |
| humulene | 0 | medium | 5 | 2 |
| oleuropein | 0 | low | 3 | 0 |
| garcinol | 0 | low | 3 | 0 |
| zearalenone | 0 | low | 7 | 0 |
| amentoflavone | 0 | low | 4 | 0 |
| baicalein | 0 | medium | 30 | 2 |
| chrysin | 0 | low | 20 | 0 |
| diosmetin | 0 | low | 3 | 0 |
| diosmin | 0 | low | 1 | 0 |
| fisetin | 0 | low | 5 | 0 |
| galangin | 0 | low | 9 | 0 |
| hinokiflavone | 0 | low | 1 | 0 |
| hispidulin | 0 | low | 4 | 0 |
| euxanthone | 0 | low | 1 | 0 |
| gentisein | 0 | low | 1 | 0 |
| isogentisin | 0 | low | 1 | 0 |
| mangiferin | 0 | low | 2 | 0 |
| mangostin | 0 | low | 8 | 0 |
| 3-methylquercetin | 0 | low | 4 | 0 |
| norathyriol | 0 | low | 1 | 0 |
| kaempferide | 0 | low | 2 | 0 |
| morin | 0 | low | 4 | 0 |
| morusin | 0 | low | 2 | 0 |
| myricetin | 0 | low | 5 | 0 |
| orientin | 0 | low | 1 | 0 |
| rhamnetin | 0 | low | 4 | 0 |
| scutellarein | 0 | low | 3 | 0 |
| tamarixetin | 0 | low | 1 | 0 |
| tricetin | 0 | low | 2 | 0 |
| tricin | 0 | low | 1 | 0 |
| wogonin | 0 | low | 5 | 0 |
| daidzein | 0 | low | 10 | 0 |
| trans-2,3',4,5'-tetrahydroxystilbene | 0 | low | 2 | 0 |
| pterostilbene | 0 | low | 9 | 0 |
| epsilon-viniferin | 0 | low | 2 | 0 |
| Echimidine | 0 | low | 1 | 0 |
| petasitenine | 0 | low | 1 | 0 |
| platyphylline | 0 | low | 1 | 0 |
| retrorsine | 0 | low | 3 | 0 |
| riddelliine | 0 | low | 9 | 0 |
| senkirkine | 0 | low | 2 | 0 |
| echinacoside | 0 | low | 2 | 0 |
| caffeic acid phenethyl ester | 0 | low | 7 | 0 |
| plantamajoside | 0 | low | 1 | 0 |
| rosmarinic acid | 0 | low | 4 | 0 |
| salvianolic acid a | 0 | low | 2 | 0 |
| shogaol | 0 | low | 10 | 0 |
| acteoside | 0 | low | 5 | 0 |
| 4'-methoxy-3',5,7-trihydroxyisoflavone | 0 | low | 1 | 0 |
| prunetin | 0 | low | 1 | 0 |
| psoralidin | 0 | low | 1 | 0 |
| wedelolactone | 0 | low | 3 | 0 |
| maytansine | 0 | medium | 8 | 2 |
| rottlerin | 0 | low | 2 | 0 |
| ellagic acid | 0 | low | 9 | 0 |
| ginkgolic acid | 0 | low | 1 | 0 |
| sdz psc 833 | 0 | low | 7 | 0 |
| l 660,711 | 0 | low | 1 | 0 |
| rutamycin | 0 | low | 1 | 0 |
| coenzyme q10 | 0 | medium | 5 | 1 |
| anandamide | 0 | low | 1 | 0 |
| astragalin | 0 | low | 1 | 0 |
| geranylgeranylacetone | 0 | low | 1 | 0 |
| metofluthrin | 0 | low | 2 | 0 |
| tranilast | 0 | low | 2 | 0 |
| 8-epi-prostaglandin f2alpha | 0 | low | 3 | 0 |
| n,n-dimethylsphingenine | 0 | low | 1 | 0 |
| tocotrienol, alpha | 0 | low | 2 | 0 |
| tocotrienol, delta | 0 | low | 4 | 0 |
| 4-hydroxyestradiol | 0 | low | 1 | 0 |
| menatetrenone | 0 | medium | 13 | 4 |
| etretinate | 0 | low | 1 | 0 |
| isotretinoin | 0 | medium | 7 | 3 |
| misoprostol | 0 | medium | 2 | 1 |
| ozagrel | 0 | medium | 2 | 1 |
| pitavastatin | 0 | low | 7 | 0 |
| zinostatin | 0 | medium | 109 | 11 |
| ethamolin | 0 | medium | 6 | 2 |
| trans-10,cis-12-conjugated linoleic acid | 0 | low | 1 | 0 |
| 13-hydroxy-9,11-octadecadienoic acid | 0 | low | 1 | 0 |
| 17-phenyltrinorprostaglandin e2 | 0 | low | 1 | 0 |
| thromboxane b2 | 0 | low | 8 | 0 |
| 20-hydroxy-5,8,11,14-eicosatetraenoic acid | 0 | low | 1 | 0 |
| 4-hydroxy-2-nonenal | 0 | low | 19 | 0 |
| oleylamide | 0 | low | 2 | 0 |
| n-oleoylethanolamine | 0 | low | 1 | 0 |
| menaquinone 6 | 0 | medium | 49 | 7 |
| sphingosine 1-phosphate | 0 | low | 22 | 0 |
| n-palmitoylsphingosine | 0 | low | 2 | 0 |
| ceramide 1-phosphate | 0 | low | 1 | 0 |
| cholesteryl oleate | 0 | low | 1 | 0 |
| purmorphamine | 0 | low | 1 | 0 |
| cinnamyl anthranilate | 0 | low | 1 | 0 |
| codeine | 0 | low | 1 | 0 |
| cyclosporine | 0 | low | 1 | 0 |
| mitolactol | 0 | low | 1 | 0 |
| phenylephrine hydrochloride | 0 | low | 7 | 0 |
| 3-amino-1,4-dimethyl-5h-pyrido(4,3-b)indole | 0 | low | 2 | 0 |
| 3-amino-1-methyl-5h-pyrido(4,3-b)indole | 0 | low | 2 | 0 |
| cyproterone | 0 | low | 11 | 0 |
| granisetron | 0 | medium | 4 | 1 |
| hydromorphone | 0 | low | 1 | 0 |
| naloxone | 0 | low | 6 | 0 |
| oxycodone | 0 | medium | 10 | 4 |
| vitamin k 1 | 0 | medium | 15 | 1 |
| proscillaridin | 0 | low | 1 | 0 |
| sirolimus | 0 | medium | 288 | 23 |
| topiramate | 0 | low | 1 | 0 |
| menaquinone 7 | 0 | medium | 2 | 2 |
| brefeldin a | 0 | low | 14 | 0 |
| alvocidib | 0 | medium | 5 | 1 |
| seocalcitol | 0 | medium | 5 | 1 |
| fenretinide | 0 | low | 15 | 0 |
| ic 261 | 0 | low | 2 | 0 |
| 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 0 | low | 10 | 0 |
| morphine | 0 | medium | 40 | 9 |
| pactamycin | 0 | low | 3 | 0 |
| su 5402 | 0 | low | 1 | 0 |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | 0 | medium | 2 | 1 |
| a 192621 | 0 | low | 1 | 0 |
| arachidonyl-2-chloroethylamide | 0 | low | 2 | 0 |
| cicaprost | 0 | low | 1 | 0 |
| 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide | 0 | low | 1 | 0 |
| clobetasol | 0 | low | 3 | 0 |
| deamino arginine vasopressin | 0 | low | 4 | 0 |
| dexmedetomidine | 0 | medium | 10 | 4 |
| fluticasone | 0 | medium | 1 | 1 |
| herbimycin | 0 | low | 4 | 0 |
| goserelin | 0 | medium | 5 | 4 |
| iloprost | 0 | low | 2 | 0 |
| 15-deoxy-delta(12,14)-prostaglandin j2 | 0 | low | 4 | 0 |
| enprostil | 0 | low | 1 | 0 |
| ono-di-004 | 0 | low | 3 | 0 |
| lysophosphatidic acid | 0 | low | 18 | 0 |
| lysophosphatidylcholines | 0 | low | 23 | 0 |
| n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | 0 | low | 3 | 0 |
| cytochalasin b | 0 | low | 19 | 0 |
| neurokinin a | 0 | low | 4 | 0 |
| calyculin a | 0 | low | 2 | 0 |
| vinorelbine | 0 | low | 2 | 0 |
| (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone | 0 | low | 1 | 0 |
| kn 93 | 0 | low | 1 | 0 |
| sulprostone | 0 | low | 2 | 0 |
| ximenynic acid | 0 | low | 1 | 0 |
| 1,2-oleoylphosphatidylcholine | 0 | low | 1 | 0 |
| casticin | 0 | low | 3 | 0 |
| biliverdine | 0 | low | 3 | 0 |
| bisdemethoxycurcumin | 0 | low | 4 | 0 |
| bufothionine | 0 | low | 1 | 0 |
| corylin | 0 | low | 2 | 0 |
| glycycoumarin | 0 | low | 3 | 0 |
| hydroxygenkwanin | 0 | low | 1 | 0 |
| andrographolide | 0 | low | 17 | 0 |
| isoegomaketone | 0 | low | 1 | 0 |
| isofraxidin | 0 | low | 2 | 0 |
| isoginkgetin | 0 | low | 1 | 0 |
| koumine | 0 | low | 2 | 0 |
| dehydrocrenatidine | 0 | low | 2 | 0 |
| icaritin | 0 | medium | 18 | 1 |
| icariin | 0 | low | 2 | 0 |
| licochalcone a | 0 | low | 6 | 0 |
| licochalcone b | 0 | low | 2 | 0 |
| neobavaisoflavone | 0 | low | 1 | 0 |
| nerolidol | 0 | low | 1 | 0 |
| notopterol | 0 | low | 1 | 0 |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | 0 | low | 12 | 0 |
| artemetin | 0 | low | 1 | 0 |
| tiliroside | 0 | low | 2 | 0 |
| angiotensin amide | 0 | low | 1 | 0 |
| rhamnazin | 0 | low | 1 | 0 |
| oridonin | 0 | low | 1 | 0 |
| caryophyllene | 0 | low | 1 | 0 |
| 1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3h-cyclopenta(c)quinolin-8-yl)ethanone | 0 | low | 1 | 0 |
| malealdehyde | 0 | low | 1 | 0 |
| fluvoxamine | 0 | low | 2 | 0 |
| globo-h | 0 | low | 2 | 0 |
| casein kinase ii | 0 | low | 19 | 0 |
| erbstatin | 0 | low | 1 | 0 |
| ag-490 | 0 | low | 9 | 0 |
| semaxinib | 0 | medium | 8 | 1 |
| orantinib | 0 | medium | 10 | 5 |
| su 11248 | 0 | medium | 177 | 28 |
| palbociclib | 0 | low | 11 | 0 |
| 2'-hydroxy-4-methoxychalcone | 0 | low | 1 | 0 |
| nifuroxazide | 0 | low | 2 | 0 |
| sclareolide | 0 | low | 1 | 0 |
| mitoguazone | 0 | low | 3 | 0 |
| fosbretabulin | 0 | low | 4 | 0 |
| fosbretabulin | 0 | low | 25 | 0 |
| ergosterol-5,8-peroxide | 0 | low | 3 | 0 |
| stilbamidine | 0 | low | 1 | 0 |
| spectinabilin | 0 | low | 1 | 0 |
| heteronemin | 0 | low | 1 | 0 |
| hemiasterlin | 0 | low | 1 | 0 |
| lead | 0 | medium | 30 | 3 |
| tin | 0 | low | 34 | 0 |
| butylidenephthalide | 0 | medium | 3 | 1 |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | 0 | low | 3 | 0 |
| 13-hydroperoxy-9,11-octadecadienoic acid | 0 | low | 1 | 0 |
| 15-hydroxy-5,8,11,13-eicosatetraenoic acid | 0 | low | 2 | 0 |
| bay 11-7082 | 0 | medium | 6 | 2 |
| bay 11-7085 | 0 | low | 1 | 0 |
| 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine | 0 | low | 2 | 0 |
| diamide | 0 | low | 5 | 0 |
| oxamflatin | 0 | low | 1 | 0 |
| antimony | 0 | low | 3 | 0 |
| cesium | 0 | low | 8 | 0 |
| 8-hydroxyadenine | 0 | low | 2 | 0 |
| barium | 0 | low | 5 | 0 |
| flavokawain a | 0 | low | 1 | 0 |
| flavokawain b | 0 | low | 1 | 0 |
| 8-oxo-7,8-dihydrodeoxyguanine | 0 | low | 1 | 0 |
| oleylamine | 0 | low | 1 | 0 |
| rubidium | 0 | low | 6 | 0 |
| sinulariolide | 0 | low | 4 | 0 |
| aluminum | 0 | low | 14 | 0 |
| 6-chloropurine | 0 | low | 1 | 0 |
| strontium | 0 | medium | 4 | 1 |
| bismuth | 0 | medium | 14 | 3 |
| thallium | 0 | low | 7 | 0 |
| alternariol | 0 | low | 3 | 0 |
| arsenic | 0 | medium | 198 | 12 |
| indium | 0 | medium | 95 | 1 |
| 4-hydroxyaminoquinoline-1-oxide | 0 | low | 1 | 0 |
| naltrexone | 0 | low | 4 | 0 |
| dextromethorphan | 0 | low | 1 | 0 |
| alternariol monomethyl ether | 0 | low | 1 | 0 |
| gallium | 0 | low | 61 | 0 |
| butorphanol | 0 | low | 1 | 0 |
| methylnaltrexone | 0 | low | 1 | 0 |
| lisinopril | 0 | low | 1 | 0 |
| batimastat | 0 | medium | 4 | 1 |
| indinavir sulfate | 0 | low | 2 | 0 |
| sulfur | 0 | medium | 144 | 1 |
| methylazoxymethanol acetate | 0 | low | 21 | 0 |
| ethyl oleate | 0 | low | 1 | 0 |
| geldanamycin | 0 | low | 4 | 0 |
| musk | 0 | low | 1 | 0 |
| costunolide | 0 | low | 5 | 0 |
| retinamide | 0 | low | 1 | 0 |
| diphenylhexatriene | 0 | low | 1 | 0 |
| 4-chlorochalcone | 0 | low | 1 | 0 |
| urolithin b | 0 | low | 1 | 0 |
| puerarin | 0 | low | 3 | 0 |
| ajoene | 0 | low | 1 | 0 |
| suillin | 0 | low | 1 | 0 |
| 3,4',5-trimethoxystilbene | 0 | low | 2 | 0 |
| sanglifehrin a | 0 | low | 1 | 0 |
| enalapril | 0 | low | 3 | 0 |
| 3,3'-diethyloxacarbocyanine | 0 | low | 1 | 0 |
| nitrofurazone | 0 | low | 1 | 0 |
| artocarpin lectin | 0 | low | 1 | 0 |
| 3-acetyldeoxynivalenol | 0 | low | 1 | 0 |
| hispanolone | 0 | low | 1 | 0 |
| nsc 600032 | 0 | low | 1 | 0 |
| sinomenine | 0 | low | 6 | 0 |
| dimyristoylphosphatidylcholine | 0 | low | 12 | 0 |
| ecdysterone | 0 | low | 2 | 0 |
| sedoheptulose | 0 | low | 1 | 0 |
| deoxyribose | 0 | low | 4 | 0 |
| fumarates | 0 | low | 5 | 0 |
| beryllium | 0 | medium | 2 | 1 |
| astatine | 0 | low | 1 | 0 |
| acetyl acetonate | 0 | low | 4 | 0 |
| cysteine | 0 | medium | 91 | 1 |
| thyronines | 0 | low | 4 | 0 |
| silicon | 0 | low | 12 | 0 |
| indium | 0 | low | 1 | 0 |
| phosphorus | 0 | medium | 61 | 2 |
| boron | 0 | medium | 17 | 3 |
| imidapril | 0 | low | 1 | 0 |
| 2,3-dehydrosilybin | 0 | low | 1 | 0 |
| concanamycin b | 0 | low | 1 | 0 |
| s-trans,trans-farnesylthiosalicylic acid | 0 | low | 8 | 0 |
| zerumbone | 0 | low | 3 | 0 |
| artepillin c | 0 | low | 2 | 0 |
| sulindac sulfone | 0 | low | 1 | 0 |
| sinularin | 0 | low | 1 | 0 |
| 1,5-bis(2-methoxy-4-nitro-5-sulfophenyl)-3-((phenylamino)carbonyl)formazan | 0 | low | 1 | 0 |
| pepstatin | 0 | low | 2 | 0 |
| phytochlorin | 0 | low | 12 | 0 |
| cefepime | 0 | medium | 1 | 1 |
| l 685458 | 0 | low | 1 | 0 |
| morusinol | 0 | low | 1 | 0 |
| baohuoside ii | 0 | low | 1 | 0 |
| pachymic acid | 0 | low | 1 | 0 |
| ici 118551 | 0 | medium | 2 | 1 |
| benzoporphyrin d | 0 | low | 1 | 0 |
| lespenefril | 0 | low | 1 | 0 |
| strontium radioisotopes | 0 | medium | 10 | 1 |
| sinigrin | 0 | low | 2 | 0 |
| manganese(iii)tetraphenylporphine sulfonate | 0 | low | 2 | 0 |
| troxerutin | 0 | low | 4 | 0 |
| talaporfin | 0 | medium | 5 | 1 |
| pregabalin | 0 | medium | 2 | 1 |
| 3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one | 0 | low | 2 | 0 |
| 1,3-dihydroxy-xanthone | 0 | low | 1 | 0 |
| baohuoside i | 0 | low | 4 | 0 |
| chlorin p6 | 0 | low | 1 | 0 |
| avicularin | 0 | low | 2 | 0 |
| alpinumisoflavone | 0 | low | 1 | 0 |
| vx680 | 0 | low | 3 | 0 |
| n-acetylsphingosine | 0 | low | 1 | 0 |
| triolein | 0 | low | 4 | 0 |
| docosapentaenoic acid | 0 | low | 1 | 0 |
| bafilomycin a | 0 | low | 1 | 0 |
| n-caproylsphingosine | 0 | low | 7 | 0 |
| benzoylamido-4'-aminostilbene-2,2'-disulfonate | 0 | low | 1 | 0 |
| 3,3'-dioctadecylindocarbocyanine | 0 | low | 3 | 0 |
| carbocyanines | 0 | low | 30 | 0 |
| salubrinal | 0 | low | 5 | 0 |
| cefotaxime | 0 | medium | 1 | 1 |
| epimedin c | 0 | low | 1 | 0 |
| quercetin-3'-o-beta-d-glucopyranoside | 0 | low | 2 | 0 |
| urobilin | 0 | low | 1 | 0 |
| 1,2-dielaidoylphosphatidylethanolamine | 0 | low | 4 | 0 |
| 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one | 0 | low | 1 | 0 |
| ammonium sulfate | 0 | low | 23 | 0 |
| 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid | 0 | low | 3 | 0 |
| ma-1 | 0 | medium | 4 | 1 |
| coomassie brilliant blue | 0 | low | 1 | 0 |
| deoxyelephantopin | 0 | low | 3 | 0 |
| lasiocarpine | 0 | low | 3 | 0 |
| germanium | 0 | low | 2 | 0 |
| selenium | 0 | medium | 180 | 6 |
| selenocysteine | 0 | low | 6 | 0 |
| tellurium | 0 | low | 17 | 0 |
| trimethoxysilane | 0 | low | 1 | 0 |
| polonium | 0 | low | 2 | 0 |
| radium | 0 | low | 14 | 0 |
| thorium x | 0 | low | 1 | 0 |
| oxalates | 0 | low | 6 | 0 |
| palonosetron | 0 | medium | 6 | 1 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | 0 | low | 8 | 0 |
| maxacalcitol | 0 | low | 1 | 0 |
| dizocilpine maleate | 0 | low | 1 | 0 |
| antimycin a | 0 | low | 7 | 0 |
| pregnanediol | 0 | low | 3 | 0 |
| cholestanol | 0 | low | 1 | 0 |
| 5-aminolevulinic acid hexyl ester | 0 | low | 1 | 0 |
| methylazoxymethanol | 0 | low | 3 | 0 |
| s-(1,2-dichlorovinyl)cysteine | 0 | low | 2 | 0 |
| dolichols | 0 | low | 14 | 0 |
| hygromycin a | 0 | low | 1 | 0 |
| ascofuranone | 0 | low | 1 | 0 |
| cilastatin | 0 | low | 4 | 0 |
| tezacitabine | 0 | low | 1 | 0 |
| sclerotiorin | 0 | low | 1 | 0 |
| bafilomycin a1 | 0 | low | 12 | 0 |
| germacrone | 0 | low | 1 | 0 |
| sarcophine | 0 | low | 1 | 0 |
| 1-oleoyl-2-acetylglycerol | 0 | low | 3 | 0 |
| brl 28500 | 0 | low | 1 | 0 |
| ro 13-6298 | 0 | low | 1 | 0 |
| involucrin | 0 | low | 1 | 0 |
| 1,2-dioleoyloxy-3-(trimethylammonium)propane | 0 | low | 8 | 0 |
| pectenotoxin 2 | 0 | low | 1 | 0 |
| dioleoyl phosphatidylethanolamine | 0 | low | 1 | 0 |
| (2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid | 0 | medium | 49 | 5 |
| concanamycin a | 0 | low | 1 | 0 |
| manumycin | 0 | low | 5 | 0 |
| plastochromanol 8 | 0 | low | 8 | 0 |
| 2-cyano-3-(1-phenylindol-3-yl)acrylate | 0 | low | 1 | 0 |
| neo-gambogic acid | 0 | low | 3 | 0 |
| cholesteryl oleyl ether | 0 | low | 1 | 0 |
| 4-o-carboxymethylascochlorin | 0 | low | 1 | 0 |
| e 3330 | 0 | low | 2 | 0 |
| erucylphosphocholine | 0 | low | 1 | 0 |
| n-(n-(7-nitro-2,1,3-benzoxadiazol-4-yl)-epsilon-aminohexanoyl)sphingosylphosphorylcholine | 0 | low | 2 | 0 |
| pregna-4,17-diene-3,16-dione | 0 | low | 4 | 0 |
| echinacin | 0 | low | 1 | 0 |
| krn 5500 | 0 | low | 1 | 0 |
| comfrey | 0 | low | 2 | 0 |
| goniothalamin | 0 | low | 3 | 0 |
| antibiotic 1233a | 0 | low | 1 | 0 |
| menahydroquinone-4 | 0 | low | 2 | 0 |
| bafilomycin c1 | 0 | low | 1 | 0 |
| dihydromicrocystin lr | 0 | low | 1 | 0 |
| n(4)-oleylcytosine arabinoside | 0 | low | 1 | 0 |
| everolimus | 0 | medium | 131 | 18 |
| isoobtusilactone a | 0 | low | 2 | 0 |
| 4-methylthio-3-butenyl glucosinolate | 0 | low | 1 | 0 |
| emerin | 0 | low | 1 | 0 |
| bifenthrin | 0 | low | 1 | 0 |
| nb 598 | 0 | low | 1 | 0 |
| hydroxysafflor yellow a | 0 | low | 4 | 0 |
| mkt 077 | 0 | low | 1 | 0 |
| ixabepilone | 0 | medium | 8 | 5 |
| ekb 569 | 0 | low | 2 | 0 |
| n-solanesyl-n,n'-bis(3,4-dimethoxybenzyl)ethylenediamine | 0 | low | 1 | 0 |
| 3,3'-dioctadecyloxacarbocyanine | 0 | low | 1 | 0 |
| 16-(2'-o-glucopyranosylglucopyranosyloxy)hexadecanoic acid 1',4''-lactone 6',6''-diacetate | 0 | low | 2 | 0 |
| cdw17 antigen | 0 | low | 1 | 0 |
| ganglioside, gd2 | 0 | low | 8 | 0 |
| asialo gm1 ganglioside | 0 | low | 19 | 0 |
| sialosylparagloboside | 0 | low | 1 | 0 |
| idb 1016 | 0 | medium | 1 | 1 |
| axitinib | 0 | medium | 20 | 10 |
| ovatodiolide | 0 | low | 3 | 0 |
| salvianolic acid B | 0 | low | 3 | 0 |
| i(3)so3-galactosylceramide | 0 | low | 8 | 0 |
| abt-100 | 0 | low | 1 | 0 |
| trilobatin | 0 | low | 1 | 0 |
| technetium tc 99m pyrophosphate | 0 | low | 7 | 0 |
| glucuronyl glucosamine glycan sulfate | 0 | low | 1 | 0 |
| brazilein | 0 | low | 1 | 0 |
| indigo carmine | 0 | low | 1 | 0 |
| cyclosporin g | 0 | low | 1 | 0 |
| beta-escin | 0 | low | 2 | 0 |
| scy-635 | 0 | medium | 1 | 1 |
| Uvangoletin | 0 | low | 1 | 0 |
| tanespimycin | 0 | low | 11 | 0 |
| verlukast | 0 | low | 1 | 0 |
| beta-escin | 0 | low | 131 | 0 |
| glucoraphanin | 0 | low | 1 | 0 |
| 4,5-diaminofluorescein diacetate | 0 | low | 1 | 0 |
| s-nitroso-n-acetylpenicillamine | 0 | low | 5 | 0 |
| nitrofurantoin | 0 | low | 2 | 0 |
| sb 269970 | 0 | low | 1 | 0 |
| cgk 733 | 0 | low | 1 | 0 |
| lactacystin | 0 | low | 2 | 0 |
| echinocystic acid | 0 | low | 1 | 0 |
| ispinesib | 0 | medium | 1 | 1 |
| gsk5182 | 0 | low | 1 | 0 |
| peplomycin | 0 | low | 6 | 0 |
| 6 beta-hydroxycortisol | 0 | low | 1 | 0 |
| butylscopolammonium bromide | 0 | medium | 4 | 1 |
| gadolinium dtpa | 0 | medium | 1,393 | 70 |
| morphinans | 0 | low | 7 | 0 |
| androstane | 0 | low | 4 | 0 |
| ergoline | 0 | low | 2 | 0 |
| corrole | 0 | low | 1 | 0 |
| carboxyl radical | 0 | low | 1 | 0 |
| 2-(quinolin-2-ylmethylene)hydrazinecarbothioamide | 0 | low | 1 | 0 |
| sq-23377 | 0 | low | 8 | 0 |
| fostriecin | 0 | low | 2 | 0 |
| fk 866 | 0 | low | 3 | 0 |
| fumagillin | 0 | low | 3 | 0 |
| enkephalin, leucine-2-alanine | 0 | low | 1 | 0 |
| teroxirone | 0 | low | 1 | 0 |
| artesunate | 0 | low | 1 | 0 |
| enkephalin-leu, ala(2)-arg(6)- | 0 | low | 1 | 0 |
| romurtide | 0 | low | 1 | 0 |
| edatrexate | 0 | medium | 2 | 2 |
| bufogenin | 0 | low | 4 | 0 |
| etoposide phosphate | 0 | low | 2 | 0 |
| vorozole | 0 | low | 1 | 0 |
| perfosfamide | 0 | low | 1 | 0 |
| d-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide | 0 | low | 1 | 0 |
| combretastatin a-4 disodium phosphate | 0 | low | 1 | 0 |
| vilazodone hydrochloride | 0 | low | 1 | 0 |
| bay 12-9566 | 0 | medium | 2 | 1 |
| cvt 313 | 0 | low | 1 | 0 |
| beta-elemene | 0 | low | 5 | 0 |
| pd 184352 | 0 | low | 1 | 0 |
| lu 208075 | 0 | low | 1 | 0 |
| jwh-133 | 0 | low | 1 | 0 |
| vildagliptin | 0 | low | 2 | 0 |
| dalcetrapib | 0 | low | 1 | 0 |
| oxi 4503 | 0 | low | 5 | 0 |
| hti-286 | 0 | low | 1 | 0 |
| belinostat | 0 | medium | 7 | 2 |
| on 01910 | 0 | low | 2 | 0 |
| corosolic acid | 0 | low | 9 | 0 |
| cysmethynil | 0 | low | 1 | 0 |
| panobinostat | 0 | low | 11 | 0 |
| 3-tyrosine | 0 | low | 1 | 0 |
| isoborneol | 0 | low | 2 | 0 |
| bromopyruvate | 0 | low | 18 | 0 |
| staurosporine | 0 | low | 31 | 0 |
| 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4h-pyran-3-yl 4-nitrobenzoate | 0 | low | 1 | 0 |
| bufalin | 0 | low | 29 | 0 |
| 1,25-dihydroxy-19-norvitamin d3 | 0 | low | 1 | 0 |
| shu 508 | 0 | medium | 136 | 20 |
| hypericum | 0 | low | 3 | 0 |
| phosphocreatine | 0 | low | 6 | 0 |
| guaiane | 0 | low | 1 | 0 |
| cholanic acid | 0 | low | 2 | 0 |
| taxane | 0 | medium | 13 | 3 |
| mannich bases | 0 | low | 1 | 0 |
| formazans | 0 | low | 14 | 0 |
| gs-7340 | 0 | low | 10 | 0 |
| triacsin c | 0 | low | 3 | 0 |
| triacsin d | 0 | low | 1 | 0 |
| ruboxyl | 0 | low | 2 | 0 |
| sabcomeline | 0 | low | 1 | 0 |
| vacuolin-1 | 0 | low | 1 | 0 |
| ferrihydrite | 0 | medium | 1 | 1 |
| s-allylcysteine | 0 | low | 3 | 0 |
| s-allylmercaptocysteine | 0 | low | 1 | 0 |
| clasto-lactacystin beta-lactone | 0 | low | 1 | 0 |
| iniparib | 0 | low | 1 | 0 |
| am 555s | 0 | medium | 7 | 2 |
| ono4819 | 0 | low | 1 | 0 |
| gw 501516 | 0 | low | 1 | 0 |
| lexipafant | 0 | low | 1 | 0 |
| amoxicillin-potassium clavulanate combination | 0 | low | 3 | 0 |
| 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin | 0 | medium | 3 | 2 |
| dolastatin 10 | 0 | medium | 1 | 1 |
| bimosiamose | 0 | low | 1 | 0 |
| plitidepsin | 0 | medium | 2 | 2 |
| bms345541 | 0 | low | 1 | 0 |
| 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol | 0 | low | 1 | 0 |
| bicyclol | 0 | low | 5 | 0 |
| abiraterone acetate | 0 | medium | 5 | 1 |
| lenvatinib | 0 | medium | 464 | 26 |
| ono 8711 | 0 | low | 2 | 0 |
| andarine | 0 | low | 1 | 0 |
| pd 0325901 | 0 | low | 1 | 0 |
| midostaurin | 0 | low | 2 | 0 |
| lu 28-179 | 0 | low | 1 | 0 |
| pd 176252 | 0 | low | 1 | 0 |
| bromotetrandrine | 0 | low | 1 | 0 |
| jasplakinolide | 0 | low | 1 | 0 |
| ro 28-2653 | 0 | low | 2 | 0 |
| sincalide | 0 | low | 16 | 0 |
| racivir | 0 | low | 1 | 0 |
| tapentadol | 0 | low | 1 | 0 |
| technetium tc 99m diphosphonate | 0 | low | 2 | 0 |
| reparixin | 0 | low | 1 | 0 |
| etomoxir | 0 | low | 3 | 0 |
| 1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone | 0 | low | 1 | 0 |
| n(6)-cyclohexyladenosine | 0 | low | 3 | 0 |
| cp 91149 | 0 | low | 1 | 0 |
| gallium maltolate | 0 | low | 1 | 0 |
| pr-104a | 0 | low | 1 | 0 |
| ursodoxicoltaurine | 0 | low | 7 | 0 |
| ki23057 | 0 | low | 1 | 0 |
| ginsenoside m1 | 0 | low | 12 | 0 |
| gambogic acid | 0 | low | 10 | 0 |
| paliperidone palmitate | 0 | low | 1 | 0 |
| pentagastrin | 0 | medium | 11 | 1 |
| conophylline | 0 | low | 1 | 0 |
| cabazitaxel | 0 | medium | 8 | 1 |
| flag peptide | 0 | low | 1 | 0 |
| kla peptide | 0 | low | 1 | 0 |
| nu 7026 | 0 | low | 2 | 0 |
| gc 1 compound | 0 | low | 3 | 0 |
| agn 194204 | 0 | low | 1 | 0 |
| mocetinostat | 0 | medium | 25 | 3 |
| sc 236 | 0 | low | 1 | 0 |
| alloin | 0 | low | 1 | 0 |
| practolol | 0 | low | 1 | 0 |
| carbobenzoxy-leucyl-leucyl-norvalinal | 0 | low | 2 | 0 |
| cgp 74588 | 0 | low | 2 | 0 |
| ticagrelor | 0 | low | 1 | 0 |
| k 7174 | 0 | low | 1 | 0 |
| cp 724714 | 0 | medium | 1 | 1 |
| rivaroxaban | 0 | low | 1 | 0 |
| bleomycin a6 | 0 | low | 5 | 0 |
| lipid a | 0 | low | 6 | 0 |
| 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid | 0 | low | 3 | 0 |
| dehydroxymethylepoxyquinomicin | 0 | low | 7 | 0 |
| 3-hydroxy-4,3',4',5'-tetramethoxychalcone | 0 | low | 1 | 0 |
| pi103 | 0 | low | 7 | 0 |
| 3,5-bis(2-fluorobenzylidene)piperidin-4-one | 0 | low | 3 | 0 |
| dapagliflozin | 0 | medium | 4 | 1 |
| gw 4064 | 0 | low | 10 | 0 |
| zd 6126 | 0 | low | 3 | 0 |
| mart-1 antigen | 0 | low | 23 | 0 |
| ginsenoside rb1 | 0 | low | 1 | 0 |
| g(m2) ganglioside | 0 | low | 6 | 0 |
| plomestane | 0 | low | 1 | 0 |
| tivozanib | 0 | medium | 2 | 1 |
| hki 272 | 0 | low | 2 | 0 |
| nb 506 | 0 | low | 1 | 0 |
| ginsenoside f2 | 0 | low | 1 | 0 |
| ginsenoside rg3 | 0 | medium | 15 | 1 |
| sorbitan monooleate | 0 | medium | 2 | 2 |
| tofacitinib | 0 | low | 1 | 0 |
| bibr 1532 | 0 | low | 1 | 0 |
| tocotrienols | 0 | low | 10 | 0 |
| rucaparib | 0 | low | 1 | 0 |
| cediranib | 0 | medium | 5 | 3 |
| tae226 | 0 | low | 1 | 0 |
| gw0742 | 0 | low | 1 | 0 |
| pd 184161 | 0 | low | 2 | 0 |
| elobixibat | 0 | low | 1 | 0 |
| pasireotide | 0 | medium | 4 | 2 |
| zeolites | 0 | medium | 5 | 1 |
| pitolisant | 0 | medium | 2 | 2 |
| npi 2358 | 0 | low | 1 | 0 |
| cp 31398 | 0 | low | 2 | 0 |
| tetramethylrhodamine | 0 | low | 1 | 0 |
| u 18666a | 0 | low | 8 | 0 |
| ym 201636 | 0 | low | 1 | 0 |
| pd 198306 | 0 | low | 1 | 0 |
| acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide | 0 | low | 1 | 0 |
| ubiquinol | 0 | low | 3 | 0 |
| g(m1) ganglioside | 0 | low | 27 | 0 |
| ganu | 0 | low | 1 | 0 |
| sr 11302 | 0 | low | 1 | 0 |
| aluminum oxide | 0 | medium | 4 | 1 |
| isojacareubin | 0 | low | 1 | 0 |
| cgp 20712a | 0 | low | 1 | 0 |
| 3-nitrooxypropanol | 0 | low | 1 | 0 |
| way-362450 | 0 | low | 1 | 0 |
| osu 03012 | 0 | low | 1 | 0 |
| actein | 0 | low | 2 | 0 |
| 5'-deoxy-5-fluorocytidine | 0 | low | 1 | 0 |
| cholest-8(14)-en-3-ol-15-one | 0 | low | 1 | 0 |
| methionine sulfoxide | 0 | low | 1 | 0 |
| isopanduratin a | 0 | low | 1 | 0 |
| metapristone | 0 | low | 1 | 0 |
| methyl 3,5-di-o-caffeoyl quinate | 0 | low | 1 | 0 |
| baicalein-7-o-diglucoside | 0 | low | 1 | 0 |
| eclalbasaponin i | 0 | low | 1 | 0 |
| hispolon | 0 | low | 2 | 0 |
| avenanthramide b | 0 | low | 1 | 0 |
| ly-2157299 | 0 | medium | 17 | 5 |
| 4-hydroxy-n-desmethyltamoxifen | 0 | low | 1 | 0 |
| givinostat hydrochloride | 0 | low | 3 | 0 |
| linagliptin | 0 | low | 1 | 0 |
| cystathionine | 0 | low | 5 | 0 |
| pazopanib | 0 | medium | 16 | 2 |
| tribulus | 0 | low | 2 | 0 |
| sepantronium | 0 | low | 4 | 0 |
| azd 6244 | 0 | medium | 14 | 2 |
| cuprous sulfide | 0 | low | 2 | 0 |
| betulin-3-caffeate | 0 | low | 1 | 0 |
| yttrium silicate | 0 | low | 1 | 0 |
| n-acetylcysteinamide | 0 | low | 1 | 0 |
| dimethylarginine | 0 | low | 1 | 0 |
| apixaban | 0 | low | 3 | 0 |
| bibw 2992 | 0 | low | 6 | 0 |
| vilanterol | 0 | low | 1 | 0 |
| gw 799388 | 0 | low | 1 | 0 |
| artenimol | 0 | low | 23 | 0 |
| jte 013 | 0 | low | 1 | 0 |
| leucamide a | 0 | low | 1 | 0 |
| ardisicrenoside a | 0 | low | 1 | 0 |
| trans-sodium crocetinate | 0 | low | 1 | 0 |
| binimetinib | 0 | low | 2 | 0 |
| aee 788 | 0 | low | 3 | 0 |
| garcinone e | 0 | low | 1 | 0 |
| saracatinib | 0 | low | 3 | 0 |
| alpha-synuclein | 0 | low | 2 | 0 |
| 3-acrylamidophenylboronic acid | 0 | low | 1 | 0 |
| demethylzeylasteral | 0 | low | 1 | 0 |
| nymphaeol c | 0 | low | 1 | 0 |
| thonningianin a | 0 | low | 1 | 0 |
| 7-aminoactinomycin d | 0 | low | 1 | 0 |
| 2-acetylfuranonaphthoquinone | 0 | medium | 5 | 1 |
| ccx282-b | 0 | low | 1 | 0 |
| ngr peptide | 0 | medium | 5 | 1 |
| crenolanib | 0 | low | 1 | 0 |
| azd3965 | 0 | low | 1 | 0 |
| 15-acetyldeoxynivalenol | 0 | low | 1 | 0 |
| (1,2-bis(1,2-benzisoselenazolone-3(2h)-ketone))ethane | 0 | low | 2 | 0 |
| cgs 24012 | 0 | low | 1 | 0 |
| 2-furoyl-ligrlo-amide | 0 | low | 1 | 0 |
| erinacine a | 0 | low | 1 | 0 |
| 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone | 0 | low | 5 | 0 |
| cay 10404 | 0 | low | 1 | 0 |
| homatropine methylbromide | 0 | low | 3 | 0 |
| calycopterin | 0 | low | 1 | 0 |
| ardisiacrispin b | 0 | low | 1 | 0 |
| volasertib | 0 | low | 2 | 0 |
| glaucocalyxin a | 0 | low | 1 | 0 |
| PB28 | 0 | low | 1 | 0 |
| peperomin e | 0 | low | 1 | 0 |
| 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid | 0 | low | 1 | 0 |
| oxadiazoles | 0 | low | 18 | 0 |
| vinflunine | 0 | medium | 7 | 3 |
| homocamptothecin | 0 | low | 3 | 0 |
| cytosporone b | 0 | low | 1 | 0 |
| aloperine | 0 | low | 1 | 0 |
| 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one | 0 | low | 2 | 0 |
| trienomycin a | 0 | low | 1 | 0 |
| artemisic acid | 0 | low | 1 | 0 |
| ucn 1028 c | 0 | low | 2 | 0 |
| ribose | 0 | low | 15 | 0 |
| 5-formylcytosine | 0 | low | 2 | 0 |
| acebutolol | 0 | medium | 4 | 1 |
| lactulose | 0 | medium | 10 | 2 |
| cyclic diadenosine phosphate | 0 | low | 1 | 0 |
| regorafenib | 0 | medium | 184 | 10 |
| acetyl-11-ketoboswellic acid | 0 | low | 2 | 0 |
| wp1066 | 0 | low | 1 | 0 |
| erastin | 0 | low | 10 | 0 |
| degrasyn | 0 | low | 1 | 0 |
| epoxomicin | 0 | low | 2 | 0 |
| abt-737 | 0 | low | 16 | 0 |
| brivanib | 0 | medium | 21 | 7 |
| euphorbia factor l1 | 0 | low | 1 | 0 |
| procyanidin b1 | 0 | low | 1 | 0 |
| amd 070 | 0 | low | 1 | 0 |
| ascochlorin | 0 | low | 2 | 0 |
| mp470 | 0 | low | 1 | 0 |
| nystatin a1 | 0 | low | 2 | 0 |
| pirarubicin | 0 | medium | 74 | 13 |
| nu 7441 | 0 | low | 3 | 0 |
| bms-690514 | 0 | low | 1 | 0 |
| cyt997 | 0 | low | 2 | 0 |
| er-086526 | 0 | medium | 13 | 2 |
| bi 2536 | 0 | low | 4 | 0 |
| karwinskia toxin t-514 | 0 | low | 1 | 0 |
| inno-406 | 0 | low | 1 | 0 |
| mitoquinone | 0 | low | 1 | 0 |
| Dihydrotanshinone I | 0 | low | 5 | 0 |
| technetium tc 99m disofenin | 0 | low | 27 | 0 |
| technetium tc 99m mebrofenin | 0 | medium | 21 | 2 |
| nutlin-3a | 0 | low | 10 | 0 |
| danusertib | 0 | low | 4 | 0 |
| alogliptin | 0 | low | 1 | 0 |
| pr-104 | 0 | medium | 1 | 1 |
| nvp-aew541 | 0 | low | 3 | 0 |
| irc-110160 | 0 | low | 1 | 0 |
| abt 869 | 0 | medium | 5 | 2 |
| 5-(2,2-difluorobenzo(1,3)dioxol-5-ylmethylene)thiazolidine-2,4-dione | 0 | low | 1 | 0 |
| arq 197 | 0 | medium | 23 | 6 |
| ginsenoside rk1 | 0 | low | 3 | 0 |
| ridaforolimus | 0 | low | 1 | 0 |
| dorsomorphin | 0 | low | 2 | 0 |
| quisinostat | 0 | low | 2 | 0 |
| ro 31-8425 | 0 | low | 1 | 0 |
| 2,5-dimethylcelecoxib | 0 | low | 3 | 0 |
| carfilzomib | 0 | medium | 5 | 1 |
| sitagliptin phosphate | 0 | low | 5 | 0 |
| resminostat | 0 | medium | 4 | 1 |
| pf 573228 | 0 | low | 1 | 0 |
| gw 2580 | 0 | low | 1 | 0 |
| idelalisib | 0 | low | 4 | 0 |
| crizotinib | 0 | medium | 19 | 1 |
| zstk474 | 0 | low | 2 | 0 |
| 2,4,3',5'-tetrahydroxystilbene | 0 | low | 2 | 0 |
| ly2109761 | 0 | low | 9 | 0 |
| ginsenoside rd | 0 | low | 1 | 0 |
| darinaparsin | 0 | medium | 1 | 1 |
| trametinib | 0 | medium | 11 | 2 |
| jbt-3002 | 0 | low | 1 | 0 |
| pf-562,271 | 0 | low | 1 | 0 |
| pha 767491 | 0 | low | 1 | 0 |
| sauchinone | 0 | low | 2 | 0 |
| losartan potassium | 0 | medium | 164 | 3 |
| excisanin a | 0 | low | 1 | 0 |
| silvestrol | 0 | low | 1 | 0 |
| guluronic acid | 0 | low | 1 | 0 |
| alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc | 0 | medium | 40 | 1 |
| td-5108 | 0 | low | 1 | 0 |
| 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose | 0 | low | 1 | 0 |
| desacetylcinobufagin | 0 | low | 1 | 0 |
| 2-((2,6-dichlorophenyl)amino)benzeneacetic acid 4-(3h-1,2-dithiol-3-thione-5-yl)phenyl ester | 0 | low | 1 | 0 |
| empagliflozin | 0 | medium | 2 | 1 |
| moxestrol | 0 | low | 2 | 0 |
| technetium tc 99m exametazime | 0 | low | 2 | 0 |
| calcimycin | 0 | low | 14 | 0 |
| dextrothyroxine | 0 | low | 2 | 0 |
| veliparib | 0 | medium | 6 | 2 |
| delta-1-pyrroline-5-carboxylate | 0 | low | 1 | 0 |
| sepharose | 0 | medium | 21 | 2 |
| indocyanine green | 0 | medium | 419 | 16 |
| scopolamine hydrobromide | 0 | low | 2 | 0 |
| cinobufagin | 0 | low | 11 | 0 |
| dactolisib | 0 | low | 11 | 0 |
| pituitrin | 0 | medium | 31 | 1 |
| podophyllin | 0 | low | 3 | 0 |
| th 302 | 0 | low | 2 | 0 |
| n-monoacetylcystine | 0 | low | 1 | 0 |
| arabinofuranosyluracil | 0 | medium | 11 | 1 |
| demethylcantharidin | 0 | low | 6 | 0 |
| 6-o-angeloylprenolin | 0 | low | 1 | 0 |
| bufotalin | 0 | low | 3 | 0 |
| phytosterols | 0 | low | 7 | 0 |
| arenobufagin | 0 | low | 4 | 0 |
| grandiflorenic acid | 0 | low | 1 | 0 |
| dihydrotachysterol | 0 | low | 2 | 0 |
| tirucallane | 0 | low | 1 | 0 |
| nomilin | 0 | low | 1 | 0 |
| rifamycins | 0 | low | 2 | 0 |
| silidianin | 0 | low | 1 | 0 |
| soyasapogenol a | 0 | low | 1 | 0 |
| eudesmanolide | 0 | low | 2 | 0 |
| clove | 0 | low | 12 | 0 |
| acid phosphatase | 0 | medium | 123 | 2 |
| esorubicin | 0 | medium | 3 | 1 |
| mefloquine | 0 | low | 1 | 0 |
| 3-aminobenzanthrone | 0 | low | 1 | 0 |
| bleomycetin | 0 | low | 2 | 0 |
| tetrahydrouridine | 0 | medium | 2 | 1 |
| 1-arabinofuranosylcytosine-5'-stearylphosphate | 0 | medium | 2 | 2 |
| medicagenic acid-3-o-glucopyranoside | 0 | low | 1 | 0 |
| aflatoxin g1 | 0 | low | 3 | 0 |
| 2',2'-difluoro-2'-deoxyuridine | 0 | low | 2 | 0 |
| bisdesmoside | 0 | low | 1 | 0 |
| astragaloside ii | 0 | low | 2 | 0 |
| alisol b monoacetate | 0 | low | 2 | 0 |
| lucidenic acid a | 0 | low | 1 | 0 |
| riccardin d | 0 | low | 1 | 0 |
| 7-n-(4-hydroxyphenyl)mitomycin c | 0 | low | 1 | 0 |
| cysteinyldopa | 0 | medium | 4 | 1 |
| nodularin | 0 | low | 7 | 0 |
| 3-methylcytidine | 0 | low | 1 | 0 |
| curcumol | 0 | medium | 5 | 1 |
| butaprost | 0 | low | 1 | 0 |
| peonidin 3-glucoside | 0 | low | 2 | 0 |
| periplocin | 0 | low | 1 | 0 |
| britannin | 0 | low | 2 | 0 |
| hypocrellin a | 0 | low | 1 | 0 |
| lyoniside | 0 | low | 3 | 0 |
| oroxylin a-7-o-glucuronide | 0 | low | 1 | 0 |
| icatibant | 0 | low | 1 | 0 |
| 6-methoxydihydrosanguinarine | 0 | low | 1 | 0 |
| jaw | 0 | low | 1 | 0 |
| adenanthin | 0 | low | 2 | 0 |
| ankaflavin | 0 | low | 1 | 0 |
| cyclosporin o | 0 | low | 1 | 0 |
| aflatoxin m1 | 0 | medium | 19 | 1 |
| cyanidin-3-o-beta-glucopyranoside | 0 | low | 2 | 0 |
| s-adenosylethionine | 0 | low | 2 | 0 |
| vibsanin b | 0 | low | 1 | 0 |
| nad | 0 | medium | 87 | 3 |
| dianhydrogalactitol | 0 | low | 2 | 0 |
| mdv 3100 | 0 | medium | 7 | 4 |
| n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | 0 | medium | 6 | 2 |
| macitentan | 0 | low | 1 | 0 |
| toceranib phosphate | 0 | low | 1 | 0 |
| enmd 2076 | 0 | medium | 1 | 1 |
| cytochrome c-t | 0 | low | 149 | 0 |
| bms-650032 | 0 | low | 10 | 0 |
| gw 4869 | 0 | low | 1 | 0 |
| rg 7128 | 0 | low | 1 | 0 |
| melitten | 0 | low | 20 | 0 |
| nosiheptide | 0 | low | 1 | 0 |
| cholecystokinin | 0 | low | 14 | 0 |
| ceruletide | 0 | low | 6 | 0 |
| motilin | 0 | low | 3 | 0 |
| atrial natriuretic factor | 0 | low | 8 | 0 |
| tachyplesin peptide, tachypleus tridentatus | 0 | low | 3 | 0 |
| tannins | 0 | medium | 1 | 1 |
| cecropin b protein, insecta | 0 | low | 3 | 0 |
| thymalfasin | 0 | medium | 14 | 5 |
| (dtpa-phe(1))-octreotide | 0 | medium | 28 | 3 |
| (4-24)-ply(a) | 0 | low | 1 | 0 |
| rpl41 protein, human | 0 | low | 1 | 0 |
| hes1 protein, human | 0 | low | 16 | 0 |
| glycoprotein e2, hepatitis c virus | 0 | medium | 22 | 1 |
| cs1 peptide | 0 | low | 1 | 0 |
| chromogranin a-derived peptide, we-14 | 0 | low | 1 | 0 |
| nociceptin | 0 | low | 3 | 0 |
| alamethicin | 0 | low | 2 | 0 |
| galanin (1-13)-spantide amide | 0 | low | 1 | 0 |
| gastrins | 0 | medium | 115 | 4 |
| glucagon | 0 | medium | 152 | 4 |
| big gastrin | 0 | low | 6 | 0 |
| beta-endorphin | 0 | medium | 8 | 1 |
| emerimicins | 0 | low | 1 | 0 |
| thymosin beta(4) | 0 | low | 3 | 0 |
| ceca1 protein, drosophila | 0 | low | 1 | 0 |
| neuropeptide y | 0 | low | 4 | 0 |
| pancreastatin | 0 | low | 13 | 0 |
| eristostatin | 0 | low | 1 | 0 |
| lactoferricin b | 0 | low | 2 | 0 |
| angiotensinogen | 0 | low | 26 | 0 |
| cortistatin 14 | 0 | low | 1 | 0 |
| tannins | 0 | medium | 26 | 2 |
| oligonucleotides | 0 | medium | 78 | 1 |
| liraglutide | 0 | low | 4 | 0 |
| glucagon-like peptide 1 | 0 | low | 7 | 0 |
| th9507 | 0 | medium | 1 | 1 |
| incretins | 0 | low | 3 | 0 |
| c-peptide | 0 | low | 23 | 0 |
| gastrin 17 | 0 | low | 3 | 0 |
| natriuretic peptide, c-type | 0 | low | 2 | 0 |
| ctce-9908 | 0 | low | 1 | 0 |
| an 207 | 0 | low | 1 | 0 |
| pr 39 | 0 | low | 2 | 0 |
| eriocalyxin b | 0 | low | 1 | 0 |
| tbe 31 | 0 | low | 1 | 0 |
| cellulose | 0 | medium | 47 | 3 |
| sodium borate | 0 | low | 1 | 0 |
| endothelin-1 | 0 | medium | 20 | 4 |
| phosphatidylcholines | 0 | medium | 93 | 2 |
| guttiferone k | 0 | low | 1 | 0 |
| barium ferrite | 0 | low | 1 | 0 |
| atractyloside | 0 | low | 1 | 0 |
| n-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine | 0 | low | 1 | 0 |
| gdc-0973 | 0 | medium | 3 | 1 |
| buparlisib | 0 | low | 4 | 0 |
| chlorophyll a | 0 | low | 13 | 0 |
| archazolid a | 0 | low | 1 | 0 |
| phenylmercuric acetate | 0 | low | 1 | 0 |
| 4-aminophenylmercuriacetate | 0 | low | 1 | 0 |
| snwo4 | 0 | low | 1 | 0 |
| pevonedistat | 0 | low | 7 | 0 |
| tg101209 | 0 | low | 1 | 0 |
| sulfoxaflor | 0 | low | 1 | 0 |
| cay10566 | 0 | low | 1 | 0 |
| ku 0063794 | 0 | low | 2 | 0 |
| uk 453,061 | 0 | low | 1 | 0 |
| dihydroceramide | 0 | low | 2 | 0 |
| pravastatin sodium | 0 | low | 1 | 0 |
| didymin | 0 | low | 1 | 0 |
| adenosine kinase | 0 | low | 2 | 0 |
| boc-d-fmk | 0 | low | 1 | 0 |
| xu 62-320 | 0 | low | 2 | 0 |
| hoe 33342 | 0 | low | 6 | 0 |
| jsh 23 | 0 | low | 2 | 0 |
| sodium salicylate | 0 | low | 2 | 0 |
| sphingosine kinase | 0 | low | 16 | 0 |
| ubiquinone | 0 | medium | 22 | 2 |
| gdc 0941 | 0 | low | 1 | 0 |
| sm 164 | 0 | low | 1 | 0 |
| cilastatin, imipenem drug combination | 0 | low | 1 | 0 |
| 1-palmitoyl-2-(6-(n-(7-nitrobenz)-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylcholine | 0 | low | 1 | 0 |
| rhenium(v)dimercaptosuccinic acid | 0 | low | 1 | 0 |
| periplocymarin | 0 | low | 2 | 0 |
| calpain | 0 | low | 33 | 0 |
| tetronic 701 | 0 | low | 1 | 0 |
| cholesteryl ester hydroperoxide | 0 | low | 1 | 0 |
| lucifer yellow | 0 | low | 3 | 0 |
| tetracosapentaenoic acid | 0 | low | 1 | 0 |
| idarubicinol | 0 | medium | 2 | 2 |
| non-ovlon | 0 | low | 1 | 0 |
| 4-borono-2-fluorophenylalanine | 0 | low | 1 | 0 |
| sapogenins | 0 | low | 10 | 0 |
| 19-iodocholesterol | 0 | low | 1 | 0 |
| 6-iodomethylcholesterol | 0 | low | 1 | 0 |
| antamanide | 0 | low | 1 | 0 |
| asparanin a | 0 | low | 1 | 0 |
| drupacine | 0 | low | 1 | 0 |
| lucidenic acid n | 0 | low | 2 | 0 |
| cathestatin b | 0 | low | 1 | 0 |
| ginsenoside rh4 | 0 | low | 1 | 0 |
| caudatin | 0 | low | 2 | 0 |
| scalaradial | 0 | low | 1 | 0 |
| ilexgenin a | 0 | low | 1 | 0 |
| 23-hydroxybetulinic acid | 0 | low | 7 | 0 |
| 13-acetoxysarcocrassolide | 0 | low | 3 | 0 |
| biotinyltyramide | 0 | low | 3 | 0 |
| menotropins | 0 | low | 2 | 0 |
| chitosan | 0 | medium | 162 | 3 |
| icotinib | 0 | low | 2 | 0 |
| ph 797804 | 0 | low | 1 | 0 |
| technetium tc 99m sestamibi | 0 | medium | 14 | 3 |
| 9-(tetrahydro-2-furyl)-adenine | 0 | low | 1 | 0 |
| potassium borohydride | 0 | low | 1 | 0 |
| 15-deoxyprostaglandin j2 | 0 | low | 2 | 0 |
| cholylglycylamidofluorescein | 0 | low | 1 | 0 |
| s-nitro-n-acetylpenicillamine | 0 | low | 3 | 0 |
| optimark | 0 | low | 1 | 0 |
| meglumine ioxithalamate | 0 | low | 1 | 0 |
| kx-01 | 0 | low | 1 | 0 |
| mesna | 0 | low | 4 | 0 |
| bucladesine | 0 | low | 60 | 0 |
| sodium bisulfite | 0 | low | 4 | 0 |
| sodium tetradecyl sulfate | 0 | medium | 3 | 1 |
| bmy 21950 | 0 | low | 1 | 0 |
| urografin 76 | 0 | low | 1 | 0 |
| sodium nitrite | 0 | low | 16 | 0 |
| amphotericin b, deoxycholate drug combination | 0 | low | 1 | 0 |
| stearates | 0 | low | 2 | 0 |
| sodium glutamate | 0 | low | 3 | 0 |
| ro13-9904 | 0 | medium | 4 | 1 |
| sodium pertechnetate tc 99m | 0 | medium | 39 | 3 |
| sodium ethylxanthate | 0 | low | 14 | 0 |
| neoarsphenamine | 0 | low | 1 | 0 |
| mersalyl | 0 | low | 1 | 0 |
| cortisol succinate, sodium salt | 0 | low | 1 | 0 |
| chiniofon | 0 | low | 8 | 0 |
| arginine | 0 | medium | 7 | 1 |
| gadofosveset trisodium | 0 | medium | 6 | 1 |
| olaparib | 0 | low | 18 | 0 |
| thiostrepton | 0 | low | 3 | 0 |
| hygromycin b | 0 | low | 4 | 0 |
| gelsemine | 0 | low | 1 | 0 |
| n-trans-feruloyloctopamine | 0 | low | 2 | 0 |
| plx 4720 | 0 | low | 1 | 0 |
| methyl jasmonate | 0 | low | 5 | 0 |
| lcl161 | 0 | low | 4 | 0 |
| pci 34051 | 0 | low | 1 | 0 |
| phosphatidylinositol 4-phosphate | 0 | low | 2 | 0 |
| s-adenosylmethionine | 0 | low | 85 | 0 |
| mk-7009 | 0 | low | 1 | 0 |
| mln 8237 | 0 | low | 6 | 0 |
| snx 2112 | 0 | low | 1 | 0 |
| nsc 177223 | 0 | low | 1 | 0 |
| gdc 0449 | 0 | low | 6 | 0 |
| gdc-0068 | 0 | medium | 2 | 1 |
| sgi 1776 | 0 | low | 1 | 0 |
| st2825 | 0 | low | 1 | 0 |
| canagliflozin | 0 | low | 10 | 0 |
| pci 32765 | 0 | low | 2 | 0 |
| madecassoside | 0 | low | 1 | 0 |
| ponatinib | 0 | low | 4 | 0 |
| ethyl cellulose | 0 | low | 3 | 0 |
| arabinogalactan | 0 | low | 8 | 0 |
| intrinsic factor | 0 | low | 2 | 0 |
| mk-1775 | 0 | low | 2 | 0 |
| tak-875 | 0 | low | 1 | 0 |
| oxymatrine | 0 | low | 6 | 0 |
| antroquinonol d | 0 | low | 1 | 0 |
| dolichol monophosphate | 0 | low | 4 | 0 |
| PP121 | 0 | low | 1 | 0 |
| niraparib | 0 | medium | 2 | 1 |
| mk 2206 | 0 | low | 11 | 0 |
| cc-122 | 0 | medium | 1 | 1 |
| navitoclax | 0 | low | 7 | 0 |
| sns 314 | 0 | low | 1 | 0 |
| jzl 184 | 0 | low | 1 | 0 |
| egg white | 0 | low | 1 | 0 |
| 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene | 0 | low | 5 | 0 |
| quetiapine fumarate | 0 | low | 3 | 0 |
| chlorin e4 | 0 | low | 2 | 0 |
| cardiovascular agents | 0 | low | 8 | 0 |
| oprozomib | 0 | low | 2 | 0 |
| pnd 1186 | 0 | low | 1 | 0 |
| trelstar | 0 | medium | 6 | 2 |
| neurotensin | 0 | low | 18 | 0 |
| fibrinopeptide a | 0 | low | 3 | 0 |
| peptide 31d | 0 | low | 1 | 0 |
| lhrh, n-ac-(4-cl-phe)(1)-(4-clphe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)- | 0 | low | 1 | 0 |
| cabozantinib | 0 | medium | 81 | 15 |
| defactinib | 0 | low | 1 | 0 |
| incb-018424 | 0 | medium | 6 | 1 |
| mannans | 0 | low | 11 | 0 |
| pexidartinib | 0 | low | 4 | 0 |
| bms-790052 | 0 | low | 25 | 0 |
| gsk 2126458 | 0 | low | 1 | 0 |
| emd1214063 | 0 | medium | 3 | 2 |
| gsk 1838705a | 0 | low | 1 | 0 |
| ixazomib | 0 | low | 1 | 0 |
| (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine | 0 | low | 1 | 0 |
| (2-phenylthiazol-4-yl)-(3,4,5-trimethoxyphenyl)methanone | 0 | low | 1 | 0 |
| azd2014 | 0 | low | 2 | 0 |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | 0 | low | 5 | 0 |
| mahanine | 0 | low | 1 | 0 |
| 9r-(9alpha(z),10alpha) of 3'-angeloyloxy-4'-acetoxy-3',4'-dihydroseselin | 0 | low | 1 | 0 |
| lysophosphatidylserine | 0 | low | 1 | 0 |
| plx4032 | 0 | medium | 8 | 1 |
| gsk 1363089 | 0 | medium | 3 | 2 |
| triiodothyronine, reverse | 0 | low | 9 | 0 |
| urushiol | 0 | low | 1 | 0 |
| 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide | 0 | low | 1 | 0 |
| glycolipids | 0 | medium | 90 | 3 |
| pki 402 | 0 | low | 1 | 0 |
| elafin | 0 | low | 4 | 0 |
| piperidines | 0 | medium | 103 | 14 |
| resolvin d1 | 0 | medium | 2 | 1 |
| bryostatin 1 | 0 | low | 1 | 0 |
| thymosin | 0 | medium | 23 | 4 |
| interleukin-8 | 0 | medium | 159 | 12 |
| dabrafenib | 0 | low | 7 | 0 |
| anagliptin | 0 | low | 2 | 0 |
| pki 587 | 0 | low | 3 | 0 |
| cblc137 | 0 | low | 2 | 0 |
| sd 1029 | 0 | low | 1 | 0 |
| kurarinol | 0 | low | 1 | 0 |
| avicin d | 0 | low | 1 | 0 |
| hamamelitannin | 0 | low | 1 | 0 |
| kahalalide f | 0 | low | 1 | 0 |
| leachianone a | 0 | low | 1 | 0 |
| ribociclib | 0 | medium | 4 | 1 |
| oclacitinib | 0 | low | 1 | 0 |
| mme | 0 | low | 1 | 0 |
| 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid | 0 | low | 1 | 0 |
| isosilybin | 0 | low | 1 | 0 |
| 4-fluoroglutamine | 0 | low | 1 | 0 |
| lb-100 | 0 | low | 1 | 0 |
| abt-450 | 0 | medium | 11 | 1 |
| scutebarbatine a | 0 | low | 1 | 0 |
| apatinib | 0 | medium | 94 | 16 |
| formylchromone | 0 | low | 1 | 0 |
| gx 15-070 | 0 | low | 5 | 0 |
| colistin | 0 | medium | 3 | 1 |
| sofosbuvir | 0 | medium | 74 | 5 |
| 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine | 0 | medium | 7 | 2 |
| exenatide | 0 | medium | 5 | 1 |
| aplysiatoxin | 0 | low | 1 | 0 |
| endrin | 0 | low | 2 | 0 |
| opium | 0 | low | 1 | 0 |
| 14-o-phosphonooxymethyltriptolide | 0 | low | 3 | 0 |
| abemaciclib | 0 | low | 2 | 0 |
| pf 3084014 | 0 | low | 3 | 0 |
| akb-9778 | 0 | low | 1 | 0 |
| wzb117 | 0 | low | 1 | 0 |
| gypenoside ix | 0 | low | 1 | 0 |
| gsk923295 | 0 | low | 1 | 0 |
| vs-5584 | 0 | low | 1 | 0 |
| dinaciclib | 0 | low | 1 | 0 |
| lgk974 | 0 | low | 1 | 0 |
| diphthamide | 0 | low | 1 | 0 |
| fructose-1,6-diphosphate | 0 | low | 4 | 0 |
| gyy 4137 | 0 | low | 1 | 0 |
| ly2874455 | 0 | low | 3 | 0 |
| bix 01294 | 0 | low | 5 | 0 |
| technetium tc 99m gluceptate | 0 | low | 2 | 0 |
| calcipotriene | 0 | low | 2 | 0 |
| alectinib | 0 | medium | 4 | 1 |
| birinapant | 0 | low | 2 | 0 |
| lusutrombopag | 0 | medium | 5 | 1 |
| abt-199 | 0 | low | 1 | 0 |
| pracinostat | 0 | low | 1 | 0 |
| encorafenib | 0 | low | 2 | 0 |
| spautin-1 | 0 | low | 1 | 0 |
| azd4547 | 0 | low | 4 | 0 |
| methylcellulose | 0 | low | 7 | 0 |
| armillaridin | 0 | low | 1 | 0 |
| sphaeropsidin a | 0 | low | 1 | 0 |
| isoquercitrin | 0 | low | 4 | 0 |
| dimethylaminomicheliolide | 0 | low | 1 | 0 |
| coronarin d | 0 | low | 1 | 0 |
| osu-2s | 0 | low | 2 | 0 |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | 0 | low | 10 | 0 |
| vasoactive intestinal peptide | 0 | medium | 46 | 2 |
| phosphomannopentaose sulfate | 0 | medium | 4 | 2 |
| antcin k | 0 | low | 1 | 0 |
| natriuretic peptide, brain | 0 | low | 6 | 0 |
| ysk05 | 0 | low | 1 | 0 |
| heme | 0 | medium | 40 | 2 |
| antrocin | 0 | low | 1 | 0 |
| chondroitin | 0 | low | 15 | 0 |
| heparitin sulfate | 0 | medium | 44 | 1 |
| cudc-907 | 0 | low | 1 | 0 |
| ascorbic acid | 0 | medium | 101 | 3 |
| novobiocin | 0 | low | 4 | 0 |
| tetracycline | 0 | low | 36 | 0 |
| chlortetracycline | 0 | low | 1 | 0 |
| oxytetracycline, anhydrous | 0 | low | 3 | 0 |
| minocycline | 0 | low | 6 | 0 |
| salicylates | 0 | low | 12 | 0 |
| dicumarol | 0 | low | 3 | 0 |
| acenocoumarol | 0 | medium | 2 | 1 |
| mobic | 0 | medium | 13 | 1 |
| warfarin | 0 | low | 95 | 0 |
| dihydroxyfumarate | 0 | low | 1 | 0 |
| gimeracil | 0 | low | 1 | 0 |
| bromfenacoum | 0 | low | 1 | 0 |
| phenprocoumon | 0 | low | 1 | 0 |
| tipranavir | 0 | low | 1 | 0 |
| tasquinimod | 0 | medium | 1 | 1 |
| 4-hydroxycoumarin | 0 | low | 1 | 0 |
| rolitetracycline | 0 | low | 1 | 0 |
| 2-o-octadecylascorbic acid | 0 | low | 1 | 0 |
| teriflunomide | 0 | low | 1 | 0 |
| 3-deazauridine | 0 | low | 1 | 0 |
| tigecycline | 0 | low | 7 | 0 |
| ilicicolin h | 0 | low | 2 | 0 |
| s 1 (combination) | 0 | medium | 377 | 34 |
| potassium ascorbyl tocopheryl phosphate | 0 | low | 1 | 0 |
| ew-7197 | 0 | low | 1 | 0 |
| abt-267 | 0 | medium | 11 | 1 |
| grn163 | 0 | low | 1 | 0 |
| abt-333 | 0 | medium | 11 | 1 |
| byl719 | 0 | medium | 3 | 1 |
| rgfp966 | 0 | low | 2 | 0 |
| nk 121 | 0 | medium | 1 | 1 |
| n,n'-bis(pyridoxal-5-phosphate)ethylenediamine-n,n'-diacetic acid | 0 | medium | 80 | 30 |
| betalains | 0 | low | 1 | 0 |
| epidermal growth factor | 0 | medium | 215 | 1 |
| pf 3512676 | 0 | low | 1 | 0 |
| zhengguangmycin | 0 | low | 4 | 0 |
| microcystin | 0 | low | 9 | 0 |
| gastrin-releasing peptide | 0 | low | 6 | 0 |
| calca protein, human | 0 | low | 4 | 0 |
| clay | 0 | low | 3 | 0 |
| charybdotoxin | 0 | low | 1 | 0 |
| rhodostomin | 0 | low | 1 | 0 |
| holothurin | 0 | low | 1 | 0 |
| transforming growth factor beta | 0 | medium | 662 | 4 |
| phytoestrogens | 0 | low | 14 | 0 |
| miravirsen | 0 | low | 1 | 0 |
| naloxegol | 0 | low | 1 | 0 |
| okadaic acid | 0 | low | 18 | 0 |
| methylglyoxal bis(cyclopentylamidinohydrazone) | 0 | low | 1 | 0 |
| glycyl-arginyl-glycyl-glutamyl-seryl-proline | 0 | low | 1 | 0 |
| ceritinib | 0 | medium | 3 | 2 |
| sybr green i | 0 | low | 3 | 0 |
| cc-223 | 0 | low | 1 | 0 |
| azd1208 | 0 | low | 1 | 0 |
| rki-1447 | 0 | low | 1 | 0 |
| xl 888 | 0 | low | 2 | 0 |
| saroglitazar | 0 | low | 1 | 0 |
| pyrethrins | 0 | low | 3 | 0 |
| epz-6438 | 0 | low | 1 | 0 |
| gsk2879552 | 0 | low | 1 | 0 |
| millepachine | 0 | low | 3 | 0 |
| vo-ohpic | 0 | low | 1 | 0 |
| sf 1126 | 0 | low | 1 | 0 |
| globotriaosylceramide | 0 | low | 3 | 0 |
| erdafitinib | 0 | low | 3 | 0 |
| ledipasvir | 0 | low | 12 | 0 |
| gs-5816 | 0 | low | 9 | 0 |
| g007-lk | 0 | low | 2 | 0 |
| gsk-2816126 | 0 | low | 2 | 0 |
| 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester | 0 | low | 1 | 0 |
| n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine | 0 | low | 1 | 0 |
| imbricatolic acid | 0 | low | 1 | 0 |
| longikaurin a | 0 | low | 1 | 0 |
| ponicidin | 0 | low | 2 | 0 |
| shizukaol d | 0 | low | 1 | 0 |
| ML355 | 0 | low | 1 | 0 |
| gsk343 | 0 | low | 1 | 0 |
| etirinotecan pegol | 0 | medium | 1 | 1 |
| cucurbitane | 0 | low | 1 | 0 |
| kiss1 protein, human | 0 | low | 13 | 0 |
| timosaponin aiii | 0 | low | 3 | 0 |
| fti 277 | 0 | low | 1 | 0 |
| sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate | 0 | low | 1 | 0 |
| leu-ser-lys-leu peptide | 0 | low | 1 | 0 |
| rome | 0 | low | 6 | 0 |
| eupalinolide a | 0 | low | 2 | 0 |
| selinexor | 0 | low | 2 | 0 |
| osimertinib | 0 | medium | 8 | 1 |
| hunanamycin a | 0 | low | 1 | 0 |
| ctx-0294885 | 0 | low | 1 | 0 |
| agar | 0 | low | 24 | 0 |
| cb-839 | 0 | low | 2 | 0 |
| arsenic trisulfide | 0 | low | 1 | 0 |
| meglumine ioglicinate | 0 | low | 1 | 0 |
| technetium tc 99m lidofenin | 0 | low | 28 | 0 |
| 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide | 0 | low | 1 | 0 |
| ivosidenib | 0 | low | 1 | 0 |
| 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | 0 | low | 1 | 0 |
| gsk-j4 | 0 | low | 1 | 0 |
| pf-06463922 | 0 | medium | 3 | 1 |
| ziyuglycoside ii | 0 | low | 1 | 0 |
| sar405 | 0 | low | 1 | 0 |
| hirudin | 0 | low | 3 | 0 |
| ephrin-a5 | 0 | low | 2 | 0 |
| imetelstat | 0 | low | 1 | 0 |
| glutaminase | 0 | low | 38 | 0 |
| ginsenoside rg5 | 0 | low | 1 | 0 |
| cyclin d1 | 0 | medium | 361 | 2 |
| contraceptives, postcoital | 0 | low | 3 | 0 |
| ganoderic acid | 0 | low | 1 | 0 |
| lysophosphatidylinositol | 0 | low | 1 | 0 |
| onc201 | 0 | low | 1 | 0 |
| caseins | 0 | low | 26 | 0 |
| ckd732 | 0 | low | 1 | 0 |
| nattokinase | 0 | low | 1 | 0 |
| ginsenoside rk3 | 0 | low | 1 | 0 |
| technetium tc 99m sulfur colloid | 0 | medium | 145 | 1 |
| azd3759 | 0 | low | 1 | 0 |
| oligomycins | 0 | low | 9 | 0 |
| ellagitannin | 0 | low | 1 | 0 |
| praliciguat | 0 | medium | 1 | 1 |
| phthalocyanine | 0 | low | 6 | 0 |
| carubicin | 0 | medium | 2 | 1 |
| g(m3) ganglioside | 0 | low | 6 | 0 |
| benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone | 0 | low | 24 | 0 |
| 2,3-dibromopropyl-2,4,6-tribromophenyl ether | 0 | low | 1 | 0 |
| nitrophenols | 0 | low | 36 | 0 |
| glaucarubin | 0 | low | 1 | 0 |
| lewis x antigen | 0 | low | 29 | 0 |
| glucagon-like peptide 2 | 0 | low | 1 | 0 |
| angiotensin i | 0 | low | 6 | 0 |
| ferric oxide, saccharated | 0 | low | 1 | 0 |
| germacranolide | 0 | low | 2 | 0 |
| gadoxetic acid disodium | 0 | medium | 980 | 50 |
| cobamamide | 0 | low | 2 | 0 |
| hyaluronoglucosaminidase | 0 | medium | 29 | 2 |
| chromostatin | 0 | low | 1 | 0 |
| adrenomedullin | 0 | low | 4 | 0 |
| mica | 0 | low | 1 | 0 |
| epoetin alfa | 0 | low | 1 | 0 |
| fumonisin b3 | 0 | low | 1 | 0 |
| lipofectamine | 0 | low | 8 | 0 |
| trichokonin vi | 0 | low | 2 | 0 |
| diospyros | 0 | low | 4 | 0 |
| plutonium dioxide | 0 | low | 3 | 0 |
| ginkgolide b | 0 | low | 2 | 0 |
| ginkgolide c | 0 | low | 1 | 0 |
| neferine | 0 | low | 4 | 0 |
| sodium aescinate | 0 | low | 1 | 0 |
| oridonin | 0 | low | 16 | 0 |
| ailanthone | 0 | low | 1 | 0 |
| chebulagic acid | 0 | low | 1 | 0 |
| ganoderic acid a | 0 | low | 1 | 0 |
| t-2 toxin | 0 | low | 4 | 0 |
| 4-acetylantroquinonol b | 0 | low | 3 | 0 |
| daptomycin | 0 | low | 1 | 0 |
| THZ531 | 0 | low | 1 | 0 |
| aldrin | 0 | low | 10 | 0 |
| ivalin | 0 | low | 1 | 0 |
| nonactin | 0 | low | 1 | 0 |
| 7-deoxynarciclasine | 0 | low | 1 | 0 |
| sanggenone c | 0 | low | 1 | 0 |
| peoniflorin | 0 | low | 5 | 0 |
| vitamin b 12 | 0 | low | 62 | 0 |
| aconitine | 0 | low | 3 | 0 |
| ferric ammonium citrate | 0 | low | 4 | 0 |
| oblimersen | 0 | medium | 2 | 2 |
| norgestrel | 0 | low | 21 | 0 |
| oxyntomodulin | 0 | low | 1 | 0 |
| transforming growth factor alpha | 0 | low | 125 | 0 |
| as 1411 | 0 | low | 3 | 0 |
| monomethylauristatin f | 0 | low | 1 | 0 |
| dehydrotomatine | 0 | low | 1 | 0 |
| psma-617 | 0 | low | 3 | 0 |
| insulin, 3-iodo-tyr(a14)- | 0 | low | 1 | 0 |
| dodecaborate | 0 | medium | 1 | 1 |
| cyclosporine | 0 | medium | 88 | 5 |
| flavin mononucleotide | 0 | low | 3 | 0 |
| tetrazanbigen | 0 | low | 4 | 0 |
| silybin | 0 | medium | 20 | 1 |
| triciribine | 0 | low | 2 | 0 |
| cytochalasin d | 0 | low | 8 | 0 |
| antipain | 0 | low | 1 | 0 |
| apicidin | 0 | low | 4 | 0 |
| peptide yy | 0 | low | 2 | 0 |
| siomycin a | 0 | low | 1 | 0 |
| lactoferrin | 0 | medium | 16 | 1 |
| danoprevir | 0 | low | 1 | 0 |
| digitonin | 0 | low | 9 | 0 |
| dehydroandrographolide | 0 | low | 1 | 0 |
| protopanaxadiol | 0 | low | 3 | 0 |
| catalpol | 0 | medium | 4 | 2 |
| peimisine | 0 | low | 1 | 0 |
| oxysophocarpine | 0 | low | 1 | 0 |
| edetic acid | 0 | low | 2 | 0 |
| icg 001 | 0 | low | 5 | 0 |
| neohesperidin | 0 | low | 1 | 0 |
| alpha-solanine | 0 | low | 3 | 0 |
| tomatine | 0 | low | 3 | 0 |
| ncx1000 | 0 | low | 1 | 0 |
| phenanthroindolizidine | 0 | low | 2 | 0 |
| 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone | 0 | low | 1 | 0 |
| asbestos, amosite | 0 | low | 1 | 0 |
| tremolite | 0 | low | 1 | 0 |
| gallium ga 68 dotatate | 0 | low | 24 | 0 |
| formosanin c | 0 | low | 1 | 0 |
| orabase | 0 | medium | 12 | 1 |
| technetium tc 99m medronate | 0 | medium | 98 | 2 |
| technetium tc-99m tetrofosmin | 0 | medium | 1 | 1 |
| apyrase | 0 | low | 10 | 0 |
| thromboplastin | 0 | low | 53 | 0 |
| muramidase | 0 | low | 23 | 0 |
| cord factors | 0 | low | 3 | 0 |
| chromomycins | 0 | low | 2 | 0 |
| nedaplatin | 0 | medium | 17 | 3 |
| lewis y antigen | 0 | low | 5 | 0 |
| sc002 | 0 | low | 2 | 0 |
| amyloid beta-peptides | 0 | low | 1 | 0 |
| lutetium lu 177 dotatate | 0 | medium | 27 | 6 |
| cyclooctatin | 0 | low | 1 | 0 |
| khasianine | 0 | low | 1 | 0 |
| chondroitin sulfates | 0 | low | 18 | 0 |
| iminoquinone | 0 | low | 1 | 0 |
| exudates | 0 | low | 38 | 0 |
| angiogenin | 0 | low | 12 | 0 |
| ganglio-n-triaosylceramide | 0 | low | 1 | 0 |
| plicamycin | 0 | low | 5 | 0 |
| tautomycin | 0 | low | 1 | 0 |
| isatidine | 0 | low | 1 | 0 |
| clivorine | 0 | low | 2 | 0 |
| protopanaxatriol | 0 | low | 1 | 0 |
| technetium tc 99m dimercaptosuccinic acid | 0 | low | 4 | 0 |
| fucosyl gm1 ganglioside | 0 | low | 3 | 0 |
| 68ga-dotanoc | 0 | low | 5 | 0 |
| akt-i-1,2 compound | 0 | low | 4 | 0 |
| entecavir | 0 | medium | 293 | 13 |
| acyclovir | 0 | low | 8 | 0 |
| osi 027 | 0 | low | 2 | 0 |
| levoleucovorin | 0 | medium | 1,172 | 321 |
| cyclic gmp | 0 | low | 46 | 0 |
| sepiapterin | 0 | low | 1 | 0 |
| deoxyguanosine | 0 | medium | 69 | 2 |
| guanosine diphosphate | 0 | low | 1 | 0 |
| guanosine diphosphate mannose | 0 | low | 2 | 0 |
| guanosine monophosphate | 0 | low | 3 | 0 |
| guanosine triphosphate | 0 | low | 17 | 0 |
| guanine | 0 | medium | 391 | 17 |
| guanosine | 0 | low | 25 | 0 |
| hypoxanthine | 0 | low | 8 | 0 |
| inosinic acid | 0 | low | 2 | 0 |
| inosine | 0 | medium | 12 | 1 |
| sapropterin | 0 | low | 4 | 0 |
| folic acid | 0 | medium | 127 | 2 |
| 3-methyladenine | 0 | low | 35 | 0 |
| cyclic imp | 0 | low | 1 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | 0 | medium | 3 | 1 |
| 7-methylguanine | 0 | low | 2 | 0 |
| neopterin | 0 | medium | 17 | 4 |
| rifampin | 0 | medium | 31 | 1 |
| clozapine | 0 | low | 1 | 0 |
| dacarbazine | 0 | medium | 110 | 20 |
| didanosine | 0 | low | 1 | 0 |
| ganciclovir | 0 | medium | 68 | 3 |
| valacyclovir | 0 | low | 1 | 0 |
| penciclovir | 0 | low | 1 | 0 |
| oxypurinol | 0 | low | 1 | 0 |
| raltitrexed | 0 | medium | 30 | 8 |
| nolatrexed | 0 | medium | 4 | 4 |
| ici 198583 | 0 | low | 1 | 0 |
| 8-azaxanthine | 0 | low | 2 | 0 |
| ro 3306 | 0 | low | 1 | 0 |
| 2-aminopurine dioxolane | 0 | low | 1 | 0 |
| inosine dialdehyde | 0 | low | 1 | 0 |
| allopurinol | 0 | medium | 50 | 3 |
| n-(4(n-((2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-l-glutamic acid | 0 | low | 1 | 0 |
| 2,2'-(hydroxynitrosohydrazono)bis-ethanamine | 0 | low | 1 | 0 |
| azaguanine | 0 | low | 9 | 0 |
| guanylyl imidodiphosphate | 0 | low | 2 | 0 |
| mrs 2211 | 0 | low | 1 | 0 |
| diazeniumdiolate | 0 | low | 6 | 0 |
| 8-hydroxyguanosine | 0 | low | 2 | 0 |
| 2,4-diaminohypoxanthine | 0 | low | 1 | 0 |
| alanosine | 0 | low | 1 | 0 |
| 2-amino-4-hydroxy-6-formylpteridine | 0 | low | 1 | 0 |
| 9-((2-phosphonylmethoxy)ethyl)guanine | 0 | low | 1 | 0 |
| pemetrexed | 0 | medium | 16 | 4 |
| 5,10,15,20-tetra(4-pyridyl)porphyrin | 0 | low | 1 | 0 |
| cytarabine | 0 | low | 8 | 0 |
| bropirimine | 0 | low | 2 | 0 |
| tirapazamine | 0 | medium | 11 | 1 |
| sildenafil citrate | 0 | low | 1 | 0 |
| aprepitant | 0 | low | 6 | 0 |
| pyrazofurin | 0 | low | 2 | 0 |
| vardenafil dihydrochloride | 0 | low | 1 | 0 |
| azilsartan | 0 | low | 1 | 0 |
| 5,6,7,8-tetrahydrofolic acid | 0 | low | 1 | 0 |
| xav939 | 0 | low | 4 | 0 |
| 8-bromocyclic gmp | 0 | low | 9 | 0 |
| 8-hydroxyguanine | 0 | medium | 14 | 1 |
| hesperadin | 0 | low | 1 | 0 |
| trypan blue | 0 | low | 34 | 0 |
| 2-azahypoxanthine | 0 | low | 1 | 0 |
| nintedanib | 0 | medium | 11 | 5 |
| lomofungin | 0 | low | 1 | 0 |
| 3'-fluoro-2',3'-dideoxyguanosine | 0 | low | 1 | 0 |
| methylnitronitrosoguanidine | 0 | low | 22 | 0 |
| 8-hydroxy-2'-deoxyguanosine | 0 | medium | 68 | 2 |
| bms 536924 | 0 | low | 1 | 0 |
| coelenterazine | 0 | low | 1 | 0 |
| 7-methylguanosine | 0 | low | 1 | 0 |
| 7-ethylguanine | 0 | low | 1 | 0 |
| amg531 | 0 | low | 1 | 0 |
| prodigiosin | 0 | low | 3 | 0 |
| 8-methylguanosine | 0 | low | 3 | 0 |
| 8-nitroguanine | 0 | low | 3 | 0 |
| galloflavin | 0 | low | 1 | 0 |
| 5-methyltetrahydrofolate | 0 | medium | 4 | 1 |
| 9-(4-fluoro-3-hydroxymethylbutyl)guanine | 0 | medium | 1 | 1 |
| hydrazinocurcumin | 0 | low | 3 | 0 |
| cytidylyl-3'-5'-guanosine | 0 | low | 7 | 0 |
| capromab pendetide | 0 | low | 1 | 0 |
| apogossypolone | 0 | low | 2 | 0 |
| ganciclovir triphosphate | 0 | low | 1 | 0 |
| alpha-(4-pyridyl-1-oxide)-n-tert-butylnitrone | 0 | low | 1 | 0 |
| 2,3-dihydro-2-(n(7)-guanyl)-3-hydroxyaflatoxin b1 | 0 | medium | 10 | 2 |
| cyclic guanosine monophosphate-adenosine monophosphate | 0 | low | 1 | 0 |
| direct black 3 | 0 | low | 1 | 0 |
| sta 9090 | 0 | medium | 3 | 1 |
| bmn 673 | 0 | low | 1 | 0 |
| 4-deoxybostrycin | 0 | low | 1 | 0 |
| 7-methyl-2-deoxyguanosine | 0 | low | 1 | 0 |
| 2'-carbodeoxyguanosine | 0 | low | 1 | 0 |
| n-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | 0 | low | 1 | 0 |
| liproxstatin-1 | 0 | low | 2 | 0 |
| aflatoxin b1-formamidopyrimidine | 0 | low | 5 | 0 |
| brucine n-oxide | 0 | low | 3 | 0 |
| sp2509 | 0 | low | 1 | 0 |
| cyanine dye 3 | 0 | low | 4 | 0 |
| alcian blue | 0 | low | 1 | 0 |
| pitstop 2 | 0 | low | 2 | 0 |
| cycloprodigiosin | 0 | low | 1 | 0 |
| texaphyrin | 0 | low | 1 | 0 |
| cephalostatin i | 0 | low | 1 | 0 |
| lipoteichoic acid | 0 | low | 3 | 0 |
| cholestyramine resin | 0 | low | 8 | 0 |
| eye | 0 | low | 9 | 0 |
| swinholide a | 0 | low | 1 | 0 |
| manganese-zinc ferrite | 0 | low | 5 | 0 |
| zinc(ii) phthalocyanine trisulfonic acid | 0 | low | 1 | 0 |
| chromomycin a3 | 0 | low | 2 | 0 |
| maltodextrin | 0 | low | 2 | 0 |
| mitotempo | 0 | low | 1 | 0 |
| acetylcellulose | 0 | medium | 3 | 2 |
| carbidopa | 0 | medium | 4 | 1 |
| ganodermanontriol | 0 | low | 1 | 0 |
| curcumenol | 0 | low | 1 | 0 |
| chaetocin | 0 | low | 3 | 0 |
| picroside ii | 0 | low | 1 | 0 |
| ganoderic acid b | 0 | low | 1 | 0 |
| pseudolaric acid b | 0 | low | 5 | 0 |
| concanavalin a | 0 | medium | 126 | 1 |
| chlorotoxin | 0 | low | 1 | 0 |
| trypsinogen | 0 | low | 5 | 0 |
| metallothionein | 0 | low | 108 | 0 |
| antimony sodium gluconate | 0 | low | 1 | 0 |
| beta, beta-dimethylacrylshikonin | 0 | low | 1 | 0 |
| ra xii | 0 | low | 1 | 0 |
| dinitrobenzenes | 0 | low | 9 | 0 |
| aluminum phthalocyanine disulfonate | 0 | low | 1 | 0 |
| 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein | 0 | low | 1 | 0 |
| phosphorus radioisotopes | 0 | medium | 78 | 4 |
| n-succinyl-chitosan | 0 | low | 1 | 0 |
| leptin | 0 | medium | 56 | 1 |
| pkh 26 | 0 | low | 2 | 0 |
| pyrimidinones | 0 | medium | 33 | 2 |
| destruxin b | 0 | low | 1 | 0 |
| sc-2001 | 0 | low | 4 | 0 |
| sinoporphyrin sodium | 0 | low | 1 | 0 |
| filipin | 0 | low | 2 | 0 |
| phenanthrenes | 0 | medium | 58 | 1 |
| sybr green ii | 0 | low | 1 | 0 |